Comparison of the physical health in adult patients with phenylketonuria (PKU) and healthy age-matched controls by Berlepsch, Juliana Freiin von
 
Aus der Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital 
der Ludwig-Maximilians-Universität München 










Comparison of the physical health 
in adult patients with phenylketonuria (PKU)  












zum Erwerb des Doktorgrades der Humanbiologie 
an der Medizinischen Fakultät der 


















Mit Genehmigung der Medizinischen Fakultät 











Berichterstatter: Professor Dr. med. Berthold Koletzko 
 
 
Mitberichterstatter: Prof. Dr. Thomas Lang 
 Prof. Dr. Yoon S. Shin-Podskarbi 
 
 
Mitbetreuung durch den 
promovierten Mitarbeiter: Dr. agr. J. Demmelmair 
 
 
Dekan: Prof. Dr. med. Dr. h. c. M. Reiser, FACR, FRCR 
 
 




Index of contents                 Page 
1 Introduction .............................................................................................................1 
1.1 Definition of phenylketonuria ............................................................................... 2 
1.2 Clinical symptoms of phenylketonuria ................................................................ 3 
1.3 Biochemistry of phenylketonuria ......................................................................... 4 
1.4 Diagnosis of phenylketonuria............................................................................... 6 
1.5 Therapy of phenylketonuria in general ................................................................ 7 
1.6 Therapy of phenylketonuria in adulthood ........................................................... 9 
1.7 Aims of the study................................................................................................. 17 
2 Materials and Methods .........................................................................................18 
2.1 Subjects and study design.................................................................................. 18 
2.2 Study procedure................................................................................................... 18 
2.2.1 Clinical investigation..............................................................................................................19 
2.2.2 Neurophysiologic testings .....................................................................................................20 
2.2.3 Neurostructural testing..........................................................................................................21 
2.2.4 Neuropsychological testings .................................................................................................22 
2.2.5 Nutritional, cardiovascular and metabolic status ..................................................................24 
2.2.6 Analysis of blood samples ....................................................................................................25 
2.2.6.1 Analysis of fatty acid profile in plasma phospholipids.......................................................... 30 
2.2.6.2 Analysis of vitamin A and E in plasma................................................................................. 33 
2.3 Data management and statistical analyses....................................................... 36 
2.4 Ethical aspects and insurance............................................................................ 37 
3 Results ...................................................................................................................38 
3.1 Subjects ................................................................................................................ 38 
3.2 Nutritional status of the patients ........................................................................ 39 
3.2.1 Measurement of fatty acids in plasma phospholipids ...........................................................39 
3.2.2 Vitamin A and E in plasma....................................................................................................41 
3.2.3 Dietary intake and nutritional supply .....................................................................................42 
3.2.4 Comparison of the nutrition data with data from patients followed at Münster.....................49 
3.3 Immune status of the patients ............................................................................ 53 
3.4 Cardiovascular risk of the patients .................................................................... 56 
3.5 Metabolic status of the patients ......................................................................... 59 
3.6 Neurological status of the patients .................................................................... 62 
3.6.1 Neurophysiological testings ..................................................................................................62 
3.6.2 Neurostructural testing..........................................................................................................65 
3.6.3 Neuropsychological tests ......................................................................................................67 
3.7 Subjetcs’ own assessment of their health......................................................... 71 
 
4 Discussion.............................................................................................................72 
4.1 Subjects ................................................................................................................ 72 
4.2 Nutritional status.................................................................................................. 73 
4.3 Immune status...................................................................................................... 78 
4.4 Cardiovascular risk.............................................................................................. 79 
4.5 Metabolic status................................................................................................... 81 
4.6 Neurological status.............................................................................................. 82 
4.6.1 Neurophysiological findings ..................................................................................................82 
4.6.2 Neurostructural findings ........................................................................................................83 
4.6.3 Neuropsychological findings .................................................................................................84 
4.7 Subjective assessment of health status............................................................ 87 
5 Summary................................................................................................................89 
6 Zusammenfassung ...............................................................................................91 
7 Attachment ............................................................................................................93 
7.1 Tables.................................................................................................................... 93 
7.2 Figures .................................................................................................................. 98 
7.3 Used information and documentation materials............................................... 99 
7.4 Acknowledgements ........................................................................................... 145 
7.5 Publication of the obtained data....................................................................... 146 
8 References…………………………………………………………………………......147  
9 Curriculum vitae…….…………………………………………………………….......158  
 
 
Index of abbreviations  
 
A1%1cm extinction coefficient 
AA arachidonic acid 
AAS atomic absorption spectrometry 
Apo A1 apolipoprotein A1 
Apo B apolipoprotein B 
APS Working Group on Paedriatric Metabolic Disorders 
AVLT auditory verbal learning test 
BH4 tetrahydrobiopterine 
BHT butylated hydroxytoluene 
BMI body mass index 
BMR basal metabolic rate 
CV coefficient of variation 
CWIT colour word interference test 
DHA docosahexaenoic acid (22:6n-3) 
DGE German Nutrition Society  
EDTA ethylene diamine tetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EPA eicosapentaenoic acid (20:5n-3) 
FAME fatty acid methyl esters 
Fig. figure 
GC gas chromatography 
HDL high-density lipoprotein 
HPA hyperphenylalaninemia 
HPLC high performance liquid chromatography 
IQR interquartil range (25.- 75. percentiles) 
IS internal standard 
LCPUFA long-chain polyunsaturated fatty acid 
LDL low density lipoprotein 
Lp (a) lipoprotein (a) 
MPT motor performance task 
MPKUC maternal phenylketonuria collaborative study 
MUFA monounsaturated fatty acids 
NCT number combination test 
NEFA non-esterified fatty acids 
NIST national institute of standards and technology 
PAL physical activity level 
Phe phenylalanine 
PKU phenylketonuria 
PUFA polyunsaturated fatty acids 
SFA saturated fatty acids 
SD standard deviation 
SEM standard error of the mean 
Tab. table 
TC total cholesterol 
TFA trans fatty acids 
TG triglycerides 




VEP visual evoked potential 




Index of figures                Page 
Fig.   1:  The major and minor pathways of Phenylalanine (Phe) metabolism 5 
Fig.   2:  Test arrangement for measuring VEP (195) 20 
Fig.   3:  Test arrangement for measuring fine motor skills (motor performance task) 21 
Fig.   4:  Thin layer chromatography of fatty acids in plasma 31 
Fig.   5:  Chromatogram of a standard mixture using UV-Vis detection* 36 
Fig.   6:  Chromatogram of a fatty acid standard mixture 39 
Fig.   7:  Spearman-Rho correlation between blood Phe-level during study and daily 
Phe-intake 43 
Fig.    8:  Spearman-Rho correlation between the blood Phe-level during study and 
blood Phe-level throughout life 43 
Fig.    9:  Macronuttrient intake of PKU-patients and controls (% of energy intake) 45 
Fig.  10: Intake of nutrients considered critical in PKU-patients (expressed as % of 
reference values; (47)) 45 
Fig. 11: Comparison of essential fatty acids, EPA and DHA (wt%) in plasma 
phospholipids  between PKU-patients and healthy omnivores (p-value, 
Mann-Whitney-U-Test) 47 
Fig. 12: Comparison of arachidonic acid and DHA levels in plasma phospholipids 
(wt%)  between PKU-patients (n=33) and healthy omnivores (n=31) 48 
Fig.  13: Macronutrient intake (expressed as % of energy intake) of all PKU-patients 
relative to reference values (47) 51 
Fig. 14: Correlation between Phe-level during study and duration of failures in PKU-
patients (Aiming) (n=32) 63 
Fig. 15: Typical periventricular deep white matter alterations (♂, 30 yrs) 66 
Fig. 16: Spearman-Rho correlation between feeling healthy and being content with life 88 
Fig. A1: Seven-point standard curves for retinol and α-tocopherol 98 
 
Index of tables                 Page 
Tab. 1: Plasma Phe and Tyr concentrations (39) 6 
Tab. 2: Metabolites excreted in the urine in untreated PKU-patients (170) 6 
Tab. 3: Basal metabolic rate (depending on age, gender, body weight) 10 
Tab. 4: Examples for average daily energy turnover 11 
Tab. 5: Amino acid mixtures for adults and pregnant women 12 
Tab. 6: D-A-CH recommendations for fat intake (47) 13 
Tab. 7: Frequency of laboratory and clinical investigations (176) 13 
Tab. 8: Recommended protein intake during pregnancy (174) 15 
Tab. 9: Recommended energy intake (11) 16 
Tab. 10: Protocol of the American MPKUC-Study (117) 16 
Tab. 11: Analyses of biochemical parameters 25 
Tab. 12: List of used chemicals for fatty acid analysis 27 
Tab. 13: List of used chemicals for vitamin A and E analysis 27 
Tab. 14: List of consumables for fatty acid analysis 28 
Tab. 15: List of consumables for vitamin A and E analysis 28 
Tab. 16: List of equipment for fatty acid analysis 28 
Tab. 17: List of equipment for vitamin A and E analysis 29 
Tab. 18: List of used standard substances for fatty acid analysis 29 
Tab. 19: List of used standards and control sera for vitamin A and E analysis 30 
Tab. 20: Composition of the internal standard for fatty acid analysis 30 
Tab. 21: Conditions of the GC for fatty acid analysis 32 
Tab. 22: Preparation of standard concentrates and dilutions 33 
 
Tab. 23:  Extinction coefficients for retinol and α-tocopherol 34 
Tab. 24:  Preparation of the seven standard dilutions for the calibration curves 34 
Tab. 25:  Calculation of the concentrations of the seven standard dilutions 34 
Tab. 26:  Program of the UV-Vis detector 35 
Tab. 27:  Baseline characteristics of the subjects 38 
Tab. 28:  Intra-assay CV of fatty acid analyses in plasma phospholipids 40 
Tab. 29:  Inter-assay CV of fatty acid analyses in plasma phospholipids 40 
Tab. 30:  Reproducibility of vitamin A and E analysis in plasma 41 
Tab. 31:  Accuracy of vitamin A and E analysis in plasma 41 
Tab. 32:  Daily dietary Phe-intake and blood Phe-levels of the PKU-patients 42 
Tab. 33:  Daily dietary intake of the PKU-patients (including amino acid mixtures) 44 
Tab. 34:  Nutritional supply of the PKU-patients (blood levels) 47 
Tab. 35:  Daily dietary intake of all PKU-patients (including amino acid mixtures) 50 
Tab. 36:  Nutritional supply of all PKU-patients (blood levels) 52 
Tab. 37:  Immune globulins of the PKU-patients 53 
Tab. 38: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and cardiovascular risk factors in PKU-patients 53 
Tab. 39:  Elisa test results of 10 PKU-patients with elevated IgE 54 
Tab. 40:  Frequency of allergic diseases in all subjects 55 
Tab. 41: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and frequency of allergic diseases in PKU-patients 55 
Tab. 42: Cardiovascular risk factors in PKU-patients compared to healthy controls 56 
Tab. 43: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and cardiovascular risk factors in PKU-patients 57 
 
Tab. 44:  Blood lipid status and homocysteine levels of the PKU-patients 57 
Tab.45:  Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and blood lipid status, as well as homocysteine levels in PKU-
patients 58 
Tab. 46: Accelerometer results of the PKU-patients and healthy controls 59 
Tab. 47: Spearman-Rho correlations between accelerometer results and activity 
dependent parameters in all subjects 60 
Tab. 48: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and accelerometer data in PKU-patients 60 
Tab.  49:  Activity parameters of the PKU-patients and healthy controls 61 
Tab. 50: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and activity parameters in PKU-patients 61 
Tab. 51: MPT results of the PKU-patients and healthy controls (measured with right 
hand) 62 
Tab. 52: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and the MPT results in PKU-patients 63 
Tab. 53:  Fine motor factors of the of the PKU-patients and healthy controls (t-values) 64 
Tab. 54: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and fine motor factors in PKU-patients 64 
Tab.  55:  VEPs and MRIs findings in PKU-patients 65 
Tab.  56:  VEP (70’) P100 latencies in PKU-patients compared with healthy omnivores 65 
Tab.  57:  Severity of deep white matter alterations in PKU-patients 66 
Tab. 58: Spearman-Rho correlations between the blood Phe-level, blood PUFA  
content and severity of deep white matter alterations in PKU-patients 66 
Tab.  59: d2 attention test results of the PKU-patients and healthy controls 67 
Tab. 60: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and results of the d2 attention test in PKU-patients 67 
 
Tab. 61:  CWIT results of the PKU-patients and healthy controls (t-values) 68 
Tab. 62: Spearman-Rho correlations between the blood Phe-level, the blood PUFA 
content and results of the CWIT in PKU-patients 69 
Tab. 63:  AVLT results of the PKU-patients and healthy controls 69 
Tab. 64: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and results of the AVLT in PKU-patients 70 
Tab. 65:  NCT results of the PKU-patients and healthy controls 70 
Tab. 66: Spearman-Rho correlations between the blood Phe-level, blood PUFA 
content and results of the NCT in PKU-patients 70 
Tab. 67: Measure of contentedness with health in the PKU-patients and healthy 
controls 71 
Tab. 68:  Feelings of the PKU-patients and healthy controls about their health status 71 
Tab. A1:  Daily nutrient intake of the PKU-patients 93 
Tab. A2: Relative fatty acid composition (wt%) of plasma phospholipids in PKU-
patients 94 
Tab. A3:  Reproducibility of fatty acid analysis in plasma PL (mean, CV) 95 
Tab. A4:  Inter-assay of retinol and α-tocopherol in control plasma 96 
Tab. A5:  Intra-assay of retinol and α-tocopherol in control plasma 96 




Introduction  1 
1 Introduction 
Phenylketonuria (PKU) is an inherited metabolic disorder that appears in about one out of 
every 10,000 births in Germany. It results from a deficient activity of the liver enzyme 
phenylalanine hydroxylase (PAH), which leads to elevated levels of the amino acid 
phenylalanine (Phe) in the blood. When a strict diet is implimentated and maintained children 
with PKU can expect normal development, whereas dietary noncompliance can result in a 
decline in mental and behavioral performance.  
As a consequence of screening newborns for today there are increasing numbers of patients 
who have been treated early in life for PKU. Current concepts propose a “diet for life”. Yet 
studies show that PKU-patients often lack an adequate medical and nutritional supervision in 
adult life (96;115;159) even after intensive care during childhood. This fact is suggested to 
additionally influence the long-term physical health of adult PKU-patients (96;159) apart from 
the early and strict diet in childhood. In contrast to the situation in the USA and Australia, 
where dedicated centers with professional medical and nutritional care for adult PKU-patients 
emerge, in Germany health care for this group of patients is not well developed. Therefore 
adequate medical and nutritional support is not provided for the majority of these patients 
living in Germany (159). 
The dietary compliance of the PKU-patients decreases with age and especially during 
adolescence since young adults strive for independence and therefore often loosen or even 
discontinue their diet (96;115). Furthermore, there is a lack of age-adapted dietary guidelines 
and nutritional education. Since many adult patients are vegetarians, diet might be 
unbalanced. This can lead to nutrient deficiencies. Studies showed inadequate intakes of 
long-chain polyunsaturated fatty acids (4;63;130;148;177), minerals (calcium, magnesium, 
zinc, copper, selenium, iron)  (5;22;24;44;67;74;110;122) and vitamins 
(41;70;144;147;153;158;177) in adult PKU-patients due to a vegetarian diet. Moreover adult 
PKU-patients tend to have high fat and sugar intakes, which might have adverse effects on 
their lipoprotein profile (156). 
While untreated PKU is characterized by microcephaly, epilepsy, severe mental retardation 
and progressive supranuclear motor disturbances, patients treated early reveal only minor 
neurological signs, such as tremors, hypo-, hyperactivity, convulsions, ataxia, loss of 
coordination and/or brisk deep tendon reflexes (96;107;120;140;173). Although these 
symptoms seem to be stable over time in the vast majority of patients, progression of 
neurological symptoms occurred (140;173;180) in a smaller number of patients. 
Psychological testings reveal lower performance in neuropsychological attention tasks, which 
is influenced by the current plasma concentration of phenylalanine (186). 
A high frequency of psychiatric disorders was detected in PKU-patients, i.e. of the 
internalizing type, especially behavioral abnormalities, depressions and emotional 
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impairment (168). However, it is unclear whether this can be attributed to the chronic 
condition itself or to disease-related impairments in the brain function. While visual evoked 
potentials (VEP) consistently show prolongation of latencies in 30 % of early-treated adult 
PKU-patients, somatosensory evoked potentials and peripheral motor nerves sensory tests 
are inconsistently prolonged in about 10 % of the patients. Early auditory evoked potentials 
mostly show normal profiles (140;184). A recent multicenter study in the USA found that 
adult PKU-patients who discontinued their diet suffer more frequently from eczema and 
bronchial asthma compared to adults who continue their diet (96). There are also indications 
that PKU-patients show alterations in the immune system (88;146). Karagoz and colleagues 
(88) found that children with PKU had lower immunoglobulin levels compared to healthy 
children.  
Thus the present work deals with the question in dispute whether and if so, how strictly adult 
patients with phenylketonuria should be treated and which effects and side effects could then 
be described as results of a low-Phe diet. 
1.1 Definition of phenylketonuria 
The autosomal-recessive inherited defect of the liver enzyme phenylalanine hydroxylase 
(PAH) leads to an increase of Phe in all body tissues by blocking and obstructing of the 
hydroxylation of the amino acid phenylalanine (Phe) into tyrosine (Tyr). Depending on the 
existing residual activity of PAH, Phe concentration increases with varying speed and 
extension in the bodies of patients. Clinical symptoms appear in untreated patients in relation 
to the amount of blood Phe concentration, mainly in the most extreme case of classical PKU 
(PAH activity <1 %). In Germany, there is a classification of PAH defects according to the 
severity code of the disorders: 
 
 Classical PKU with blood Phe concentrations above 20 mg/dl (>1205 µmol/dl) without 
diet and a Phe tolerance below 400 mg/day 
 Mild PKU with blood Phe concentrations between 10 and 20 mg/dl (602-1205 
µmol/dl) and Phe tolerances between 400 and 600 mg/day 
 HPA with blood Phe concentrations maximal 10 mg/dl (>603 µmol/dl) 
 Tetrabiopterine (BH4) sensitive PAH defect with a normally maximal blood Phe 
concentration of 20 mg/dl (1205 µmol/l) 
 
In the English literature HPA describes all conditions with an increase of blood Phe 
concentration regardless of the causes. 
Eponymous for the disease is the increasing excretion of phenylketones like phenylpyruvate, 
which is a direct degradation product of Phe (58).  
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In contrast to PKU and HPA maternal PKU describes an independent clinical picture in 
newborns caused by high blood Phe-levels of a mother with PKU. High blood Phe 
concentrations of the mother are dangerous for a developing fetus and can lead to an 
embryopathy without any relation to the genetic status of the fetus. Therefore women with 
PKU who are off the special PKU-diet should restart it and have their blood Phe-levels 
carefully monitored. 
1.2 Clinical symptoms of phenylketonuria 
If classical PKU remains untreated, developmental delays appear, as well as a special 
mousy odor and an eczema-like rash can appear at 5-6 months of age or even earlier. In the 
following early years of life the deficient mental development with microcephaly, mental and 
psychosocial retardation or fair hair and skin become more explicit (140;161). 
In untreated patients with HPA symptoms may appear later or milder than in patients with 
PKU due to a relatively high residual activity of PAH. Sometimes developmental delays are 
not even detected until the investigation for school enrolment. 
 
Thus, typical clinical symptoms of untreated, lately detected and/or badly adjusted patients 
with classical PKU are the following: 
 mental retardation (IQ score < 50) 
 motor disturbances 
 microcephaly 
 EEG alterations in 50 % of the cases 
 hyperactivity 
 increased muscle tone and more active muscle tendon reflexes 
 vomiting 
 fairer hair and skin than other family members  
 irritability and eczema-like rash 
 typical mousy odor to the urine (phenylpyruvate) 
Less frequently: 
 prominent cheek and upper jaw bones 
 widely spaced teeth 
 poor development of tooth enamel 
 cataracts 
 decreased body growth (lack of growth hormone) 
 
The higher the residual activity of PAH and the lower the blood Phe-levels the milder are the 
clinical symptoms. Residual activities below 2 % seem to lead to the classical picture of PKU. 
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Intelligence deficits do appear, if blood Phe concentrations are permanently above 8 mg/dl 
(484 µmol/l) during infancy. Children with blood Phe-levels up to 13 mg/dl (792 µmol/l) often 
show significant disorders related to attentiveness (12). 
However, in the literature some symptom-free cases are described in spite of very high Phe-
levels. So far, no explanations have been found why these did not develop the typical clinical 
picture of PKU although lower Phe-levels were found in the brain tissue of such subjects than 
in patients with the classical PKU phenotype (140;189). 
Infants born to mothers with elevated Phe-levels during pregnancy are at risk for mental 
retardation, microcephaly, low birth weight (< 2500 g), spontaneous abortions, congenital 
heart diseases and dysmorphic face similar to alcohol embryopathy depending on the Phe-
level. Due to an active Phe transport, blood Phe-levels of the fetus are twice as high as in the 
placenta. The most severe defects were observed in mothers with blood Phe-levels above 20 
mg/dl (1210 µmol/l). Furthermore a lack of tyrosine, protein and/or energy and vitamins, as 
well as too little weight gain can contribute (116). 
1.3 Biochemistry of phenylketonuria 
There are many investigations into the pathologic mechanisms that lead to the development 
of the severe mental damage resulting from high Phe-levels, which indicate that it is most 
likely caused by a multifactor process. A shared, energy-dependant carrier transports the 
amino acids Phe, Tyr and Trp, which are very important for the brain, but also Val, Ile, Leu, 
Lys and His. In PKU there is an enormous imbalance of amino acids with very high levels of 
Phe, as well as normal or even reduced concentrations of other amino acids which lead to an 
overloading of the carrier with suppression of the other amino acids and reduced intracellular 
concentrations (43;121). The lack of Trp mainly results in aggregation disorders of the 
polyribosomes with a reduction in protein synthesis (10;169). It works as a limitating factor of 
the protein synthesis. Moreover the sulfate synthesis is possibly inhibited by the reduction of 
cyclic AMP and phosphoadenosin-5-phosphorsulfate, which is needed for sulfate synthesis 
(81). Furthermore, a reduction of cerebroside synthesis due to reduced cerebroside 
concentrations is assumed with regard to previous investigations in deceased PKU-patients. 
Recent investigations in mice with PKU indicate that elevated Phe-levels can block the 
cerebral cholesterol synthesis and thus cause alteration of the oligodendrocyte function, as 
well as a reduction of melanin synthesis (51).  
In addition an inhibition of synaptogenesis in neuronal cell cultures was found (76). 
It has not become clear so far, whether the inhibition of protein synthesis, energy 
metabolism, cholesterol, cerebroside or sulfate synthesis or combinations of these 
parameters might cause alterations in myelinisation and morphologic brain structure. 
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Moreover the important neurotransmitter dopamine is synthesized from tyrosine and dopa. It 
has been demonstrated in patients with PKU that their dopamine are reduced as was 
confirmed by studies of liquor. In addition to that the synthesis of serotonin and Trp is 
restrained. A lack of these neurotransmitters leads to an inadequate development of the 
dendrites and thus to alterations of the brain function with a loss of cognitive skills. Some 
studies have also shown that e.g. the nerve conduction and most cognitive functions depend 
explicitly on the serotonin and 5-hydroxyindol acetate levels in the liquor, which in turn 
strongly depends on Phe-levels. So it is obvious that Phe influences brain metabolism in 
many ways (111). 
A further possibly important reason for the reduced synthesis of dopamine is the direct 
inhibition of tyrosine hydroxylase. Phe concentrations of approximately 15 mg/dl inhibited 
tyrosine hydroxylase up to 80 % (133) which seems to indicate a lack of neurotransmitters, 
too. Perhaps the inhibition of amino acid transport into brain is not the considerable cause of 
structural and functional alterations in the brain. In patients with tyrosinemia type II and 
histidinemia e.g. similar imbalances of amino acids are observable but do not lead to 
alterations of neurotransmitters (79). 
An overview of the metabolism of Phe is shown in figure 1: 
 
 
Fig. 1: The major and minor pathways of Phenylalanine (Phe) metabolism 
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1.4 Diagnosis of phenylketonuria 
Newborn screening for elevated blood Phe-levels generally allows for an early diagnosis of 
the different types of HPA with normal protein intake. The method measures even small 
changes in Phe-levels. Current methods based on mass spectrometry are much more 
sensitive and replace the bacteriologic inhibition test pioneered by Robert Guthrie (69). In 
Germany, today the neonatal screening for inherited metabolism disorders is carried out 
exclusively by tandem mass spectrometry (1). The optimal time of blood withdrawal is on the 
3rd day of life. An early detection within the first 36 hours is definitely possible by measuring 
Phe, Tyr and their quotient. Phe-levels above 2.4 mg/dl and a ratio of Phe to tyrosine above 
2 in the first 36 hours of life are suspicious, but should be confirmed by a 2nd measurement 
preferable on the 3rd, 4th or 5th day of life, or thereafter. 
 
Biochemical findings 
Typical for patients with PKU is a marked elevation of Phe-levels relative to normal levels, 
and reduced levels of tyrosine (table 1). Table 2 shows different metabolites produced by 
degradation of Phe and excreted in the urine (128): 
 
Tab. 1: Plasma Phe and Tyr concentrations (39) 
 
Status Phe (mg/dl) Tyr (mg/dl) 
Normal  
(birth to 3rd month) Up to 3 Up to 3.6 
Normal, not fasting  
(3rd month-14 yrs) 0.3-2.2 0.6-1.8 
Normal, fasting  
(3rd month-14 yrs) 0.5-1 0.6-1.4 
Classical PKU  
(older than 72 hrs) >3 <1 
Untreated classical PKU  
(not later than babyhood) >15 <1 
 
 








Phenylpyruvate 0-4 300-1,000 
Phenyllactate <2 200-1,000 
2-hydroxy phenylacetate <2 50-2,000 
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The activity of PAH can be measured directly in liver biopsates. Activities below 1 % lead to 
the clinical picture of classical PKU and those above 5 % (up to 35 %) lead to HPA. In a few 
patients with mild PKU direct measurements were carried out in vivo by application of 
deuterized Phe (161). 
 
Genetic findings 
The gene encoding PAH is located on chromosome 12q22-q24.2. So far more than 530 
mutations have been described (72;72;106;142;161;194). There are three main types of 
mutations observed in about 50 % of German patients. 
While the prevalence of classical PKU in Germany is one in about 11,600, HPA occurs 
significantly less often (54). However, in other countries PKU is more (1:7,400 in Turkey or 
1:4,500 in Ireland) or less common (1:20,000 in Bulgaria and very rarely in Finland) and in 
Japan HPA is more common than PKU. 
 
The detection of heterozygotes is possible by: 
 Measurement of Phe and Tyr levels in blood, as well as Phe metabolites in urine after 
exposure with protein and Phe (100 mg/kg body weight L-Phe or protein) 
 Examination of PAH activity by liver biopsy 
 Determination of Phe turnover e.g. by 13C breath test (27) 
 Detection of mutations in the PAH gene 
1.5 General treatment concepts for phenylketonuria  
Since the beginning of the 1950s patients with PKU and HPA have been treated with 
success (20) if a strict diet was started very early and maintained at least up until puberty 
(31;140). Cases have been described recently, in which the administration of BH4 in the 
scope of the differential diagnosis of the HPA led to an decrease of blood Phe-levels (often 
within 8-24 hours after administration of BH4) even without the presence of severe inborn 
disorders in BH4 metabolism. The maximal Phe concentrations were mostly below 20 mg/dl 
(1205 µmol/l). Investigation in the PAH gene showed very different mutations. In some 
patients the Phe-levels were permanently reduced to normal values by substitution of BH4 
without any further dietetic treatment (17;104). 
 
Principles of dietetic treatment 
The treatment normally consists of a low-Phe but Tyr-enriched diet, which should start 
without delay after an early diagnosis in the neonatal period. After detection of elevated Phe-
levels by newborn screening a differential diagnosis must be made to determine if there is an 
inborn defect in the BH4 metabolism (BH4 is a cofactor of PAH). Therefore a BH4 loading test 
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is carried out by exposing the patient with 20 mg BH4/kg body weight followed by an 
observation time of at least 24 hours. Phe-levels from at least 6 mg/dl (364 µmol/l) at the time 
of administration are considered to be an optimal precondition (17). 
If the cause of Phe elevation is a lack of the cofactor BH4, e.g. due to a synthesis defect, this 
results in a rapid decrease of Phe and increase of Tyr levels after oral administration of BH4. 
Additionally, different pteridines in the urine before and after administration of BH4, as well as 
the activity of dihydropteridine reductase in dried blood samples can be measured to 
differentiate BH4 metabolism defects. BH4-responsive forms of PAH defects often lead to a 
marked decrease of blood Phe-levels after approx. 24 hours (at all events later than 8 hours). 
However, the low-Phe diet in patients with Phe-levels above 8 mg/dl (485 µmol/l) is not to be 
started until a lack of BH4 is excluded (21). 
The main principle of dietetic treatment is a strict restriction of protein supply and a reduction 
of Phe-intake down to the amount required for protein synthesis. In infancy and during 
growth spurts such as puberty, the tolerable Phe-intake per kg body weight is higher than 
during other times of childhood. Since there is a lack of tyrosine, its additional administration 
is advisable. In practice, the low-Phe diet requires the exclusion of protein rich foods such as 
meat, fish, eggs, milk, dairy products, nuts, wheat, grains, corn, beans and lentils, whereas 
fruits, vegetables, rice and potatoes are at least allowed in controlled quantities. Due to the 
limited intake of natural protein (60-80 % lower than in healthy subjects) administration of an 
amino acid mixture containing all essential amino acids and tyrosine is necessary to cover 
the requirements for nitrogen, and this is enriched with vitamins, minerals and trace elements 
to secure the needs also of these nutrients. Above all these factors, an adequate energy 
intake is essential to reach normal growth rates and to prevent degradation of body proteins. 
Basically this diet is achieved with the help of commercial dietetic products low in protein and 
by replacing foods rich in protein, as well as fat and carbohydrates (178). 
The patient should adhere to the diet for their entire lifespan, but beyond the age of 10 years 
the diet can be gradually loosened (31). Since patients with HPA do have a higher Phe 
tolerance, a low-protein diet without supplementation of amino acids may be sufficient. HPA 
patients with plasma Phe-levels <600 µmol/l (<10 mg/dl) do not require any dietetic treatment 
(188), and in BH4–responsive patients often an administration of BH4 alone will suffice. 
 
Thus the aims of the dietetic treatment are: 
 Reduction and maintenance of the recommended blood Phe-levels  
 Maintenance of normal plasma Tyr concentrations 
 Normal equilibrium and mental development 
 Normal weight gain up to the end of infancy and weight maintenance in adulthood 
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 Prevention of catabolic conditions (degradation of protein surpasses synthesis) due to an 
insufficient energy and protein intake, which leads to elevation of Phe 
 Fast termination of catabolic conditions (e.g. fever, vomiting, diarrhea, physical strain, 
weight loss) by high energy and adequate protein intake 
 
First adjustment in newborns 
If no defects in pteridine metabolism have been shown in the BH4 loading test, a Phe-free 
diet is started for approximately three days (total withdrawal of natural protein and Phe) to 
reduce the initially elevated Phe-levels. During these days, breastfeeding mothers have to 
pump and freeze breast milk to maintain milk production for subsequent breastfeeding. The 
baby is fed only Phe-free formula made of L-amino acids, lipids, carbohydrates which is 
enriched with minerals, trace elements and vitamins. The aim of this treatment is to reduce 
blood Phe-levels below 4 mg/dl (242 µmol/l). Empirically one can assume that Phe-levels 
decrease approximately by 4 mg/dl (242 µmol/l) per day. Once the Phe-levels are 8 mg/dl 
(484 µmol/l) or lower some natural protein can be given in addition to the Phe-free formula, 
e.g. by provision of breast milk. Initially about 30 mg/dl Phe per kg body weight can be 
administered. 
1.6 Therapy of phenylketonuria in adulthood 
Adult PKU-patients are a very heterogeneous group: 
1) Diagnosed late and untreated 
2) Diagnosed late but treated 
3) Treated early but early termination of the diet  
4) Early treated but badly adhered to diet 
5) Early treated with consequently maintained diet 
6) Maternal PKU 
 
Diagnosed late and untreated 
These patients often live in special institutions for handicapped people, where a dietetic 
treatment is often poorly administered. However, experience supports to continue treatment 
or even starting treatment at a late age. Starting this treatment might even reduce the 
nursing costs and may improve the quality of life. 
 
Diagnosed late but treated 
The later the diagnosis, the later treatment is started and therefore the worse the prognosis 
is for adulthood. Nevertheless, often even treatment started at a later time leads to a better 
cognitive performance. 
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Treated early but early termination of the diet  
Early termination of the diet results in more marked clinical symptoms in adulthood. 
 
Early treated but badly adhered to diet 
Similar observations are also possible for this group when the diet was consequently not 
maintained during infancy.  
 
Early treated with consequently maintained diet 
An early diagnosis, immediately followed by proper treatment and maintenance of said diet 
leads to adequate physical and mental development.  
 
Dealing with such a heterogeneous group of the PKU-patients, realistic aims of the therapy 
should be defined and discussed for the individual case in cooperation with the treating 
expert. Following the recommendations of the Working Group on Pediatric Metabolic 
Disorders (Arbeitsgemeinschaft Pädiatrische Stoffwechselstörungen, APS), patients at an 
age of 16 years and older should have serum Phe-levels below 20 mg/dl (1200 µmol/l). If 
there are neurological symptoms and/or behavioral disturbances detectable, a reduction of 
the symptoms may be accomplished with a stricter dietetic treatment. In case of a terminated 
diet, regular cognitive and neuropsychological tests should be performed (11;176). The 
individual’s life situation, their physical and cognitive development as well as their personal 
aims should be taken into consideration. 
 
Energy supply following the D-A-CH recommendations (47) 
The energy requirements of patients with PKU are considered same as in healthy subjects 
and depend on basal metabolic rate (table 3), working metabolic rate, thermogenesis after 
feeding, and added requirements such as those for growth, pregnancy and the nursing 
period. An important part of the energy turnover is the energy requirement for physical 
activities expressed as the physical activity level (PAL), a factor calculated depending on the 
intensity of the daily physical activities as shown in table 4. 
 
Tab. 3: Basal metabolic rate (depending on age, gender, body weight) 
 
Age Body weight male                    female 
Basal metabolic rate (kcal/day) 
male                  female 
19 < 25 yrs 74 60 1820 1460 
25 < 51 yrs 74 59 1740 1340 
51 < 65 yrs 72 57 1580 1270 
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Tab. 4: Examples for physical activity levels  
 
Severity of work and behavior in free-time PAL* Examples 
Sleeping 0.95  
Exclusively sitting or lying way of life 1.2 Old, frail people 
Exclusively sitting activity with little or no 
strenuous free-time activity 1.4-1.5
Office employee,  
precision mechanic 
Sitting activity, temporary also additional energy 
demand for walking or standing activities* 1,6-1.7
Laboratory assistant, lorry driver, 
student, assembly-line worker 
Mainly walking and standing work* 1.8-1.9 Housewife, shop assistant, waiter, mechanic, workman 
Physically strenuous professional work* 2.0-2.4 Construction worker, farmer, miner, competitive athlete 
* For 30-40 min strenuous free-time activities 4-5 times a week 0.3 PAL units can be added daily 
 
Protein supply 
The PKU diet is very restricted in protein content, and the amount of natural protein provided 
depends on the individual’s Phe tolerance. Every protein containing food item has a content 
of approx. 3-6 % Phe, on average about 5 %. The natural protein intake from foods is not 
sufficient; therefore an Phe-free amino acid mixture should be taken several times per day to 
compensate for the low protein intake. 
There is no reliable data about the biological equivalency and the bioavailability of nitrogen 
from amino acid mixtures. Therefore protein intake is often calculated following the 
recommendations of the German Nutrition Society (DGE) from 1985, which lie markedly 
above the current D-A-CH recommendations (47). This extra intake is supposed to 
compensate for a lower quality of the nitrogen source and the very fast resorption and 
metabolisation of the amino acids (59). Further scientific investigations are needed to 
determine the adequate amino acid intake for PKU-patients. 
 
Phe tolerance 
The amount of Phe provided depends on the individual’s Phe tolerance and the target value 
for blood levels. If this is not known it should be determined. The upper limit of the patient’s 
tolerance depends primarily on the residual activity of PAH and the individual’s target value. 
In adults the desired Phe intake values usually are between 150 and 1,000 mg per day (131). 
 
Amino acid mixture 
The amino acid mixtures (tab. 5) should be given in at least three portions per day which are 
dissolved in adequate amounts of liquid (water, juice, lemonade, fruit puree or sugared 
instant powder) or semi liquid foods (e.g. apple puree) to prevent possible side effects from 
Introduction  12 
high osmolarity such as abdominal disturbances or diarrhea. The amino acid supplement 
should be taken together with a meal providing natural protein and hence Phe for better 
utilisation. Studies showed that after the intake of free amino acids the levels of the amino 
acids initially increased but subsequently decreased faster than normal. The amino acids are 
quickly reabsorbed and then seem to break down oxidatively especially if insufficient 
amounts of Phe are available for protein synthesis (59). 
 
Tab. 5: Some amino acid mixtures for adults and for pregnant women available in Germany 
 
P-AM 3 SHS 
p-am Anamix (flavored) SHS 
p-am Easiphen or Lophlex (flavored, ready to drink) SHS 
P-AM maternal (during pregnancy) SHS 
PKU 3 advanta Milupa 
PKU 3 shake or active (flavored) Milupa 
PKU 3 tempora (during pregnancy) Milupa 
 
New generation of amino acid mixtures 
The new amino acid mixtures (p-am Anamix, PKU 3 shake or active) are prepacked in 
portion sizes that can be dissolved directly in an adequate amount of drinking water or even 
ready to drink (p-am Easiphen or Lophlex). Handling of these portions in everyday life has 
become a lot easier and at the same time the physiological osmolality supports better 
tolerance. An increase in the metabolic utilization of these amino acids is supposed to be 
achieved by the enrichment of these portions with fat, carbohydrates, minerals, vitamins, as 
well as trace elements. Different flavors are available to cover different tastes. 
These amino acid mixtures enable the patient to handle them easily even outside the house, 
at the work place, at school, at the university or on holiday etc. Combinations with 
conventional amino acid mixtures are also possible. 
 
Fat intake 
Due to a lack of hidden fats, one has to use margarine, butter and oils for meeting the 
recommendations (tab. 6). The intake of soy, canola or walnut oil is recommended due to 
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Tab. 6: D-A-CH recommendations for fat intake (47) 
 
30 % of total energy intake 
Saturated fatty acids  <10 % of total energy intake 
Monounsaturated fatty acids  >10 % of total energy intake 
Polyunsaturated fatty acids 7-10 % of total energy intake 
Linoleic acid (omega-6)   2.0 % of total energy intake 
Linolenic acid (omega-3)   0.7 % of total energy intake 
 
Carbohydrate intake 
Foods rich in carbohydrates are mainly the special low-protein products and sugar. The 
assortment of fruits and vegetables eaten depends on the Phe tolerance and can be included 
in the menu by calculation or estimation. The recommendation of 30 g roughages per day 
often cannot be met due to a restriction of food assortment. 
Patients with loosened dietary restrictions, i.e. only mild restrictions of protein intake and 
without the intake of an amino acid mixture, have to pay attention to ingest an adequate 
amount of minerals, vitamins and trace elements. Supplementation might become necessary 
(e.g. with the product Seravit). Patients with only minor restriction of protein intake may still 
require supplementation of protein intake by amino acid mixtures in special situations with 
high rates of protein synthesis, e.g. competitive sports or bodybuilding. 
 
Possible critical nutrients 
Iron, selenium, zinc, vitamins B and omega-3 fatty acids are possible critical nutrients in 
patients with PKU so that the calculation of micro nutrients at larger time intervals is 
recommended by food records (129). 
 
Therapy monitoring 
The following table shows the frequency of laboratory and clinical investigations in adult 
PKU-patients recommended by the Working Group on Pediatric Metabolic Disorders (11): 
 
Tab. 7: Frequency of laboratory and clinical investigations (176) 
 
Age Laboratory investigation Clinical investigation 
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Treatment of an elevated Phe-level 
If Phe-levels are elevated the intake of natural protein has to be reduced, while still providing 
a sufficient energy supply. An increase of the dosage of the amino acid mixture might 
become necessary. With a reduction of the Phe-intake by 50 % a decrease of Phe-levels of 4 
mg/dl can be expected. In such circumstances more frequent testing of lab parameters is 
often indicated. Additionally, an analysis of the causes of the increase in Phe-levels should 
be carried out to prevent a further increase of the serum Phe-levels. 
 
Possible causes for an elevated Phe-level include: 
 Increased intake of protein 
 Disease (influenza, fever, vomiting, diarrhea) 
 Insufficient energy intake 
 Weight loss (catabolic condition, break down of protein) 
 Stop of taking the amino acid mixture (insufficient protein supply) 
 
Special situations 
For traveling a sufficient amount of the amino acid mixture and other low-protein products 
should be packed to supply for the duration of the trip. Furthermore certificates for the amino 
acid mixture should be taken along to provide to customs officials, depending on the country 
visited. In many hotels there are breakfast buffets including selections of salads, vegetables, 
vegetarian dishes and fruits. If a restaurant visit is planned, Phe may be “saved” during the 
day to enlarge the choices. Often only minor alterations in the choice of side dishes or types 
of vegetables eaten are sufficient to create a meal with a lower content of Phe. A further 
possibility for adults is a mild loosening of the diet during holidays but, depending on its 
extent, the amino acid mixture should be taken regularly. 
 
Further possibilities of treatment 
In addition to the diet, there are the following further possibilities of treating patients with 
phenylketonuria: large neutral amino acids (LNAAs), phenylalanine ammonia-lyase (PAL) 
and somatic gene therapy. 
Phe as well as other LNAAs are transported across the blood-brain barrier by means of an L-
type amino acid carrier. High Phe-levels reduce the brain uptake of other LNAAs. Some 
LNAAs such as tyrosine and tryptophan are precursors of neurotransmitters, and it has been 
suggested that impaired neurotransmitter synthesis would be an additional factor contributing 
to the cognitive dysfunction observed in PKU. Thus a new therapeutic strategy particularly for 
adult patients is based on moderate protein restriction combined with supplementation of 
LNAAs except for Phe. It has not become clear so far, whether supplementation of LNAAs is 
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effective in patients with classical PKU or not. An elevation of tyrosine levels in the brain was 
previously demonstrated (9;97;118;123), but further studies are needed. 
Another therapeutic resource currently under development for PKU treatment is the oral 
administration of phenylalanine ammonia-lyase (PAL). This enzyme acts by degrading Phe 
into ammonia and non-toxic trans-cinnamate, preventing the absorption of Phe. Thus Phe 
can be degraded in the intestinal lumen. The main problems associated with this approach is 
PAL inactivation by digestive enzymes. Adequate dosages are yet to be determined. So far, 
PAL has only been tested as a purified enzyme in humans, which has the disadvantage of 
high production costs. Organisms secreting genetically modified PAL offer better economical 
viability but have been tested only in animal models. Thus, preliminary results appear to be 
promising, but further clinical studies are still needed. 
The ideal treatment of genetic diseases would consist of taking a normal copy of the 
defective gene and transferring it into the patient’s cells, which should express it. Research 
based on conventional somatic gene therapy has seen some success (38;71;90;138), but the 
lack of truly appropriate vectors for gene transfer still needs to be overcome. 
 
Maternal PKU 
In contrast to determining an individual’s target therapy in the heterogeneous group of adults, 
there are defined target values for the period of preconception and pregnancy.  The serum 
Phe-level should lie between 2-6 mg/dl (120-360 µmol/l) and the tyrosine level between 0.8-
1.8 mg/dl (45-100 µmol/l) (174). The amino acid mixture already contains tyrosine but should 
be prescribed additionally in case of persistent low serum levels. The target level of the 
therapy should be kept during the entire pregnancy to avoid intrauterine damage to the 
embryo and fetus due to elevated Phe-levels. Good Phe-levels should already be obtained in 




Pregnant women with PKU should get more than 75 g of protein per day (table 8). For 
overweight pregnant women no recommendations exist. 
 
Tab. 8: Recommended protein intake during pregnancy (174) 
 
I. trimenon       1.1 g / kg body weight* 
II.- III. trimenon 1.3-1.4 g / kg body weight* 
*natural protein and amino acid mixture 
 
Phe tolerance 
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The individual’s Phe tolerance should be tested. Normally it lies between 200-600 mg/day 
and increases enormously after the 20th week of pregnancy because of elevated protein 
requirements due to fetal and uterine growth (approx. 10-5 mg/kg). Furthermore, the activity 
of PAH increases in the fetal liver (132;174). 
 
Energy intake 
In the first instance, an adequate weight gain during the entire pregnancy and especially 
during the first trimester is important to avoid catabolism with elevation of blood Phe-level 
(tab. 9). This can be measured by the BMI. Table 10 gives an overview of the recommended 
weight gain during pregnancy. 
 
Tab. 9: Recommended energy intake (11) 
 
I. trimenon 30-35 kcal / kg body weight 
II.- III. trimenon 35-40 kcal / kg body weight 
 
In some cases and especially at the beginning of the pregnancy, additional preparations for 
enhancing energy intake can become necessary to temporarily obtain an adequate weight 
gain (e.g. by use of maltodextrine). Due to long-lasting insufficient calorie intake caused by 
e.g. emesis or disease, a catabolic metabolism may develop and result in degradation of 
endogenous body proteins, with a resulting elevation of serum Phe-levels, against which an 
increased energy intake should be employed. 
 
Tab. 10: Protocol of the American MPKUC-Study (117)  
 








I. trimenon 2.3 kg 1.6 kg 0.9 kg 
II.+ III. trimenon 0.5 kg/week 0.5 kg/week 0.3 kg/week 




The fat intake should ideally be 30-35 % of the total energy intake following the D-A-CH 
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Minerals, vitamins and trace elements 
The amino acid mixture is enriched with minerals, vitamins and trace elements so that a 
substitution of iron, iodine, vitamin B12 and selenium is not necessary but depends on 
dosage and the kind of supplement. 
In patients with HPA, lower quantities of the amino acid mixture are provided, thus 
supplementation on folic acid and iodine should be provided. 
A relative lack of selenium, carnitine and vitamin B12 was observed in adolescents after 
long-term treatment but no firm recommendations for their supplementation can be given. 
 
Therapy management 
The regular monitoring (twice a week) of serum Phe and tyrosine levels is of special 
importance so that the Phe-intake can be adapted following Phe tolerance. At baseline and 
in the 12th, 24th, and 36th week of pregnancy there should be a full amino acid profile and a 
major lab control. A weekly control of the body weight is useful. Continuous outpatient care is 
required due to regular lab controls and the monitoring and adaptation of the diet. In 
between, telephone contact usually suffices to give short therapy and practical advices. In 
the preconception period and during pregnancy an ambulant care of the patients is 
necessary. If there are extremely high values or patients who are hard to lead, an in-patient 
treatment can become necessary next to social indications. The treating gynecologist should 
be provided with general information, information about the treatment and laboratory test 
results.  
1.7 Aims of the study  
We aimed to study the quality of life and the nutritional, immune, cardiovascular, metabolic 
and neurological status of adult PKU-patients without interventions. 
  
Hypotheses to be tested: 
 Due to the diet, adult PKU-patients develop nutrient deficiencies (LCPUFA, minerals, 
trace elements and vitamins). 
 An unbalanced diet in PKU-patients has implications for their immune system and 
cardiovascular risk profile. 
 In comparison with healthy subjects of the same age, adult PKU-patients show distinct 
neurological abnormalities. 
Materials and Methods  18 
2 Materials and Methods 
2.1 Subjects and study design 
Thirty-three adult PKU-patients attending the Department of Metabolic Diseases of the Dr 
von Hauner Children’s Hospital, University of Munich, as well as 33 healthy subjects of the 
same gender and age took part in the investigations. The control persons received financial 
compensation for their participation in the study. 
Ethical permission of the study was obtained from the Bavarian Board of Physicians in 
February 2005. The study was conducted between June 2005 and July 2006.  
 
Eligible were persons who fulfilled the following inclusion criteria: 
 PKU-patients had to have a confirmed clinical diagnosis of PKU 
 Age ≥ 25 years  
 Written informed consent 
 Controls had to be omnivores  
 Controls should not suffer from metabolic, cardiovascular or psychological disorders 
 Controls should not be on drugs influencing the lipometabolism during the last 3 months 
2.2 Study procedure 
The adult PKU-patients from the local PKU database and the control group were contacted. 
If they indicated consent, an appointment for the tests was made and informations about the 
study as well as the three-day dietary protocol and the leaflet with the site plan were sent to 
them (see 7.3.). 
The duration of all investigations totaled approximately 4 hours for each patient, but only 2 
hours for the controls since they did not need VEP, MRI, or blood withdrawal. 
 
At the appointed day, the following schedule took place at the Dr von Hauner Children’s 
hospital: 
 Reception of the study subjects 
 Oral study explanation 
 Receiving 3-day dietary protocol and MRI 
 Clinical investigation 
 Standardized interview 
 Atopic disease questionnaire 
 Drawing and preservation of venous blood 
 Visual Evoked Potential (VEP) 
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 Motor Performance Task (MPT) 
 Auditory Verbal Learning Test (AVLT) 
 d2 attention test (d2) 
 Number Combination Test (NCT) 
 Color Word Interference Test (CWIT) 
 Handing out of the accelerometer 
2.2.1 Clinical investigation 
First, anthropometrical measurements were carried out followed by standardized medical 
procedures. For weight measurement, the subject stood over the center of the scale platform 
(Seca 702, Vogel & Halke, Hamburg) with the body weight evenly distributed between both 
feet. Weight was recorded to the nearest 100 g, and 1 kg was subtracted for the light clothes 
that were worn. Their height was measured using the stadiometer of the same scale. The 
subject was wearing socks so that positioning of the body could be seen and its weight was 
distributed evenly on both feet with the heels placed together. The head was in upright 
position and the moveable headboard was brought onto the most superior point on the head. 
The height was recorded to the nearest 0.1 cm. The body mass index (BMI) was calculated 
by dividing the measured body weight in kilograms by the square of body height in meters.  
Blood pressure and heart rate were determined using a digital sphygmanometer (Dinamap 
pro series 100 V2, GE Medical Systems, Milwaukee) wrapping the cuff round the upper right 
arm, locating the brachial pulse medial to the biceps tendon and the arrow on the cuff over 
the brachial artery. The subject was sitting comfortably with the right arm at approximately 
heart level. After resting for five minutes, blood pressure was measured automatically by the 
digital sphygmanometer. 
Skin disturbances and symptoms of atopic disease were investigated by physical 
examination and filling out a special questionnaire. 
Furthermore, subjects were asked for personal data, education, dietetic treatment, 
contentedness with health and subjective health feelings by using a standardized interview. 
This applied interview is a revision of a structured questionnaire established at the University 
Children’s Hospital Münster some years ago. The first part consists of questions about 
personal data, education, health, diet and the family of the patient, whereas the second part 
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2.2.2 Neurophysiologic testings 
Visual evoked potential (VEP) 
Visual evoked potentials are normally used to evaluate optic neuritis, optic disorders, retinal 
disorders and demyelineating diseases such as multiple sclerosis. VEPs were measured in 
all patients and controls from the eye to the brain for detection of any differences of the 
nervous system function between both groups, and furthermore whether any reduction 
occurs in nerve conduction velocity in patients with PKU.  
For measurement, a Medtronic Keypoint workstation (Medtronic Functional Diagnostics A/S, 
Skovlunde, Denmark) with the manufacture’s computer software was used. The VEPs were 
performed with a 1.5 Hz alternating black-and-white checkerboard pattern (12 x 16 squares, 
check size 70’) displayed on a 17-inch monochrome computer monitor in a darkened, quiet 
room. The subjects were seated comfortably 100 cm from the screen (fig. 2) wearing optical 
correction if needed, and the untested eye was patched focusing on a small spot of red light 
in the center of the computer screen. The recording electrode was placed at the Oz position 
of the 10-20 International System; the reference electrode was placed at the Fz position and 
the ground electrode was placed above the right eyebrow. All electrodes were fixed by 
contact paste and electrode impedence was kept below 5 kΩ. Signals were filtered with a 
bandwidth of 1 to 100 Hz. VEP recordings were performed twice with at least 50 stimulations 
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Motor Performance Task (MPT) 
The motor performance task was applied to measure fine motor abilities through static and 
dynamic tasks for finger, hand and arm movement. It is a battery of tests developed by 
Schoppe based on Fleishman's factor-analytic examinations of fine motor abilities. The MPT 
analyzes six factors of fine motor abilities: aiming of motion, hand unrest (tremor), precision 
of arm-hand movements, manual dexterity and finger dexterity, rate of arm and hand 
movements, as well as wrist-finger speed. The dimensions of the work panel are 
300x300x15mm and it is covered with boreholes, grooves and contact surfaces (fig. 3). A 
pen is attached to each edge (left and right). The right pen is black, the left one red. The 
following tasks have to be carried out on the work panel: steadiness (holding pen 32 sec 
vertically into hole without touching sides), line tracking (following line without touching 
sides), aiming (rapid hitting of all points within a line), inserting pins (rapid inserting of pins 
into holes of a line) and tapping (tapping 32 sec onto small plate as often as possible). The 
result table shows speed and/or accuracy measurements calculated for the right and left 
hand for one-handed and two-handed administrations. The testing time is about 15 to 20 










Fig. 3: Test arrangement for measuring fine motor skills (motor performance task) 
2.2.3 Neurostructural testing 
 
Magnetic resonance imaging (MRI) 
Magnetic resonance imaging of the cranium was performed in PKU-patients due to a 
standardized protocol (T2 weighted FLAIR sequence using a 1 or 1.5 Tesla MR scanner). As 
shown in other studies, the aim was to discover deep white matter alterations that correlated 
to the most recent blood Phe concentrations, as well as to brain Phe concentrations 
measured by magnetic resonance spectroscopy. The MRIs were performed by practicing 
radiologists. The generally symmetrical white matter abnormalities were graded from T2-
weighted images according to their extension in six anatomical areas (frontal, temporal, 
parietal and occipital lobes; cerebellum; brainstem). This score was calculated as follows:  
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1 point for lesions restricted to deep white matter of the cerebral lobes, 2 points for 
abnormalities extending to subcortical white matter involving the region of the arcuate fibers 
and 2 additional points for changes in the brainstem or cerebellum. Therefore MRI grades 
could ranged between zero (normal MRI) and 12 (involving the subcortical white matter in all 
cerebral lobes as well as the brainstem and cerebellum) (141). 
2.2.4 Neuropsychological testings 
 
Auditory Verbal Learning Test (AVLT) 
The Auditory Verbal Learning Test (Lezak 1995, Rey 1941) consists of two lists of 15 words 
each (lists A and B), arranged in a fixed order. The examiner reads list A aloud and 
immediately thereafter the patients must recall as many words as they can (A1). The 
examiner then repeats the same procedure four more times (A2 to A5). In a normal 
performance the patient recalls an increasing number of words throughout the essays, which 
is usually referred to as the learning curve. List B is read aloud only once, after the fifth 
recollection of List A (A5) and the patient receives the same previous instructions. List B is 
actually a distracter to prevent rehearsal of the material held in short-term memory. The 
examiner then asks the patient to recall List A again without reading it (immediate free recall, 
A6). After 15 minutes, another free recall is requested (delayed free recall, A7). Recognition, 
the last stage of the test, consists of a list of 30 words read aloud by the examiner and the 
patient must indicate which words were on List A. 
 
d2 Attention Test 
The d2 attention test established by Brickenkamp in 1994 was used to estimate the 
neuropsychology of individual’s attention and concentration. The test was originally 
developed to measure driver aptitude and skill. This test has become one of the most widely 
used measures of attention, particularly visual attention, throughout Europe. Areas of usage 
include transport and pharmaceutical sectors, as well as sports, educational and clinical 
psychology. The test consists of a single 'recording blank'. The front page of this is reserved 
for recording the respondent's personal data and performance results. There is also a 
practice example so that the respondent can become acquainted with the task. On the 
reverse side is the standardized test form in a landscape layout of 14 test lines with 47 
characters in each line. Each character consists of the letter d or p marked with one, two, 
three, or four small dashes (see 7.3.). The respondent is required to scan the lines and cross 
out all occurrences of the letter d with two dashes while ignoring all other characters. Two 
scoring keys are provided; one for identifying errors of omission (missing characters that 
should have been crossed out) and one for identifying errors of commission (crossing out 
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characters that should not have been crossed out). The reliability of the test is high. 
Extensive norms according to age, sex and education are included. The test-time is about 8 
minutes including instructions and it can be applied in patients between 9 and 60 years of 
age. 
 
Number Combination Test (NCT) 
The number combination test (Oswald and Roth, 1997) is a trail-making test mainly used to 
diagnose brain performance disturbances by measuring the basal and genetically 
determined cognitive performance velocity, which is related to the so-called perceptual 
speed. The test is a pencil and paper test consisting of the numbers 1 to 90, which subjects 
have to join chronologically as fast as possible (see 7.3.). The time taken to complete this 
task is measured by a stopwatch and used for data analysis. Test scores indicate speed of 
information processing and furthermore the IQ. The test can be done in 5-10 minutes and 
can be applied in patients between 8 and 60 years of age. 
 
Color-Word Interference Test (CWIT) 
The so-called Stroop test established in 1935 examines the mental vitality and flexibility and 
the color-word interference respectively. It is based on the assumption that reading speed of 
a color-word is slower, if the word is written in a differently colored font. There is always a 
delay in naming the color of this word, if color and color-word do not match. It is a fair and 
highly reliable assessment of the ability to inhibit overlearned answers to simple tasks used 
to detect impairments of the reading speed or color recognition due to interfering information. 
There are two experimental conditions without interfering influences: determination of the 
reading speed of a colored word alone and determination of the color naming speed. This 
initial performance can be used as a baseline and can be related to the two so-called 
interference conditions. The reading speed of the color word decreases if the word is written 
in a different color and naming the color is made more difficult since the color-word and the 
color in which it was written do not match. Therefore, the task is to first read three columns of 
words written in black and then the color-words (red, green, yellow, blue), then say the color 
of 3 columns with color-strokes, and finally read 3 columns with color-words written in 
different color than the word says. This task has to be done three-times. The main variables 
are reading interference (the difference of the reaction time medians of naming interference 
condition and naming baseline). Additionally, the following variables are issued for each 
individual test part: median reaction time and number of incorrect answers. The test protocol 
shows each single reaction of the respondent with reaction time of the respondent and 
evaluation of the reaction. The testing time is about 15 minutes. 
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2.2.5 Nutritional, cardiovascular and metabolic status 
 
The nutritional status of the PKU-patients was determined by recording of dietary intakes 
using self-reported three-day estimated dietary protocols (see 7.3.). Additionally, analyses of 
blood samples were performed (see 2.2.5). Thus, the content of those nutrients as minerals 
and vitamins were measured (see 3.2), which often are low in patients following a low-protein 
diet. Values from the food record were compared with the D-A-CH recommendations (47) 
and blood level ranges which were given from the laboratory. To determine cardiovascular 
risk, homocysteine and the lipoprotein profiles (TC, LDL, HDL, VLDL, TG, Apo A, Apo B, Lp 
(a)) were measured in blood. Furthermore, all patients and controls received accelerometers 
recording of an array of physiological data. 
 
3-day dietary protocol 
As dietary protocols, we used a modified form of the “Freiburger Ernährungsprotokoll” adding 
special low-protein products often consumed by PKU-patients. The protocol consists of 
different food groups with typical foods. The patients estimated the quantities of consumed 
foods and beverages using common household measures according to provided instructions 
(slice, piece, teaspoon, tablespoon, cup, mug etc.). They were asked to make precise 
descriptions e.g. the content of fat. Their food consumption was recorded over three 
consecutive days covering two weekdays and one day at the weekend. For calculation of the 
nutrient intake, recorded dietary intakes were entered into the software PRODI, version 4.5 
LE 2003 (NutriScience GmbH, Freiburg, Germany) based on the German Nutrient Data Base 
BLS, version II.3 (BgVV, Berlin, Germany). The results were compared with recommended 
ranges of the German Nutrition Society (47). 
 
Sense wear 
All patients and controls were asked to wear for 3 days a SenseWear armband (SenseWear 
Pro 2, BodyMedia, Pittsburgh, USA) acting as a wearable metabolic monitor collecting and 
analyzing physical activity level and lifestyle information in a free-living context. The Sense 
Wear armband continuously records an array of physiological data, which is analyzed by 
special software (InnerView Professional, version 5.0, BodyMedia, Pittsburgh, USA). The 
resulting information can be organized into graphs and reports that clearly display energy 
expenditure, duration and level of physical activity level, number of steps taken, sleep/wake 
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2.2.6 Analysis of blood samples 
 
Venous blood samples (18 ml) were collected from an antecubital vein of the forearm into 
serum tubes or EDTA containing tubes (Sarstedt, Nümbrecht, Germany) in sitting or lying 
position of the subject. Tubes were centrifuged at 4 °C (1300 g for 7 minutes) immediately 
after blood withdrawal and the obtained serum and plasma were aliquoted into plastic 
storage vials. Plasma samples for vitamin A and E, as well as for fatty acid analysis were 
stored at -80°C until analysis, whereas the aliquots for all other analyses were sent to the 
laboratories by using cooling elements immediately after centrifugation. 
The venous blood samples were analyzed for: 
 Homocysteine and lipoprotein profile (TC, LDL, HDL, VLDL, TG, Apo A, Apo B, Lp (a)) 
 Calcium, magnesium, zinc, copper, selenium and ferritin 
 Vitamin A and E, vitamin B12, 25(OH) vitamin D3 and folic acid 
 Fatty acid composition of plasma phospholipids 
 IgG, IgA, IgM and total IgE 
 Specific IgE, if total IgE was elevated 
 
Vitamin A and E, fatty acids and selenium, as well as specific IgE were analyzed during up to 
12 months of storage whereas all other biochemical parameters were analyzed at the day of 
blood drawing. Selenium was analyzed in the laboratories of the National Research Centre 
for Environment and Health (GSF). All other biochemical parameters were determined using 
established routine methods in the clinical chemistry laboratories of our hospital at Munich.  
Phe was examined from dried blood spots on filter paper, which all patients three times 
(every four weeks) sent to the laboratory of Becker, Olgemöller & Colleagues in Munich.  
All used methods, as well as the analytical equipment are shown in the following tables: 
 
Tab. 11: Analyses of biochemical parameters 
 
Parameter Test kit / method Analytical equipment 
Phenylalanine Fingerhut et al. (55) API 365 ESI-MS/MS (PE-SCIEX GmbH, Darmstadt) 
Total cholesterol 
CHOD-PAP-method                     
(Greiner Diagnostic GmbH, 
Bahlingen) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
Triglycerides 
GPO-PAP-method                        
(Greiner Diagnostic GmbH, 
Bahlingen) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
LDL cholesterol Enzymatic test LDL-C (Wako Chemicals GmbH, Neuss) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
HDL cholesterol 
Immune inhibitation method 
HDL-C (Wako Chemicals 
GmbH, Neuss) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
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VLDL cholesterol Calculated Hitachi 911 (Roche Diagnostics GmbH, Mannheim) 
Apo A1 APO A-I ver.2 (Roche Diagnostics GmbH, Mannheim) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
Apo B APO B vers.2 (Roche Diagnostics GmbH, Mannheim) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
Lp(a) Lp (a)-HA (Wako Chemicals GmbH, Neuss) 
Hitachi 911 (Roche Diagnostics GmbH, 
Mannheim) 
Homocysteine Advia Centaur Assay (Bayer HealthCare, Leverkusen) 
Advia Centaur Reagents (Bayer 
HealthCare, Leverkusen) 
Calcium Photometric Colour Test    (Olympus, Hamburg) AU 2700 (Olympus, Hamburg) 
Magnesium Photometric Colour Test    (Olympus, Hamburg) AU 2700 (Olympus, Hamburg) 
Iron Photometric Colour Test    (Olympus, Hamburg) AU 2700 (Olympus, Hamburg) 





AAS 3110 (PerkinElmer, Darmstadt) 





AAS 3110 (PerkinElmer, Darmstadt) 
Selenium graphite-furnace atomic absorption spectrometry GFAAS  (PerkinElmer, Darmstadt) 
Folate Cobas Vitamin B 12 (Roche Diagnostics GmbH, Mannheim) 
Elecsys2010 (Roche Diagnostics GmbH, 
Mannheim) 
Vitamin B12 Cobas Folate II (Roche Diagnostics GmbH, Mannheim) 
Elecsys2010 (Roche Diagnostics GmbH, 
Mannheim) 
25(OH) vit. D3 RIA Berthold LB 2111 
IgG Turbidimetric End Point Method (Olympus, Hamburg) AU 2700 (Olympus, Hamburg) 
IgA Turbidimetric End Point Method (Olympus, Hamburg) AU 2700 (Olympus, Hamburg) 
IgM Turbidimetric End Point Method (Olympus, Hamburg) AU 2700 (Olympus, Hamburg) 
IgE N Latex IgE mono  (Dade Behring, Marburg) (Dade Behring, Marburg) 
Cytokines 
Immunoassay Elisa 
(R&D Systems Inc., 
Minneapolis) 
Elisa reader & components 
(R&D Systems Inc., Minneapolis) 
Elisa tests 
Phleum pratense Immunoassay Elisa  (Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
Secale cereale Immunoassay Elisa  (Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
Quercus alba Immunoassay Elisa  (Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
Artemisia vulgaris Immunoassay Elisa  Allercoat 6 Microtiter  
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(Euroimmun AG, Lübeck) (Euroimmun AG, Lübeck) 
Cat dander Immunoassay Elisa  (Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
Dog dander Immunoassay Elisa  (Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
Cladosporium 
herbarum 
Immunoassay Elisa  
(Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
Dermatophagoides 
pteronyssinus 
Immunoassay Elisa  
(Euroimmun AG, Lübeck) 
Allercoat 6 Microtiter  
(Euroimmun AG, Lübeck) 
 
 
For analysis of the fatty acid profile in plasma phospholipids, as well as vitamin A and E, in 
our laboratory the following chemicals, consumables and equipment were used: 
 
Tab. 12: List of used chemicals for fatty acid analysis 
 
Chemicals Source Quality 
2.7 Dichlorfluorescein Merck, Darmstadt for analysis 
2-Propanol Merck, Darmstadt for analysis 
Acetic acid Merck, Darmstadt for analysis 
Butylated hydroxytoluene (BHT) Fluka, Neu-Ulm ≥ 99% GC 
Chloroform Merck, Darmstadt extra pure 
Diisopropyl ether Merck, Darmstadt for analysis 
Ethanol  Baker, Deventer, Holland absolute 
Methanol Merck, Darmstadt for analysis 
Methanolic HCl (3N) Supelco, Bellefonte, USA for analysis 
n-Heptane Merck, Darmstadt for analysis 
n-Hexane Merck, Darmstadt for analysis 
Sodium carbonate Merck, Darmstadt anhydrous for analysis 
Sodium hydrogen carbonate Merck, Darmstadt for analysis 
Sodium sulfate Merck, Darmstadt for analysis 
 
 
Tab. 13: List of used chemicals for vitamin A and E analysis 
 
Chemicals Source Quality 
Acetonitrile  Merck, Darmstadt LiChrosolv 
Ammonium acetate  Merck, Darmstadt Fractopur 
Butylated hydroxytoluene (BHT) Fluka, Neu-Ulm ≥ 99% GC 
Chloroform Merck, Darmstadt LiChrosolv 
Distilled water Braun, Melsungen ad iniectabilia 
Ethanol  Baker, Deventer, Holland absolute 
Methanol  Merck, Darmstadt LiChrosolv 
n-Hexane Merck, Darmstadt LiChrosolv 
Tetrahydrofuran  Merck, Darmstadt LiChrosolv 
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Tab. 14: List of consumables for fatty acid analysis 
 
Consumables Source 
Brown glass bottle R1, G4 CS-Chromatographie Service, Langerwehe 
Crimp cap R11-1.0 CS-Chromatographie Service, Langerwehe 
Micro inlay G30/6 CS-Chromatographie Service, Langerwehe 
Pipette tip CP100 Gilson, Villiers-le-Bel, France 
Pipette tip 50-1000 µl, 500-2500 µl Eppendorf, Hamburg 
Pipette tip 10-100 µl, 100-1000 µl Greiner bio-one, Frickenhausen 
Screw cap G13 CS-Chromatographie Service, Langerwehe 
Sealing disc G13 CS-Chromatographie Service, Langerwehe 
TLC plate, silica gel 60 Macherey-Nagel, Düren 
 
 
Tab. 15: List of consumables for vitamin A and E analysis 
 
Consumables Source 
Brown glass bottle G1, G4 CS-Chromatographie Service, Langerwehe 
Micro inlay G30/5 CS-Chromatographie Service, Langerwehe 
Pipette tip CP100, CP250, CP1000 Gilson, Villiers-le-Bel, France 
Pipette tip 50-1000 µl Eppendorf, Hamburg 
Pipette tip 10-100 µl, 100-1000 µl Greiner bio-one, Frickenhausen 
Screw cap G8-L, G13 CS-Chromatographie Service, Langerwehe 
Sealing disc G13 CS-Chromatographie Service, Langerwehe 
Silicone-PTFE septum Merck, Darmstadt 
Silicone-PTFE septum, slitted Merck, Darmstadt 
 
 
Tab. 16: List of equipment for fatty acid analysis 
 
Equipment Source 
Analytical balance type 1801 Sartorius, Göttingen 
Centrifuge Beckman GPR Beckman, Bucks, UK 
Centrifuge Hettich Universal 1200 Hettich, Tuttlingen 
Centrifuge Universal 30 F Hettich, Tuttlingen 
Centrifuge glass tube, conical angle 30° (12 ml) Schott Duran, Mainz 
Funnel D35m Duran Schott, Mainz 
Metal block thermostat type 2102 Bachofer, Reutlingen 
Nitrogen evaporation system type 5000 6101 Bachofer, Reutlingen 
Pipette 10-100 µl, 100-1000 µl (Transferpette) Brand, Wertheim 
Pipette 50-250 µl, 500-2500 µl Eppendorf, Hamburg 
Pipette Microman M100 Gilson, Villiers-le-Bel, France 
Solvent chamber for thin layer chromatography Desaga, Heidelberg 
Ultraviolet lamp Benda, Wiesloch 
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Vortexer VF2 IKA-Labortechnik, Heitersheim 
Gas chromatography  
Autosampler A200S Carlo Erba Instruments, Milan, Italy 
Capillary column, BPX-70 (60 m x 0.32 mm)  SGE, Weiterstadt 
Controller HP 7673 Hewlett Packard, Böblingen 
Gas chromatograph HP 5890 Series II Hewlett Packard, Böblingen 
Integrator HP 3396 Series II Hewlett Packard, Böblingen 
Software EZChromEliteV2.61 Scientific Software, Pleasanton, USA 
 
 
Tab. 17: List of equipment for vitamin A and E analysis 
 
Equipment Source 
Analytical balance type 1801 Sartorius, Göttingen 
Brown glass bottle (25 ml) Schott Duran, Mainz 
Centrifuge Universal 30 F Hettich, Tuttlingen 
Nitrogen evaporation system type 5000 6101 Bachofer, Reutlingen 
Pipette 10-100 µl, 100-1000µl (Transferpette) Brand, Wertheim 
Pipette 50-250µl Eppendorf, Hamburg 
Pipette Microman M100, M250, M1000 Gilson, Villiers-le-Bel, France 
Quartz cuvette SUPRASIL Hellma, Müllheim 
Ultrasonic bath Sonorex Super RK 102 H Bandelein, Berlin 
UV/Vis Spectrophotometer Cary 1E Varian, Darmstadt 
Volumetric flask 10 ml, 25 ml Schott Duran, Mainz 
Vortexer VF2 IKA-Labortechnik, Heitersheim 
HPLC chromatography  
Autosampler AS-2000 Merck Hitachi, Darmstadt 
Column, LiChroCART 250-3, LiChrospher 100, 
RP18 (5 µm) 
SGE, Weiterstadt 
Column oven STH 585 Gynkotek, Germering 
Pump L-6200 Intelligent Pump Merck Hitachi, Darmstadt 
D-2500 Chromoato-Integrator Merck Hitachi, Darmstadt 
UV/Vis detector L-4250 Merck Hitachi, Darmstadt 
 
 
Tab. 18: List of used standard substances for fatty acid analysis 
 
Standard substance Source 
Internal standard  
Cholesteryl pentadecanoic acid Sigma, Deisenhofen 
Dipentadecanoyl phosphatidylcholine Sigma, Deisenhofen 
Pentadecanoic acid Sigma, Deisenhofen 
Tripentadecanoin Sigma, Deisenhofen 
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Standards for peak identification 
GLC-85 (reference standards) Nu-Chek, Elysian, MN, USA 
14:1t Sigma, Deisenhofen 
16:1t Sigma, Deisenhofen 
18:1n-7 Sigma, Deisenhofen 
18:2tt Sigma, Deisenhofen 
18:4n-3 Sigma, Deisenhofen 
20:3n-9 Sigma, Deisenhofen 
20:5n-3 Sigma, Deisenhofen 
22:1t Sigma, Deisenhofen 
22:4n-6 Sigma, Deisenhofen 
22:5n-3 Sigma, Deisenhofen 
22:5n-6 OmegaTech, CO, USA 
24:0 Sigma, Deisenhofen 
 
Tab. 19: List of used standards and control sera for vitamin A and E analysis 
 
Standards/Control sera Source Quality 
Internal standard   
Tocol  Eisai, Tokyo, Japan for HPLC 
Standards for peak identification   
α-tocopherol Supelco, Bellefonte, PA, USA Purity 99.3% 
Retinol Merck, Darmstadt Purity >98% 
Control serum   
NIST Standard Reference Material 
968c Gaithersburg, USA  
 
2.2.6.1 Analysis of fatty acid profiles in plasma phospholipids 
Fatty acids in plasma lipid fractions were quantified using defined concentrations of 
cholesteryl pentadecanoic acid, dipentadecanoyl phosphatidylcholine, pentadecanoic acid 
and tripentadecanoin (equalled 10 µg 15:0 per 100 µl for each lipid fraction). 
 
Tab. 20: Composition of the internal standard for fatty acid analysis 
 







Cholesteryl pentadecanoic acid 611.0 2.52 50.47 
Dipentadecanoyl 
phosphatidylcholine 706.0 1.46 29.22 
Pentadecanoic acid 242.4 1.00 20.05 
Tripentadecanoin 765.3 1.05 21.06 
Materials and Methods  31 
The different amounts shown in table 20 were dissolved in 200 ml mixture of methanol and 
chloroform (35+15 by vol.) with added 2 g/l BHT, aliquoted in 4 ml brown glass bottles and 
stored at -80 °C until usage.  
For the extraction of plasma lipids according to a modified method of Kolarovic & Fourier 
(98), 100 µl internal standard and 2 ml mixture of hexane and isopropanol (3+2 by vol.) were 
added to 250 µl plasma. After 30 seconds of vortexing and 7 minutes of centrifugation (1000 
g), the hexane phase was transferred into a 4 ml brown glass vial. Thereafter, two 
extractions with 2 ml hexane were performed and the combined extracts were taken to 
dryness under a gentle stream of nitrogen.  
The lipid residue was then dissolved in a 400 µl mixture of chloroform and methanol (1+1 by 
vol.) and deposited on a thin layer chromatography plate (TLC). Phospholipids, free 
cholesterol, non-esterified fatty acids (NEFA), triglycerides and cholesterol esters were 
separated using a mixture of heptane, diisopropylether and acetic acid (60+40+3 by vol.) as 
mobile phase (36). The plate was dried and sprayed with 2.7-dichlorofluorescein (1% in 
ethanol). Bands were visualised by UV-light using an ultraviolet lamp. The fluorescending 
band with the phospholipid fraction was scraped from the TLC plate (fig. 4) and transferred 




Fig. 4: Thin layer chromatography of fatty acids in plasma  
 
Methyl esters of fatty acids (FAME) were obtained by reaction with 3M methanolic 
hydrochloric acid at 85 °C for 45 min. After neutralization by mixture of sodium carbonate, 
sodium hydrogen carbonate and sodium sulphate buffer (1+2+2 by weight), 1 ml hexane was 
added. After centrifugation at 1000 g for 4 min, the hexane layer was transferred into a 2 ml 
brown glass vial. The hexane extraction was repeated and the combined extracts were taken 
to dryness under a gentle stream of nitrogen. For storage until GC analysis at -80 °C, the 
samples were dissolved in 50 µl hexane with 2g/l BHT added.   
FAME were separated by injection of 3 µl sample into the gas chromatograph (GC). The 
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Tab. 21: Conditions of the GC for fatty acid analysis 
 
Oven temperature  
Initial temperature 130°C 
Initial time 0.50 min 
Rate 3.0°C / min 
Final temperature 150°C 
Final time 0.00 min 
Rate A 1.5°C / min 
Final temperature 180°C 
Final time 0.00 min 
Rate B 3.0°C / min 
Final temperature 210°C 
Final time 23.00 min 
Pressure  
Initial pressure 1.10 bar 
Rate 0.025 bar/min 
Final time 40.00 min 
Injector/Detector  
Injector temperature 250°C 
Detector temperature 300°C 
 
Flame ionization detector signals were evaluated using special scientific software (EZ-Chrom 
Elite version 2.6, Scientific Software, Pleasanton, USA) and identified by comparison with the 
retention times of a standard mixture run previously. The instrument was calibrated regularly 
by using a quantitative standards mixture (GLC-85, Nu-Chek, Elysian, MN, USA). 
Absolute fatty acid concentrations (mg/l) of all identified fatty acids with 14–24 carbon atoms 
were determined via comparison with peak area of the internal standard (15:0) and 
correction by accordant response factors. In plasma phospholipids, the area of the internal 
standard equaled 10 µg 15:0 / 250 µl plasma = 40 mg 15:0/l plasma.  
The fatty acid weight percentages (wt %) were calculated following this formula: 
 
Individual fatty acid (mg/l) x 100                            
Individual fatty acid (wt%) = 
Sum of all identified C14 – C24 fatty acids (mg/l)  
 
Intra-assay reproducibility was assessed by analyzing eight pool samples in the same 
analytical run, whereas inter-assay reproducibilities of the used methods were assessed by 
analyzing five pool samples during 5 weeks. 
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2.2.6.2 Analysis of vitamin A and E in plasma 
The analysis of vitamin A and E was performed according to a modified method of Schaffer 
(151) and Göbel et al. (65) using an isocratic mobile phase consisting of acetonitril, 
tetrahydrofuran, methanol and 1 % ammonium acetate (684+220+68+28 by vol.) (73). For 
avoiding the formation of explosive peroxides from tetrahydrofuran, the mobile phase was 
prepared prior to use and degassed ultrasonically. 
 
Preparation of the internal standard 
For consideration of losses during the extraction process, as well as unsteady injection 
amounts into the HPLC system, tocol was added as internal standard to plasma and 
standard samples at the beginning of the analysis. To prepare the internal standard, the 
concentrate consisting of 250 mg tocol dissolved in 100 ml ethanol/BHT (0.0625 %) was 
diluted 1:1000 to a concentration of 2.5 mg/l to get an adequate peak height in the 
chromatogram. The internal standard was frozen at -80 °C until usage. 
 
Prearrangements for calibration curves 
For preparation of standard concentrates, the amounts of retinol and α-tocopherol (tab. 22) 
were dissolved in 10 ml ethanol each. From these standard concentrates, dilutions were 
prepared as described in table 22. Standard concentrates and dilutions were stored at  
-80°C until usage. 
 
Tab. 22: Preparation of standard concentrates and dilutions 
 
Substance Standard concentrate Standard dilution 
Retinol 10 mg/10 ml ethanol  200 µl concentrate/10 ml ethanol (=0.02 g/l)
α-tocopherol 50 mg/10 ml ethanol 1000 µl concentrate/10 ml ethanol  (=0.5 g/l)
 
Preparation of standard curves for vitamin A and E 
For preparation of new standard curves, the standard dilutions were defrosted and their 
absorbance was measured on a spectrophotometer at 325 nm for retinol and at 292 nm for 
α-tocopherol (tab. 23). Lambert-Beer Law was used to determine the exact concentration (c) 
from absorbance (A) (A1%1cm, extinction coefficient of a compound at a certain wave length;  
d, thickness of cuvette). 
 
Used formula:                 A = A1%1cm * c (g/dl) * d (cm) 
Calculation of the concentration: c (g/dl) = A / [A1%1cm * d (cm)] 
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Tab. 23: Extinction coefficients for retinol and α-tocopherol 
 






Retinol 286.5 325 1780 (151) 
α-tocopherol 430.7 292 75.8 (151) 
 
Based on the photometrically determined concentrations, separate stock standards (which 
equal the highest concentrated standard of the standard curve) were obtained for each 
vitamin from standard dilutions. According to plasma levels in healthy adults, the following 
concentrations were chosen as the highest concentrated standards. 
Retinol               ∼1.0 mg/l 
α-tocopherol    ∼20.0 mg/l 
 
Exact concentrations of stock standards for retinol and alpha-tocopherol were determined 
photometrically as described above. For preparation of the 7-point calibration curve, the 
following volumes of the internal standard and each stock standard were pipetted into brown 
bottles:  
 
Tab. 24: Preparation of the seven standard dilutions for the calibration curves  
 
 Std.7 Std.6 Std.5 Std.4 Std.3 Std.2 Std.1 
Tocol (ISTD) 250 µl 250 µl 250 µl 250 µl 250 µl 250 µl 250 µl 
Retinol 250 µl 210 µl 170 µl 130 µl 90 µl 50 µl 10 µl 
α-tocopherol 250 µl 210 µl 170 µl 130 µl 90 µl 50 µl 10 µl 
 
The concentrations of standards 1-7 were calculated according to their dilution factors as 
shown in the example for the seven standard dilutions for retinol and α-tocopherol calibration 
curves (mg/l): 
 
Tab. 25: Calculation of the concentrations of the seven standard dilutions 
 
 Std. 7  Std. 6  Std. 5  Std. 4  Std. 3  Std. 2  Std.1  
Dilution factor x1 x0.84 x0.68 x0.52 x0.36 x0.2 x0.04 
Retinol 1.00* 0.84 0.68 0.52 0.36 0.20 0.04 
α-tocopherol 20.0* 16.8 13.6 10.4 7.2 4.0 0.8 
* determined photometrically (Lambert-Beer-Law), equals stock standard concentration 
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These seven standards were dried under a gentle stream of nitrogen. The dried extract was 
redissolved in 100 µl mobile phase, shaken mechanically for 10 min and transferred into 
microvials. For UV-Vis detection, 20 µl were injected into the HPLC system with an isocratic 
flow rate of 0.65 ml/min.  
A 7-point standard curve was constructed for retinol and α-tocopherol using the software 
Microsoft Excel 97 SR-2 (Microsoft GmbH, Unterschleißheim) by plotting vitamin 
concentrations (tab. 24) against the peak-area ratios (vitamin/ IS, x-axis) (fig. A1). 




Tab. 26: Program of the UV-Vis detector 
 
Time (min) Wave length (nm) Detection of 
0 325 Retinol 
4 292 α-tocopherol 
 
Extraction of plasma samples 
For protein precipitation, 250 µl plasma, 250 µl internal standard and 500 µl ethanol/BHT 
(62.5 mg/dl) were pipetted into a 4 ml brown glass vial and vortexed for 15 seconds. Then, 
two extraction steps followed using 1 ml Hexan/BHT (5 mg/dl) and one further extraction step 
using 1 ml Hexan. After every extraction, the samples were vortexed for 30 sec each and 
centrifuged for 5 min (2.300 U/min). Thereafter, vials were placed on ice for 5 min. The upper 
phases were transferred into a 1.5 ml brown glass bottle and taken to dryness under a gentle 
stream of nitrogen. The dried extract was redissolved in 100 µl mobile phase, shaken 
mechanically for 10 min and transferred into microvials. For UV-Vis detection, 20 µl were 
injected into the HPLC system with an isocratic flow rate of 0.65 ml/min. The program of the 
UV-Vis detector is shown in table 26. Detector signals were evaluated with an automatic 
integrator (Chromato-Integrator D-2500, Merck-Hitachi, Darmstadt) and identified by 
comparison with the retention times of a standard mixture run previously (fig. 5).  
For calculation of the vitamin concentrations, peak-area ratios (vitamin/ IS) were computed 
for retinol and α-tocopherol. The appropriate concentrations were calculated using the 
equations of the standard curves (see 7.2, fig. A1).  
Intra-assay reproducibility was assessed by analyzing six pool samples in the same 
analytical run, whereas inter-assay reproducibilities of the used methods were assessed by 
analyzing nine pool samples during one week. 
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Fig. 5: Chromatogram of a standard mixture using UV-Vis detection* 
 
2.3 Data management and statistical analyses 
The information collected from each enrolled subject was stored in paper form and 
electronically for statistical analysis in consultation with a statistician using the software 
Statistical Package for Social Sciences (Version 12.0, SPSS Inc., Chicago, USA).  
For all data, mean values and corresponding standard deviations were calculated. Whether 
the data were normally distributed was tested by visual inspection, as well as by 
Kolmogorov-Smirnov test. Parametric tests were used for normally distributed variables and 
nonparametric tests for variables that were not normally distributed. For all nonparametric 
tests, exact significances were calculated. 
If normal distribution was probable, Student’s unpaired t-test was used for between group 
comparisons; otherwise, tests according to Mann-Whitney were applied.  
Correlations between parameters were estimated by computing Pearson’s correlation 
coefficient in case of normally distributed values and the Spearman-Rho correlation 
coefficient in case of other distributions respectively. For bivariate tabular analysis, exact 
calculation by chi-square test was used, whereas in case of expected values smaller than 
five, the fisher exact test was used. 













   
   
   
   
   
   
   
   
   
   
   
   
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   






       
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




        
   
   
   
   
   
    
   
   
   
   
   
   
   
   
   
   








3.38               5.88                    8.90 
            
        Retention time (min) 
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2.4 Ethical aspects and insurance 
Ethical permission of the study was obtained from the Bavarian Board of Physicians after 
reviewing the study protocol. During our study, physical health was determined by clinical 
investigation, the questionnaire of atopic disease, three-day dietary food records, 
accelerometer data, biochemical measurements, neurophysiological and neuropsychological 
testings. Since no adverse effects were observed, all investigations seemed to be justified. 
The liability insurance of the patients of the clinical trial would have been affected according 
to the requirements, but was not necessary in any case. 
The study subjects received written and oral information about the nature of the study and 
associated procedures to clarify all arising questions before giving written consent. 
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3 Results 
3.1 Subjects 
The present study is based on 33 adult PKU-patients aged 26 to 59 years (12 men, 21 
women) out of 53 adult patients with PKU from the database of the Dr von Hauner Children’s 
Hospital. Five out of the 53 patients did not want to take part in the investigations, further five 
subjects were too handicapped and 10 PKU-patients failed to have left their current 
addresses or telephone numbers. For comparison of the study results, thirty-three healthy, 
age- and gender-matched subjects (11 men, 22 women) at an age between 23 and 49 years 
were recruited as controls by intranet advertisement on the website of the Ludwig Maximilian 
University hospitals. 
The mean age of the patients (34.5 ± 6.3 yrs) was not significantly different from the mean 
age of the controls (34.6 ± 7.6 yrs), whereas the height was significantly lower and the body 
weight significantly higher in PKU-patients compared to the controls. The BMI, as well as 
diastolic and systolic blood pressure were revealed to be highly significantly larger in adults 
with PKU. The education level was different between both groups (p=0.054) because the 
control group was chosen according to the education level of the population reported by the 
Statistical Yearbook (2). 
 
Tab. 27: Baseline characteristics of the subjects 
 
Mean ± SD or N as appropriate 
 




Gender ♀ / ♂    21 / 12   22 / 11  0.796 
Age (yrs) 34.5 ± 6.3 34.6 ± 7.6  0.949 
Education1  3 / 14 / 9 / 5  0 / 9 / 11 / 13  0.054 
Height (cm) 168.5 ± 9.2 172.8 ± 8.6  0.036 
Weight (kg)    75.6 ± 16.6    67.5 ± 12.2  0.027 
BMI (kg/m2)  26.5 ± 4.5  22.5 ± 3.1 <0.001 
Blood pressure (mm Hg) 
Systolic 140.6 ± 22.0  126.3 ± 16.2  0.006 
Diastolic   87.6 ± 13.7    75.4 ± 10.9 <0.001 
Heart rate (beats/min)   79.9 ± 13.7    73.0 ± 12.5  0.080 
* derived from Student’s unpaired t-test, Mann-Whitney-U-test, Chi-square-test or Fisher’s exact test as appropriate 
1 German schools: Sonderschule / Hauptschule / Realschule / Gymnasium; 2 patients have no graduation 
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3.2 Nutritional status of the patients 
3.2.1 Measurement of fatty acids in plasma phospholipids 
The applied gas chromatography method (2.2.5.1.) allowed the separation of the following 
fatty acids identified by comparison with the peaks of a standard mixture (fig. 6): 
 
 Saturated fatty acids:  
14:0, 15:0, 16:0, 17:0, 18:0, 20:0, 22:0, 24:0 
 Trans fatty acids:  
14:1t, 16:1t, 18:1t, 18:2tt, 22:1t 
 Monounsaturated fatty acids:  
14:1n-5, 15:1n-5, 16:1n-7, 17:1n-7, 18:1n-9, 18:1n-7, 20:1n-9, 22:1n-9, 24:1n-9 
 Polyunsaturated fatty acids:  
18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 




Fig. 6: Chromatogram of a fatty acid standard mixture 
 
Reproducibility 
For most of the fatty acids in plasma phospholipids, intra- and inter-assay variation tests 
proved a good reproducibility. Intra-assay coefficients of variation (CV) of the described n-3 
and n-6 fatty acids (absolute and relative concentration) remained below 5 % as expected 
and mostly even below three, whereas inter-assay CV remained mostly below 6 %. The 
Minutes.
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following two tables show the determined coefficients of variation for selected n-6 and n-3 
fatty acids, for complete intra-assay and inter-assay CV see the attached table A3. 
 
 
Tab. 28: Intra-assay CV of fatty acid analyses in plasma phospholipids 
 
CV (%) of fatty acid concentrations (n=8) 
 
Absolute (mg/l) Relative (wt%) 
n-6 fatty acids 18:2n-6 1.75 0.19 
 18:3n-6 3.13 2.90 
 20:3n-6 1.80 0.41 
 20:4n-6 1.79 0.36 
 22:4n-6 2.47 1.00 
 22:5n-6 2.31 1.00 
n-3 fatty acids 18:3n-3 3.21 1.42 
 20:5n-3 2.07 0.71 
 22:5n-3 2.05 0.67 




Tab. 29: Inter-assay CV of fatty acid analyses in plasma phospholipids 
CV (%) of fatty acid concentrations (n=5) 
 
Absolute (mg/l) Relative (wt%) 
n-6 fatty acids 18:2n-6 3.28 0.52 
 18:3n-6 1.54 3.85 
 20:3n-6 5.20 2.48 
 20:4n-6 4.91 2.40 
 22:4n-6 4.55 1.93 
 22:5n-6 5.31 3.59 
n-3 fatty acids 18:3n-3 5.40 2.62 
 20:5n-3 5.19 3.46 
 22:5n-3 6.85 4.36 
 22:6n-3 7.11 5.20 
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3.2.2 Vitamin A and E in plasma 
Linearity of calibration curves 
The calculated coefficients of determination (r2) obtained by the described method (2.2.5.2) 
using seven vitamin concentration levels within the stated concentration range are the 
following ones: 0.040 – 1.005 mg/l (r2 = 0.9989) for retinol and 0.812 – 20.299 mg/l (r2 = 
0.9986) for α-tocopherol (fig. A1). 
 
Reproducibility 
The performed variation tests proved very good reproducibilities of the used method. Table 
30 shows the determined coefficients of variation for retinol and α-tocopherol, which 
remained below 1 % in the intra-assay and below 3 % in the inter-assay for both substances. 
More details show the attached tables A4 and A5. 
 
Tab. 30: Reproducibility of vitamin A and E analysis in plasma 
 
 Intra-assay (n = 6) Inter-assay (n = 9) 
 Mean (mg/l) CV (%) Mean (mg/l) CV (%) 
Retinol 0.40 0.94 0.40 2.97 
α-tocopherol 8.96 0.68 8.95 2.91 
 
Accuracy of the measurements 
The results for the α-tocopherol level proved to be in good correspondence with the 
approved values of the NIST standard reference material (bias < 5 %), whereas the retinol 
level exceeded the certified values about 9.7 %. However, the coefficients of variation for 
accuracy were excellent (1.53 % for retinol, 0.45 % for α-tocopherol). 
 
Tab. 31: Accuracy of vitamin A and E analysis in plasma 
 
Mean ± SD in mg/l or % as appropriate 
 
Certified value1 Measured value (n=4) Bias2 
α-tocopherol 7.47 ± 0.47 7.66 ± 0.03 + 2.68 
Retinol 0.484 ± 0.012 0.53 ± 0.01  + 9.69 
1 true concentration expected with 95 % confidence to be in the interval (certified value ± expanded uncertainty)  
2 bias= mean of samples - certified value * 100% / certified value 
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3.2.3 Dietary intake and nutritional supply 
During the study, sixteen of the patients (48.5 %) were still or again adhering to the low-
protein diet supplemented with special amino acid mixtures, three of these had begun again 
due to health problems (n=1) or pregnancy (n=2). The daily dietary intake of Phe calculated 
from the applied food records amounted to 2362 mg. Eleven (34.4 %) patients exceeded the 
recommendations of the APS (11) with a blood Phe-level greater than 20 mg/dl. The mean 
blood Phe-level during the study amounted to 15.9 mg/dl and the mean blood Phe-level 
throughout life (mean of all yearly medians of Phe-levels since start of treatment collected in 
patient files) amounted to 13.6 mg/dl (tab. 32).  
 




Mean SD Median 
Phe-intake per day (mg)  2362 1755 1904 
Blood Phe-level during study# (mg/dl) 15.9  8.1 14.5 
Blood Phe-level throughout  life* (mg/dl) 13.6  3.9 12.8 
# including very small levels in subjects with strict diet due to pregnancy or desire to have a child (n=5) 
* Phe-level throughout life= mean of all yearly medians of Phe-levels since start of treatment (collected in patient 
  files); excluding very low values of pregnant patients with a lack of Phe-levels during life (n=6) 
 
The following two figures show the highly significant correlation between the blood Phe-level 
during the study (excluding very low values, n=6) and daily mean Phe-intake calculated from 
the applied food records (fig. 7) or the blood Phe-level throughout life respectively (fig. 8). 
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Fig. 7: Spearman-Rho correlation between blood Phe-level during study and daily Phe-intake 
 
 
Fig.  8: Spearman-Rho correlation between the blood Phe-level during study and blood Phe-
level throughout life 
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Each patient filled in estimated dietary protocols for three days. The evaluation of the applied 
food records shows intakes of energy, protein, fat, carbohydrates, as well as of vitamins, 
minerals and trace elements. Table 33 gives an overview of the dietary intake of energy, 
macronutrients and some critical nutrients; further results are shown in the attached table A1. 
The mean intakes of carbohydrates, folic acid, vitamin D, EPA and DHA, as well as of fiber, 
cholesterol, iodine and fluoride were found to be lower than recommended. The mean 
intakes of saturated fatty acids, as well as of the vitamin A, B-group vitamins, vitamin C, α-
tocopherol and of minerals like sodium, potassium, magnesium, iron, zinc, copper, chloride 
and manganese exceeded the recommendations. All other parameters met more or less the 
reference values. 
 
Tab. 33: Daily dietary intake of the PKU-patients (including amino acid mixtures) 
 
PKU-patients (n=31; 7 ♂, 24 ♀) 
 Mean 
♀ / ♂ 
SD 
♀ / ♂ 
Median 
♀ / ♂ 
Reference  
value* 
♀ / ♂ 
Mean in % of 
reference 
value 
Energy (kcal) 2283 / 2772 646 / 565 2180 / 2843 2300 / 2900 99 / 96 
Protein (g) 74 / 90  34 / 31 72 / 93 68.5 / 86.3 108 / 104 
Total fat (g) 82 / 92 41 / 39 72 / 96 74.2 / 93.5 111 / 98 
Carbohydrates (g) 259 / 356 79 / 84 297 / 354 314.9 / 397 82 / 90 
PUFA (g) 12.5 / 13.4  6.7 / 6.0 10.8 / 13.9 < 24.7 / 31.2  51 / 43 
MUFA (g) 26.6 / 29.6  18.0 / 17.4  20.1 / 26.3 > 24.7 / 31.2 108 / 95  
SFA (g) 30.5 / 36.3  19.1 / 19.7  25.8 / 33.1 < 24.7 / 31.2 123 / 116 
Retinol (mg) 1.4 / 1.5 0.8 / 1.1 1.3 / 1.1 0.8 / 1.0 175 / 150 
Vitamin B12 (µg) 5.2 3.4 4.7 3 170 
Folic acid (µg) 332 182 288 400 83 
Vitamin D (µg) 4.6 4.8 2.7 5 92 
Vitamin E (mg) 18.6 / 11.9 15.5 / 2.5  15.4 / 11.5 12 / 14 155 
Calcium (mg) 1084 427 993 1000 108 
Magnesium (mg) 412 / 472 129 / 127 440 / 421 300 / 350 137 / 135 
Iron (mg) 19 / 18 9.1 / 5.6 17.6 / 18.3 15 / 10 193 / 121 
Zinc (mg) 15.1 / 15.0  7.5 / 5.4 14.1 / 16.4 7 / 10 216 
Copper (µg) 2604 1083 2453 1250 208 
Linoleic acid (g) 10.4 / 10.5 5.6 / 4.4 8.7 / 10.3 6.2 / 7.8 168 / 135 
α-Linolenic acid (g) 1.3 / 1.5 1.0 / 0.8 1.0 / 1.7 1.2 / 1.6 108 / 94 
EPA (g) 0.002 0.01 0.0 > 0.23 / 0.29 1.1 / 1.1 
DHA (g) 0.042 0.01 0.0 > 0.23 / 0.29 19.7 / 19.5  
* reference values derive from D-A-CH recommendation (47); for EPA and DHA  from ISSFAL (86) 
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The proportion of macronutrients (means) in comparison with recommended ranges or 
values of the German Nutrition Society (47) shows figure 9. According to that, PKU-patients 
tend to have higher intakes of fat and protein (or protein equivalent), but lower intakes of 
carbohydrates compared with German recommendations.  
 
Fig.  9: Macronuttrient intake of PKU-patients and controls (% of energy intake) 
 
Fig.  10: Intake of nutrients considered critical in PKU-patients (expressed as % of reference 
values; (47))  
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Figure 10 gives an overview of nutrients whose median intakes are lower than the reference 
values. Bottom and top edges of the box indicate 25th and 75th percentiles, the horizontal line 
in the box indicates the median value of the data, the whiskers extend to a maximum of 1.5 
times the interquartil range and the points outside the ends of the whiskers are outliers or 
suspected outliers. It is shown that the intakes of fiber, fluoride, PUFA, EPA and DHA are 
less than reference intakes in more than 75 % of the PKU-patients. Table 34 gives an 
overview of the nutritional supply of the patients with some important nutrients. The listed 
nutrients might prove to be too low in patients on a diet without foods rich in protein. For 
detection of deficiencies, measured blood concentrations were compared with reference 
ranges given from the laboratory.  
The iron or zinc concentrations in the blood of almost 38 % of the patients were found below 
the laboratory’s reference range. Furthermore, two PKU-patients had low contents of ferritin. 
In 56 % of the subjects, reduced blood levels of selenium were found. One subject had a 
retinol concentration below the reference value and three patients had reduced levels of α-
tocopherol. 
In some patients, higher concentrations compared with reference ranges were revealed. 
Thus, two patients had higher calcium, one patient higher ferritin, three patients higher 
selenium, seven patients higher copper, two patients higher retinol, five patients higher folic 
acid and one patient higher cobalamin levels than regarded as normal. Blood levels of 
selenium were significantly correlated with blood Phe-levels during life (Spearman-Rho, 
r=0.451, p=0.024). 
Figure 11 shows the proportions of selected plasma fatty acids of the PKU-patients in 
comparison to relative fatty acid levels in 31 healthy adult omnivores of a comparable age 
and gender ratio (Kraft et al., unpublished data). PKU-patients had lower mean levels of 
linoleic acid and DHA, no difference was observed for α-linolenic acid levels.  
In addition to these reported values the median arachidonic acid proportion in plasma 
phospholipids of adults with PKU proved to be higher and the median DHA level was lower 
compared to healthy omnivores (fig. 12) which could explain the alterations in the immune 
status. Comparing both groups p-values showed significant differences regarding Linoleic 
acid (p<0.001) and DHA (p=0.013).  
However, compared with reference values of our own laboratory (derived from healthy 
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Mean SD Median Reference range 
Below /in /above 
reference 
range* 
Calcium (mmol/l) 2.4 0.14 2.4 2.05-2.65  0 / 31 / 2 
Magnesium (mmol/l) 0.83 0.07 0.80 0.65-1.20  0 / 32 / 0 
Iron (µg/dl) 99 34 101 80-180  9 / 24 / 0 
Ferritin (µg/l) ♀ / ♂ 45 / 219 31 / 131 35 / 220 15-160 / 30-300  2 / 30 / 1 
Selenium (µg/l) 78 21 80 80-100 18 / 11 / 3 
Zinc (µg/dl) 82 18 81 75-140  9 / 24 / 0 
Copper (µg/dl) 112 38 98 75-130  0 / 24 / 7 
Retinol (mg/l) 0.61 0.13 0.57 0.33-0.85  1 / 29 / 2 
Folic acid (ng/ml) 12.6 4.3 12.5 2.0-17.5   0 / 26 / 5 
Vitamin B12 (pg/ml) 509 205 466 185-1100   0 / 32 / 1 
Vitamin D (ng/ml) 29 9 28 10-120   0 / 30 / 0 
Vitamin E (mg/l) 7.6 1.7 7.6 5.7-13.3   3 / 29 / 0 
* one patient could not come into the hospital, therefore only some parameters were measured by her family 
doctor; and in few cases parameters could not be measured due to too less material 
 
 
Fig. 11: Comparison of essential fatty acids, EPA and DHA (wt%) in plasma phospholipids  
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Fig. 12: Comparison of arachidonic acid and DHA levels in plasma phospholipids (wt%)  
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3.2.4 Comparison of the nutritient status data with data from patients followed at 
Münster 
Besides the present study based on 33 adult PKU-patients aged 26 to 59 years (12 men, 21 
women), blood samples and estimated dietary protocols from further 52 adult PKU-patients 
out of the database of the University Hospital of Muenster were evaluated in the Dr von 
Hauner Children’s Hospital in Munich. The mean age of the PKU-patients from Münster (32.3 
± 6.3 yrs; 28 men, 53 women) was not significantly different from the mean age of the patient 
group of Munich (34.5 ± 6.3 yrs). 
Table 35 gives an overview of the dietary intake of energy, macronutrients and some critical 
nutrients. Further results are shown in the attached table A6. As previously reported in the 
patient group of Munich the mean intakes of carbohydrates, folic acid, vitamin D, EPA and 
DHA, as well as of fiber, cholesterol, iodine, fluoride, PUFA, linoleic and α-linolenic acid were 
lower than reference intake values. In contrast to the results of PKU-patients from Munich 
(tab. 33), the intake of energy was found to be slightly lower than recommended evaluating 
both patient groups together. Furthermore, the intake of EPA was remarkably lower (1.1 vs. 8 
or 10 %) and DHA was approximately 10 % lower. The mean intakes of saturated fatty acids, 
as well as of the vitamin A, B-group vitamins, vitamin C, α-tocopherol and of minerals like 
sodium, potassium, magnesium, iron, zinc, copper, chloride and manganese exceeded the 
recommendations in the PKU-patients from Munich as well as in the PKU-patients from 
Münster. All other parameters met more or less the reference values. 
 
Figure 13 shows the proportion of macronutrients (means) in comparison with reference 
ranges or values of the German Nutrition Society (47). PKU-patients tend to have higher 
intakes of fat and protein, but lower intakes of carbohydrates compared to German reference 
values. Evaluating data from Munich and Münster together showed even more unpropitious 
results. The intake of fat and protein in the combined group was higher than in the Munich 
patient group alone (33 vs. 32 % and 14 vs. 13 %) and the intake of carbohydrates was lower 










Results  50 
Tab. 35: Dietary intake of all PKU-patients (including amino acid mixtures) 
 
PKU-patients (n=73, 24 ♂, 59 ♀) 
 Mean 
♀ / ♂ 
SD 
♀ / ♂ 
Median 
♀ / ♂ 
Reference  
value* 
♀ / ♂ 
Mean in % of 
reference 
value 
Energy (kcal) 2015 / 2436 628 / 671 2009 / 2076 2300 / 2900 89 / 83 
Protein equivalent 
(g) 66 / 79 31 / 27 59 / 74 68.5 / 86.3 99 / 98 
Total fat (g) 74 / 91 35 / 39 69 / 78 74.2 / 93.5 100 / 97 
Carbohydrates (g) 259 / 299 86 / 96 255 / 275 314.9 / 397 84 / 71 
PUFA (g) 11.7 / 13.3  6.0 / 6.8 10.1 / 12.4 < 24.7 / 31.2 47 / 44 
MUFA (g) 24.8 / 30.4 14.8 / 16.0 20.8 / 25.2 > 24.7 / 31.2 101 / 96 
SFA (g) 26.9 / 34.1 15.8 / 16.6 24.2 / 32.5 < 24.7 / 31.2 108 / 111 
Retinol (mg) 1.8 / 1.5 1.7 / 1.1 1.3 / 1.0 0.8 / 1.0 215 / 149 
Vitamin B12 (µg) 4.4 / 5.8 3.3 / 3.6 3.4 / 4.9 3 162 / 185 
Folic acid (µg) 256 / 281 111 / 116 232 / 260 400 72 / 77 
Vitamin D (µg) 4.8 / 4.2 5.6 / 3.8 2.3 / 2.2 5 98 / 88 
Vitamin E (mg) 13.2 / 12.0 7.2 / 3.8 11.3 / 11.3 12 / 14 131 / 90 
Calcium (mg) 981 / 1006 475 / 363 879 / 986 1000 102 / 107 
Magnesium (mg) 391 / 458 143 / 142 393 / 437 300 / 350 134 / 135 
Iron (mg) 16.1 / 17.0 7.6 / 7.4 14.5 / 14.8 15 / 10 150 / 132 
Zinc (mg) 12.2 / 13.4 6.1 / 5.7 10.6 / 14.8 7 / 10 185 / 139 
Copper (µg) 2234 / 2558 895 / 896 2188 / 2166 1250 188 / 214 
Linoleic acid (g) 9.9 / 10.5 5.2 / 5.1 8.6 / 10.1 6.2 / 7.8 158 / 142 
α-Linolenic acid (g) 1.2 / 1.5 0.8 / 0.7 0.9 / 1.3 1.2 / 1.6 96 / 94 
EPA (g) 0.03 / 0.005 0.15 / 0.01 0.00 / 0.00 > 0.23 / 0.29 10 / 8 
DHA (g) 0.06 / 0.08 0.16 / 0.10 0.00 / 0.03 > 0.23 / 0.29 27 / 35 
* reference values derive from D-A-CH recommendation (47); for EPA and DHA from ISSFAL (86) 
 



























Fig.  13: Macronutrient intake (expressed as % of energy intake) of all PKU-patients 
   relative to reference values (47) 
In PKU-diet, the vast amount of protein is consumed as amino acid mixtures for which 
protein-equivalents are calculated by multiplying the percentage of nitrogen from 
amino acids in a diet with the factor 6.25. 
 
In comparison to table 34, table 36 includes data from the PKU-patients of Münster showing 
the supply of some important nutrients. The listed nutrients might prove to be too low in 
patients on a diet without foods rich in protein.  
In the group of patients from Munich and Münster, zinc blood levels of 40 % of the patients 
were found below the laboratory’s reference range. In almost 42 % of all PKU-patients low 
selenium levels and in approximately 10 % low copper blood levels were detected. In 14 % of 
the subjects, reduced blood levels of Vitamin E were found. Nine subjects had a Vitamin D 
concentration below the reference value and six patients had reduced levels of ferritin. 
Furthermore, three PKU-patients were found to have lower retinol concentrations than 
recommended and two patients showed a lack of vitamin B12.  
In two patients higher calcium blood levels were revealed, two patients had higher ferritin, 23 
patients higher selenium, 27 patients higher copper, six patients higher retinol, eight patients 
higher folic acid, two patients higher cobalamin and one patient higher vitamin E levels than 
regarded as normal.  
However, compared with reference values of the Children’s hospital laboratories in Munich 
(derived from healthy controls), most of the PKU-patients were within normal ranges.  
The combining data from Munich and Münster shows even greater nutritional deficiencies as 
data from Munich alone. 
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Mean SD Median Reference range 
Below /in /above 
reference range* 
(N) 
Calcium (mmol/l) 2.44 0.11 2.44 2.05-2.65  0 / 105 / 2 
Magnesium (mmol/l) 0.85 0.06 0.85 0.65-1.20  0 / 106 / 0 
Iron# (µg/dl) 99 34 101 80-180  9 / 24 / 0 
Ferritin (µg/l) ♀ / ♂ 56 / 156 44 / 97 47 / 141 15-160 / 30-300 6 / 99 / 2 
Selenium (µg/l) 88 24 86 80-100  39 / 31 / 23 
Zinc (µg/dl) 77 17 77 75-140 42 / 63 / 0 
Copper (µg/dl) 112 41 97 75-130  10 / 66 / 27 
Retinol (mg/l) 0.60 0.15 0.59 0.33-0.85  3 / 97 / 6 
Folic acid (ng/ml) 9.6 4.6 8.3 2.0-17.5 0 / 97 / 8 
Vitamin B12 (pg/ml) 463 207 431 185-1100  2 / 103 / 2 
Vitamin D (ng/ml) 22 10 20 10-120   9 / 94 / 0 
Vitamin E (mg/l) 7.3 2.0 6.6 5.7-13.3 15 / 90 / 1 
*one patient could not come into the hospital, therefore only some parameters were measured by her family 
doctor; and in few cases parameters could not be measured due to too less material 
# iron was only measured in PKU-patients from Munich 
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3.3 Immune status of the patients 
For detection of alterations in the immune status due to the PKU-diet, a questionnaire about 
atopic disease was used, immunoglobulins were measured and in case of elevated total IgE, 
an immunoassay for special IgE was carried out.  
Regarding the concentrations of immunoglobulins there were no great abnormal results 
detectable for IgG, IgA and IgM. IgG was normal in all patients, elevated IgA was found in 
one and two PKU-patients had greater IgM values compared with normal ranges. The most 
significant result was that about 30 % (n=10) of all patients had elevated IgE levels in blood. 
In these patients, an Elisa immunoassay was performed for measurement of special IgE (tab. 
39). There were significant positive correlations detectable between IgE and blood Phe-level 
in the study (p=0.029) and furthermore significantly negative correlations between PUFA 
blood level and IgA (p=0.036), as well as IgE (p=0.012) as shown in table 38. 
 




Mean ± SD Median Min Max Reference ranges 
Below /in /above
reference range 
IgG (mg/dl)  997 ± 169 982 732 1394  700-1800  0 / 33 / 0 
IgA (mg/dl) 196 ± 97 169 44 551  70-450  1 / 31 / 1 
IgM (mg/dl) 162 ± 197 128 59 1222  40-250  0 / 31 / 2 
IgE (U/ml) 1839 ± 9358 70 0.5 53930 <200    0 / 23 / 10 
 
Tab. 38: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 
cardiovascular risk factors in PKU-patients 
 




Sum of PUFA# in wt% 
(n=32)  
r p r p r p 
IgG (mg/dl) -0.265 0.143 -0.066 0.749 -0.252 0.164 
IgA (mg/dl)  0.089 0.628  0.001 0.997  -0.371* 0.036 
IgM (mg/dl)  0.157 0.392  0.131 0.524 -0.065 0.723 
IgE (U/ml)   0.387* 0.029  0.388 0.050  -0.440* 0.012 
*significant, **highly significant, #sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
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As shown in table 39, patients had positive results in different allergens of the Elisa 
immunoassay. Most of the 10 patients with elevated IgE showed allergic reactions with 
phleum pratense (n=6), secale cereale (n=5), quercus alba (n=4), as well as 
dermatophagoides pteronyssinus (n=4). 
Using a questionnaire, atopic disease was diagnosed if the subject had or ever had had at 
least one of the diseases listed in table 40. Almost 55 % of all PKU-patients were suffering 
from atopic disease compared with only 21 % of the age-matched controls, which means that 
adults with PKU suffered highly significantly more often from atopic disease than the controls 
(tab. 40). As shown by the p-values, adults with PKU had significantly more often hay fever, 
allergic coryza or allergic conjunctivitis. A trend towards a higher prevalence of asthma in 
PKU-patients compared to healthy controls was observed (p=0.053). A running nose and 
swollen eyes as typical allergic symptoms, as well as neurodermitis, urticaria or food allergy 
were not significantly but still more often observable in patients compared with controls.  
Searching for correlations there was no significant correlation between the frequency of 
allergic diseases and blood Phe, or blood PUFA level observable in PKU-patients (tab. 41). 
 
Tab. 39: Elisa test results of 10 PKU-patients with elevated IgE 
 









Phleum pratense 4 0 1 2 3 6 
Secale cereale 5 0 1 4 0 5 
Quercus alba 6 0 1 2 1 4 
Artemisia vulgaris 9 0 1 0 0 1 
Cat dander 7 1 1 0 1 3 
Dog dander 9 0 0 1 0 1 
Cladosporium  
herbarum 10 0 0 0 0 0 
Dermatophagoides
pteronyssinus 6 0 0 2 2 4 
* Elisa was carried out in 10 PKU-patients with elevated IgE, # phleum pratense= timothy grass, secale cereale= 
ray grass, quercus alba= white oak, artemisia vulgaris= mugwort, cladosporium herbarum = common species of 
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Atopic disease# 18 7 25 0.005 
Asthma 5 0 5 0.053 
Hay fever,  
allergic coryza / 
conjunctivitis 
14 6 20 0.032 
Running nose, 
swollen eyes 11 6 17 0.159 
Neurodermitis 5 2 7 0.230 
Urticaria 2 1 3 0.555 
Food allergy 3 2 5 0.642 
* derived from Chi-square-test or Fisher’s exact test as appropriate 




Tab. 41: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 







Sum of PUFA# in 
wt% (n=32)  
r p r p r p 
Atopic disease# -0.014 0.941  0.165 0.422 -0.125 0.494 
Asthma -0.014 0.939 -0.195 0.339 -0.308 0.092 
Hay fever,  
allergic coryza / 
conjunctivitis 
 0.024 0.896  0.279 0.167 -0.059 0.750 
Running nose, 
swollen eyes -0.245 0.177  0.012 0.955 -0.103 0.574 
Neurodermitis -0.051 0.780  0.000 1.000 -0.200 0.271 
Urticaria  0.056 0.761  0.077 0.709 0.168 0.359 
Food allergy -0.296 0.100 -0.019 0.926 0.180 0.324 
* excluding extreme values, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9,  
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
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3.4 Cardiovascular risk markers of the patients 
For evaluating the cardiovascular risk of the PKU-patients, BMI, consumption of cigarettes, 
blood pressure, hypertension, heart rate and blood parameters like homocysteine and the 
lipoprotein profile (TC, LDL, HDL, VLDL, TG, Apo A1, Apo B, Lp (a)) were determined.  
Table 42 shows highly significantly higher values for BMI, blood pressure and heart rate in 
PKU-patients compared with controls. Subjects with PKU were significantly more often 
obese. Eleven patients in contrast to only three of the controls had BMI values of 25 - <30, 
obesity of the grade I (BMI 30 - <35) was revealed in 4 of the patients but in only 2 of the 
controls and BMI values of 35 and higher were found solely in two of the adults with PKU. 
Subjects from the control group were not significantly but more often smokers. Hypertension 
was not revealed to be significantly different comparing in both groups. Six of the patients but 
eight of the controls had mild, two patients but six controls moderate and only one subject of 
the control group suffered from heavy hypertension. 
 
Tab. 42: Cardiovascular risk factors in PKU-patients compared to healthy controls 
 










BMI (kg/m2) 26.5 ± 4.5 22.5 ± 3.1 24.5 ± 4.3 <0.001 
Obesity1 (n) 11 / 4 / 2  3 / 2 / 0 14 / 6 / 2  0.011 
Smoker (n) 3 7 10  0.170 
Blood pressure (mmHg)    
Systolic 140.6 ± 22.0 126.3 ± 16.2 133.4 ± 20.5  0.004 
Diastolic 87.6 ± 13.7 75.4 ± 10.9 81.5 ± 13.7 <0.001 
Hypertension2  (n) 6 / 2 / 0 8 / 6 / 1 14 / 8 / 1  0.175 
Heart rate (beats/min) 79.9 ± 13.7 73.0 ± 12.5 76.5 ± 13.5  0.037 
* derived from Student’s unpaired t-test, Mann-Whitney-U-test, Chi-square-test or Fisher’s exact test as appropriate 
1  BMI between 25-<30 / 30-<35 / 35-<40, no subject had BMI>40  




Regarding the blood lipid status and blood homocysteine levels of the PKU-patients, 
elevated levels (compared to the laboratory’s reference range) were often observed: 3 % up 
to 19 % had higher concentrations of blood parameters that are considered as risk factors for 




Results  57 
Tab. 43: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 







Sum of PUFA# 
in wt% (n=32)  
r p r p r p 
BMI (kg/m2)  0.437* 0.012 0.181 0.376 0.242 0.182 
Obesity (n)  0.423* 0.016 0.194 0.342 0.161 0.378 
Smoker (n) 0.308 0.087 0.217 0.288 0.064 0.728 
Blood pressure (mmHg)       
Systolic 0.306 0.088  0.405* 0.040 0.112 0.542 
Diastolic 0.266 0.141  0.399* 0.044 0.210 0.250 
Hypertension (n) 0.275 0.128  0.473* 0.015 0.104 0.571 
Heart rate (beats/min) 0.273 0.130  0.505* 0.008 0.109 0.552 
* significant, ** highly significant, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3;  Obesity = BMI >25 
 
Thus, five patients (15 %) had higher total cholesterol and six (18 %) higher triglyceride 
levels. Regarding the different cholesterol types there were again higher VLDL 
concentrations detectable in six adults with PKU (19 %), in one patient, the LDL level 
exceeded the reference range and two subjects had LDL/HDL quotients above the 
laboratory’s reference range. Furthermore, Lp (a) was elevated in six patients (18 %), Apo 
A1 also in six (19 %) and Apo B was too high in one of the subjects with PKU. Homocysteine 
was found to be beyond the reference range in 16 % of the patients.  
Searching for significant correlations between cardiovascular risk factors and blood Phe, or 
blood PUFA level, significantly positive differences between the concurrent blood Phe-levels 
and BMI (p=0.012), or obesity (p=0.016) respectively. Additionally, the blood Phe-level 
throughout life and the blood pressure, as well as hypertension and heart rate showed 
significant positive correlations (tab. 43). Additionally, blood PUFA content in wt% was 
significantly positive related to body weight (r=0.396, p=0.025). 
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Mean SD Median Reference ranges 
Below /in /above 
reference 
range 
Total cholesterol (mg/dl) 203.8 41.2 204.0 120-240 0 / 28 / 5 
Triglycerides (mg/dl) 125.0 68.0 111.0 50-200 2 / 25 / 6 
LDL (mg/dl) 125.8 34.7 123.0 60-190 0 / 32 / 1 
HDL (mg/dl)* 56.4 15.3 55.0 35-75 2 / 28 / 2 
LDL/HDL 2.4 0.9 2.4 1-4 1 / 30 / 2 
VLDL (mg/dl)* 21.4 10.3 22.0 5-30 1 / 25 / 6 
Lp (a) (mg/dl) 22.4 24.8 10.0 <30 0 / 27 / 6 
Apo A1 (mg/dl)* 150.2 29.1 140.0 100-180 0 / 26 / 6 
Apo B (mg/dl)* 91.8 25.6 88.0 45-150 0 / 31 / 1 
Homocysteine* (mol/l) 11.5 3.1 11.2 <13.9 0 / 27 / 5  




Tab. 45: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 







Sum of PUFA# 
in wt% (n=32)  
r p r p r p 
Total cholesterol (mg/dl)  0.418* 0.017  0.099 0.630 -0.004 0.981 
Triglycerides (mg/dl)  0.349* 0.050  0.134 514 -0.125 0.497 
LDL (mg/dl) 0.286 0.113 -0.010 0.962 -0.115 0.530 
HDL (mg/dl)* 0.086 0.640  0.084 0.684  0.075 0.684 
LDL/HDL 0.174 0.342 -0.013 0.948 -0.199 0.275 
VLDL (mg/dl)*  0.355* 0.033  0.149 0.476 -0.021 0.907 
Lp (a) (mg/dl) 0.093 0.614  0.250 0.218 -0.141 0.440 
Apo A1 (mg/dl)* 0.265 0.149  0.144 0.491  0.209 0.260 
Apo B (mg/dl)* 0.284 0.128 -0.001 0.995 -0.034 0.857 
Homocysteine* (mol/l) 0.258 0.162 -0.005 0.980  0.070 0.709 
* significant, ** highly significant, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
 
Testing correlations between cardiovascular risk factors and blood Phe, or blood PUFA level 
significantly positive differences were detected between the blood Phe-level during the study 
and total cholesterol (p=0.017), as well as TG (p=0.050) and VLDL (p=0.033) shown in table 
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45. Additionally, blood DHA content in wt% was significantly positive related to HDL (r=0.466, 
p=0.007), as well as to LDL/HDL (r=0.371, p=0.036) and ApoA1 (r=0.514, p=0.003). 
3.5 Metabolic status of the patients 
For determination of differences in metabolic parameters, all patients and controls were 
asked to wear an accelerometer for three days. Thus, the total and the active energy, the 
duration of physical activity level, the number of steps taken, as well as the lying and 
sleeping duration could be compared between patients and controls. 
The total energy expenditure, the number of steps taken, as well as the sleeping duration 
showed no significant differences between the two groups (tab. 46). The lying duration tends 
to be different with 8.6 hours for patients and only 8.1 hours per day for the controls (n.s.). 
Significantly higher values for the daily active energy expenditure were found in the control 
group, as well as highly significant greater physical activity levels per day. 
 
Tab. 46: SenseWear results in the PKU-patients and healthy controls 
 
Mean ± SD 




PKU vs. controls 
p-value* 
Total energy expenditure 
(kcal/day) 2791 ± 578 2896 ± 799 0.801 
Active energy expenditure 
(kcal/day)   595 ± 513   977 ± 659 0.013 
Physical activity (min/day) 115 ± 99 180 ± 89 0.009 
Number of steps (per day) 10930 ± 4201 11170 ± 3733 0.667 
Lying duration (hrs/day)   8.6 ± 1.5   8.1 ± 2.3 0.051 
Sleeping duration (hrs/day)   6.6 ± 1.4   6.2 ± 1.4 0.203 
* derived from Student’s unpaired t-test or Mann-Whitney-U-test as appropriate 
 
 
The significant correlations found between SenseWear results and activity parameters are 
emphasized. Significant positive correlations were found between active energy expenditure, 
as well as physical activity level and the duration of doing sports per week, but significantly 
negative correlations between the duration of watching TV per day and activity expenditure, 
as well as physical activity level per day. Furthermore, a significant positive correlation was 
found between the active energy expenditure and obesity, as well as the body weight, but a 
negative relation between the physical activity level per day and obesity, as well as the body 
weight. In addition, the number of steps taken per day and body weight were significantly 
positively correlated (tab. 47). 
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Tab. 47: Spearman-Rho correlations between accelerometer results and activity dependent 

















r 0.072 -0.220 0.156 0.049 0.135 0.141 Total energy  
expenditure (kcal/day) p 0.573 0.083 0.223 0.705 0.293 0.269 
r   0.349**   -0.355** -0.045   -0.473**   0.357**   0.414** Active energy  
expenditure (kcal/day) p 0.005 0.004 0.727 <0.001 0.004 0.001 
r 0.299*   -0.346** -0.128  -0.583**  -0.455**  -0.559**Physical activity  
(min/day) p 0.017 0.006 0.317 <0.001 <0.001 <0.001 
r 0.082 -0.182 -0.198 -0.154 -0.143   0.335** Number of steps  
(per day) p 0.525 0.153 0.120  0.229 0.263 0.007 
r 0.033 0.128 -0.117 0.129 0.064 0.103 Lying duration  
(hrs/day) p 0.798 0.315 0.356 0.309 0.614 0.417 
r -0.024 0.189 0.034 0.105 0.076 0.201 Sleeping duration  
(hrs/day) p 0.850 0.134 0.788 0.407 0.550 0.112 
Obesity = BMI >25 
 
Testing correlations between accelerometer data and the blood Phe-level, or blood PUFA 
level there was a significant positive correlation determined between the blood PUFA content 
and the physical activity level (r=0.371, p=0.040), as well as the number of steps taken 
(r=0.406, p=0.023) shown in table 48. 
 
Tab. 48: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 







Sum of PUFA# 
in wt% (n=32)  
r p r p r p 
Total energy expenditure 
(kcal/day) 0.060 0.746  0.212 0.308  0.071 0.704 
Active energy expenditure 
(kcal/day) 0.104 0.576  0.139 0.507  0.336 0.064 
Physical activity (min/day) 0.062 0.740  0.069 0.744  0.371* 0.040 
Number of steps (per day) 0.067 0.722 -0.018 0.933  0.406* 0.023 
Lying duration (hrs/day) 0.092 0.618  0.087 0.673 -0.029 0.877 
Sleeping duration (hrs/day) 0.081 0.659  0.206 0.314 -0.158 0.388 
* significant, ** highly significant, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
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Moreover, asking for free-time activities showed that healthy adults do highly significantly 
more frequently sports but watch highly significantly less frequently television than adults 
with PKU. The duration of using the computer during free time was not significantly but 
different between patients and controls (tab. 49).  
 
Tab. 49: Activity parameters of the PKU-patients and healthy controls 
 
Mean ± SD 
 PKU-patients 
(n=33) Controls (n=33) 
PKU vs. controls 
p-value* 
Doing sports (min/week)     96 ± 119 223 ± 197 0.002 
Watching TV (min/day) 117 ± 73 78 ± 52 0.016 
PC work (min/day)   26 ± 54 44 ± 57 0.205 
* derived from Student’s unpaired t-test or Mann-Whitney-U-test as appropriate 
 
Searching for significant correlations between activity parameters and the blood Phe-level, or 
the blood PUFA level there were no significant differences observable (tab. 50). 
 
Tab. 50: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 







Sum of PUFA# 
in wt% (n=32)  
r p r p r p 
Doing sports (min/week) -0.133 0.467 -0.281 0.165 0.158 0.387 
Watching TV (min/day) -0.149 0.419 -0.186 0.363 0.229 0.207 
PC work (min/day)  0.004 0.981  0.271 0.181 0.068 0.710 
* excluding extreme values, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9,  
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
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3.6 Neurological status of the patients 
Neurophysiological testings and neuropsychological tests were performed to explore 
potential dietary effects on neurological outcomes. 
3.6.1 Neurophysiological testings 
Motor performance task (MPT) 
For detection of alterations of fine motor skills, all patients and controls were asked to do the 
motor performance task (MPT). The number of failures and the duration of the different 
tasks, as well as fine motor factors like the aiming of motion, the hand unrest (tremor), the 
arm-hand precision, the arm-hand and the wrist-finger speed were compared between PKU-
patients and controls. 
Table 51 shows that adults with PKU committed about three times more failures in the 
steadiness task, compared to the controls, with almost one third more in line tracking 
(statistically significant) and approximately twice as many failures in aiming. Regarding the 
measured duration of failures, significant differences were found for the steadiness and 
differences for the line tracking. The total duration of line tracking and aiming were proven to 
be highly significant for inserting pins. Controls had a higher rate of hits in tapping and almost 
as many hits as the PKU-patients in aiming.  
 
Tab. 51: Motor performance task results of the PKU-patients and healthy controls (measured 
with the right hand) 








NF 6.1 ± 8.0 2.4 ± 3.2 0.051 
Steadiness 
DF 2.1 ± 6.3   0.22 ± 0.38 0.049 
NF   26.0 ± 12.6 18.9 ± 7.0 0.015 
DF 3.0 ± 3.1  1.6 ± 0.8 0.004 Line tracking 
TD   30.2 ± 13.2  28.6 ± 11.2 0.584 
NF 1.6 ± 1.9 1.0 ± 1.7 0.162 
DF   0.12 ± 0.16    0.39 ± 0.06 0.164 
TD 9.3 ± 2.9 7.4 ± 1.5 0.006 
Aiming 
NH 19.7 ± 1.3  19.9 ± 0.6 0.513 
Inserting pins TD 48.9 ± 9.2 43.3 ± 6.3 0.003 
Tapping RH 186.7 ± 35.5 203.3 ± 20.3 0.057 
* derived from Student’s unpaired t-test, or Mann-Whitney-U-test as appropriate 
NF=number of failures, DF=duration of failures, TD=total duration, HN=number of hits, RH=rate of hits  
For explanations of the different tasks please have a look on pages 20/21. 
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Tab. 52: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 






Sum of PUFA# in 
wt% (n=32)  
r p r p r p 
NF  0.370* 0.031  0.090 0.667  0.103 0.573 
Steadiness 
DF 0.241 0.191  0.262 0.206 -0.038 0.838 
NF 0.289 0.114  0.167 0.424  0.051 0.782 
DF 0.262 0.154  0.182 0.384  0.190 0.297 Line tracking 
TD 0.030 0.872  0.033 0.874 -0.089 0.628 
NF  0.398* 0.026 -0.012 0.956  0.058 0.751 
DF  0.469** 0.008  0.110 0.599 -0.002 0.991 
TD 0.389* 0.031  0.090 0.667 -0.216 0.234 
Aiming 
NH -0.020 0.916  0.175 0.404 -0.216 0.234 
Inserting pins TD -0.327 0.073 -0.318 0.121  -0.361* 0.042 
Tapping RH 0.241 0.191  0.262 0.206 -0.012 0.948 
MPT=motor performance task, *significant, **highly significant, #sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-





Fig. 14: Correlation between Phe-level during study and duration of failures in PKU-patients 
(Aiming) (n=32) 
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Table 52 shows a significant positive correlation between the blood Phe-level in the study 
and the number of failures in steadiness (r=0.370, p=0.031) and aiming (r=0.398, p=0.026), 
the duration of failures in aiming (r=0.469, p=0.008), as well as the total duration of aiming 
(r=0.389, p=0.031). Additionally, a significantly negative correlation was found between the 
blood PUFA content and the total duration of inserting pins (r=-0.361, p=0.042) (tab. 52). 
As shown in figure 14, the results of the PKU-patients were significantly correlated with the 
blood Phe-level in the study (Spearman-Rho). 
The raw values obtained were transformed into t-values by using tables with normative 
values. Conceptually, t-values represent the mean number of standard units varying from the 
average of 50 within a scale between 0 and 100 points. The higher t-values are, the better. 
Differences in motor performance became observable by comparison of fine motor factors 
obtained by the motor performance task. The PKU-patients showed worse t-values for every 
factor compared with controls. The differences in the aiming of motion, the arm-hand 
precision, as well as in the arm-hand speed were significant. Non significant trends were 
found for the hand unrest and the wrist-finger speed.  
Investigating potential correlations between fine motor factors and blood Phe or blood PUFA 
levels, we found a significant negative correlation between the current blood Phe-level and 
the aiming of motion, as well as the arm-hand speed (tab. 54). 
 









Aiming of motion 60.16 69.86 0.019 
Hand unrest (tremor) 56.00 63.86 0.067 
Arm-hand precision 24.69 37.14 0.005 
Arm-hand speed 25.05 36.73 0.009 
Wrist-finger speed 26.47 35.11 0.056 
* derived from Mann-Whitney-U-test or Student’s unpaired t-test as appropriate 
 
Tab. 54: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 






Sum of PUFA# in 
wt% (n=32)  
r p r p r p 
Aiming of motion -0.430* 0.016  0.005 0.980 -0.055 0.765 
Hand unrest (tremor) -0.307 0.093 -0.303 0.141 -0.012 0.947 
Arm-hand precision -0.277 0.131 -0.179 0.391 -0.136 0.459 
Arm-hand speed -0.387* 0.031 -0.104 0.619  0.289 0.109 
Wrist-finger speed -0.328 0.072 -0.131 0.127 -0.020 0.915 
AVLT= auditory verbal learning test, *significant, **highly significant, #sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 
18:4n-3, 20:2n-6, 20:3n-9, 20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
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Visual evoked potentials (VEP) 
VEPs were measured for P100 latencies. Pathological VEPs were observed in more than  
50 % of the PKU-patients (tab. 55). From evaluable VEP results (n=23) a mean latency of 
110.5 ms was calculated for PKU-patients as shown in table 56. In comparison, mean VEP 
(70’) latency in 30 healthy omnivores of a comparable age and gender ratio amounted to 
100.8 ms (100). P100 latencies above 115 ms were classified as prolonged, based on 
clinical experience (Prof. W. Müller-Felber, Munich). In eight (34.8 %) of all 23 evaluable 
VEPs prolonged P100 latencies above 115 ms were determined, whereas in none of the 30 
omnivores prolonged latencies were found. 
 
Tab. 55: VEPs findings in PKU-patients  
N (%) 
 
Pathologically altered Normal 
VEPs (n=30)*   15 (51.7)    14 (48.3) 
*some patients did not want to take part in these neurological tests 
 
 
Tab. 56: VEP (70’) P100 latencies in PKU-patients compared with healthy omnivores 
Mean ± SEM$ 
 
PKU-patients* (n=23) DHAVEG-Study# (n=30) 
Latency P100 (ms) 110.5 ± 3.2 100.82 ± 1.08 
* derived from 23 patients, others were not evaluable due to pathological alterations  
# Kraft et al., unpublished data; * SEM = standard error of the mean 
 
 
3.6.2 Neurostructural testing 
 
Magnetic Resonance Imagings (MRI) 
MRIs of the PKU-patients were evaluated to explore neurological abnormalities. All 
measured MRIs turned out to be abnormal. Pathological alterations were found in all of the 
16 performed MRIs. Figure 15 shows the MR image of a 30-year-old male patient. The MRI 
made during the study shows an atrophy of the brain as well as focal high signal intensity in 
the periventricular white matter.  
The severity of these findings ranged from one up to 6 points according to their extension. 
These generally symmetrical white matter abnormalities were graded as follows: 1 point for 
lesions restricted to deep white matter of the cerebral lobes (six areas), 2 points for 
subcortical alterations and 2 additional points for changes in the brainstem or cerebellum. 
MRI grade could therefore total between zero (normal MRI) and 12 (subcortical white matter  
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in all cerebral lobes, brainstem and cerebellum) (141). Table 55 shows the number of 
pathological altered MRIs in PKU-patients, whereas table 57 shows the severity of the 
detected alterations.  
Searching for significant correlations between severity of deep white matter alterations and 
blood Phe, or blood PUFA level no significant correlation was detected (tab. 58). 
 
Tab. 57: Severity of deep white matter alterations in PKU-patients  
Number N (%) of points given for alterations 
 
0 1 2 3 4 5 6 7-12 
Pathological MRIs 
(n=16) 0 2 (13) 3 (19) 3 (19) 5 (31) 2 (13) 1 (6) 0 
 
 
Tab. 58: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 






Sum of PUFA# 
in wt% (n=32)  
r p r p r p 
Severity of deep white matter 
alterations in PKU-patients 0.328 0.215 -088 0.764 0.190 0.482 
*excluding extreme values, #sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9,  





Fig. 15: Typical periventricular deep white matter alterations (♂, 30 yrs) 
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3.6.3 Neuropsychological tests 
d2 attention test 
From the variety of neuropsychological tests, the d2 attention test, the color-word 
interference task, the auditory verbal learning test and the number combination test were 
chosen for the PKU-patients and the healthy controls. 
Regarding the d2 attention test (tab. 59), subjects from the control group could complete a 
significantly higher number of items in the whole test, they achieved a higher number of 
items completed subtracted by failures, as well as a higher concentration performance 
(number of crossed out characters minus failures) compared to the PKU-patients. The 
number and percentage of failures, as well as the spread of the number of items completed 
(between the lines) did not differ significantly comparing the PKU-patients and the controls.  
 
Tab. 59: d2 attention test results of the PKU-patients and healthy controls 
Mean ± SD 
 PKU-patients 




Number of items completed (n)   336.2 ± 89.0   465.5 ± 99.3 <0.001 
Number of failures (n)     23.1 ± 23.4     32.0 ± 29.4 0.194 
Failures (%)     7.6 ± 8.3     10.0 ± 13.7 0.410 
Number of items completed minus 
failures (n)   309.8 ± 95.0   447.1 ± 79.5 <0.001 
Concentration performance # (n)   120.0 ± 46.1   188.9 ± 79.2 <0.001 
Spread between lines (n)  13.5 ± 7.2   12.6 ± 5.0 0.591 
*derived from Mann-Whitney-U-test or Student’s unpaired t-test as appropriate 
#Concentration performance = number of crossed out characters minus number of failures 
 
 
Tab. 60: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 






Sum of PUFA# in 
wt% (n=32)  
r p r p r p 
Number of items completed (n) -0.435* 0.018 -0.201 0.357 -0.072 0.706 
Number of failures (n) 0.521** 0.004  0.422* 0.045 0.016 0.931 
Failures (%) 0.566** 0.001  0.456* 0.029 0.033 0.862 
Number of items completed 
minus failures (n) -0.512** 0.005 -0.265 0.222 0.020 0.917 
Concentration performance# (n) -0.607** <0.001 -0.428* 0.041 0.008 0.966 
Spread between lines (n) 0.286 0.133 0.089 0.686 -0.037 0.847 
*significant, **highly significant, #sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
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In PKU-patients (n=30), the number and the percentage of failures were significantly 
correlated with the blood Phe-level in the study and throughout life, whereas the number of 
items completed, the number of items completed minus failures, as well as the concentration 
performance were significantly negative correlated with the blood Phe-level in the study and 
throughout life. In addition to that, the concentration performance was significantly negative 
correlated with the blood Phe-level throughout life (tab. 60).  
 
Color-word interference test 
Differences in the color-word interference test (CWIT) comparing results of the PKU-patients 
and of the controls are shown in table 61. Significant differences were detected in the 
reading duration of the color-words, the color-strokes, as well as of the interference list 
comparing the PKU-patients and the controls. The raw values obtained were transformed 
into t-values by using tables with normative values (196). The subjects from the control group 
had higher t-values in the reading duration of all three tasks. No differences were observed 
between both groups for results of the nomination and the selectivity skills. Significant 
negative correlations were found between the reading duration of all three different tasks and 
blood Phe-levels in the study (tab. 62). 
 
Tab. 61: Color-word interference test results of the PKU-patients and controls (t-values) 
Mean ± SD 
 PKU-patients 




Reading duration of color-words 47.7 ± 9.3 54.9 ± 8.2 0.002 
Reading duration color-strokes  45.1 ± 11.7  54.1 ± 10.2 0.003 
Reading duration of interference task 49.1 ± 9.4 56.1 ± 7.4 0.001 
Nomination  48.9 ± 14.4  49.1 ± 10.5 0.928 
Selectivity  57.8 ± 10.2 57.7 ± 8.3 0.994 
CWIT= color-word interference test, *derived from Mann-Whitney-U-test or Student’s unpaired t-test  
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Tab. 62: Spearman-Rho correlations between the blood Phe-level, the blood PUFA content 






Sum of PUFA# 
in wt% (n=32)  
R p r p r p 
Reading duration of color-words -0.593** 0.001 -0.392 0.064 -0.176 0.353 
Reading duration color-strokes -0.517** 0.004 -0.519* 0.011 0.121 0.523 
Reading duration of interference 
task -0.454* 0.013 -0.608** 0.002 0.117 0.538 
Nomination 0.086 0.658 0.043 0.845 0.131 0.491 
Selectivity 0.265 0.164 0.102 0.644 -0.017 0.928 
CWIT= color-word interference test, *significant, **highly significant, #sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 
18:4n-3, 20:2n-6, 20:3n-9, 20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
 
Auditory verbal learning test 
Table 63 shows results of the auditory verbal learning test (AVLT) used in the present study. 
Significant differences between PKU-patients and controls were detected in the number of 
immediately recalled words (of 15 presented words) and in the number of recalled words 
after the fifth recollection, whereas there were no significant differences for the learning and 
the recalling performance, for loss after distraction, and for the total number of recognized 
words. 
 
Tab. 63: Auditory verbal learning test results of the PKU-patients and healthy controls 
Mean ± SD 
 




Immediately recalled words (n) 5.4 ± 1.6 6.4 ± 2.2 0.047 
Recalled words after 5th 
recollection (n) 10.9 ± 3.1 12.9 ± 2.1 0.007 
Learning performance# (n) 5.5 ± 2.5 6.5 ± 2.3 0.129 
Recalling performance$ (n) 11.4 ± 2.9 12.8 ± 2.1 0.073 
Loss after distraction (n) -0.29 ± 1.13 0.13 ± 1.19 0.160 
Recognized words (n) 13.8 ± 1.8 14.5 ± 1.1 0.102 
AVLT= auditory verbal learning test 
* derived from Mann-Whitney-U-test or Student’s unpaired t-test as appropriate 
# number of recalled words after 5th recollection minus number of words of the first recalling 
$ number of recalled words after reading the 5th recollection and after recalling of another distracting list of words 
 
There were significant negative correlations between the blood Phe-levels throughout life 
and the number of recalled words after the fifth recollection, the learning performance, as 
well as the recalling performance in PKU-patients. The blood Phe-level in the study showed 
a significan negative correlation with the recalling performance and a positive one with the 
loss after distraction as (tab. 64). 
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Tab. 64: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 






Sum of PUFA# in 
wt% (n=32)  
r p r p r p 
Recalled words after the 
fifth recollection (n)  -0.347 0.056  -0.520** 0.008 0.218 0.232 
Learning performance # (n)  -0.270 0.142  -0.531** 0.006 0.310 0.084 
Recalling performance $ (n)  -0.482** 0.007  -0.544** 0.006 0.146 0.432 
Loss after distraction (n)   0.489** 0.006 0.073 0.733 0.101 0.587 
* significant, ** highly significant, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 18:4n-3, 20:2n-6, 20:3n-9, 
20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
 
Number combination test 
Significant differences regarding the number combination test (NCT) results were found 
between the PKU-patients and the healthy controls. The PKU-patients needed more time to 
complete the whole test (tab. 65). Furthermore, values of the IQ equivalent were found to be 
much higher in the controls (mean IQ 104) compared with the PKU-patients (mean IQ 85). 
 
Tab. 65: Number combination test results of the PKU-patients and healthy controls 
Mean ± SD or N as appropriate 
 




Total duration (sec)  418.4 ± 170.8 286.7 ± 81.0  0.001 
IQ equivalent  84.7 ± 18.5 104.1 ± 16.8 <0.001 
NCT, number combination test 
* derived from Mann-Whitney-U-test or Student’s unpaired t-test as appropriate 
 
 
Current and lifetime blood Phe levels were significantly correlated with total duration of the 
NCT, as well as the IQ equivalent the Phe-level, whereas PUFA content showed no 
correlation (table 66). 
 
Tab. 66: Spearman-Rho correlations between the blood Phe-level, blood PUFA content and 






Sum of PUFA#  
in wt% (n=32)  
r p r p r p 
Total duration (sec) 0.689** <0.001 0.591** 0.004 -0.074 0.703 
IQ equivalent 0.673** <0.001 0.564** 0.006  0.065 0.739 
NCT, number combination test, * significant, ** highly significant, # sum of following PUFA: 18:2n-6, 18:3n-6, 18:3n-3, 
18:4n-3, 20:2n-6, 20:3n-9, 20:3n-6, 20:4n-6, 20:3n-3, 20:5n-3, 22:2n-6, 22:4n-6, 22:5n-6, 22:5n-3, 22:6n-3 
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3.7 Subjects’ own assessment of their health 
For verification of the hypothesis that adults with PKU are less healthy than age-matched 
controls all subjects were asked for their health status, as well as how healthy they feel.  
Although there was no significant group difference detected, the following two tables show an 
indication that PKU-patients might be less content with their health compared to controls. 
The same number of patients, as well as of the controls felt content, but about 39 % of the 
controls in contrast to only 8 % of the PKU-patients felt very content with his health status 
(table 67). In comparison with the controls more PKU-patients feel less content (12 % 
compared with 0 %) or even not at all content (6 % compared with 3 %). 
 
Tab. 67: Measure of contentedness with health in the PKU-patients and healthy controls 
N (%) 
 









PKU-patients (n=33) 2 (6.1)  4 (12.1) 19 (57.6)    8 (24.2) 
Controls (n=33) 1 (3.0) 0 (0.0) 19 (57.6) 13 (39.4) 
Total (n=66) 3 (4.5) 4 (6.1) 38 (57.6) 21 (31.8) 
0.130 
* derived from Chi-square test 
 
 
Asking for the feelings about their health in more detail, there are again some trends 
detectable. As shown in table 68, more than 50 % of the PKU-patients, as well as of the 
controls feel healthy, but the proportion of the controls feeling very healthy exceeds that one 
in the group of the PKU-patients (39 % vs. 27 %). Five PKU-patients felt less healthy in 
contrast to only one of the controls and one PKU-patient compared to none of the controls. 
 
Tab. 68: Feelings of the PKU-patients and healthy controls about their health status 
N (%) 
 









PKU-patients (n=33) 1 (3.0)  5 (15.2) 18 (54.5)   9 (27.3) 
Controls (n=33) 0 (0.0) 1 (3.0) 19 (57.6) 13 (39.4) 
Total (n=66) 1 (1.5) 6 (9.1) 37 (56.1) 22 (33.3) 
0.198 
* derived from Chi-square test 
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4 Discussion 
4.1 Subjects 
The present study is based on 33 adult PKU-patients aged 26 to 59 years (12 men, 21 
women) out of a total of 53 adult patients aged >25 years with PKU from the metabolic 
outpatient clinic at the Dr von Hauner Children’s Hospital, Univ. of Munich. Five out of the 53 
patients did not want to take part in the investigations, further five subjects were too 
handicapped and for 10 PKU-patients current addresses or telephone numbers could not be 
determined. As a reference goup, thirty-three healthy, age- and gender-matched subjects (11 
men, 22 women) at an age between 23 and 49 years were recruited. The number of patients 
was comparable to other PKU studies in which the number of cases was sufficient to obtain 
significant test results for the comparison of the PKU-patients and the control group. For 
example, Moseley et al. (130) determined a significant decline in serum fatty acids in 27 adult 
PKU-patients, and Weglage et al. (185) showed significant alterations in the motor 
performance, as well as a positive correlation with the elevated Phe-levels in 20 PKU-
patients.  
The educational level tended to be different comparing both of our groups (p=0.054) because 
the control group was chosen according to the educational level of the current German 
population reported by the Statistical Yearbook (2) for adults of the same age like the 
patients. Thus, two patients did not have any graduation at all; three patients had graduated 
from special school (Sonderschule) compared to none of the controls; and 13 controls were 
qualified for University entrance (Gymnasium) compared to only 5 of the patients (tab. 27). 
The mean age of the patients (34.5 ± 6.3 yrs) matched with the one of the control group 
(34.6 ± 7.6 yrs).  
There was no difference between the groups with respect to gender, age and heart rate; 
whereas PKU-patients were significantly shorter than the control group. Fisch et al. (57) and 
Verkerk et al. (179) reported a significantly smaller longitudinal growth in untreated patients 
with PKU, even after adjustment of the Phe-levels <3 mg/dl (78). One possible explanation 
for that might be a lower supply of Phe and other amino acids, vitamins, minerals and trace 
elements (162) e.g. malnutrition of zinc and other trace elements (149). Weight and BMI 
were highly significantly greater in adults with PKU. Avoidance of sport club activities due to 
reported social isolation and anxiety (167) of the PKU-patients might explain the higher 
weight and BMI. Besides, three of the patients live in homes with sportive activities only once 
a week. Additionally, Acosta et al. (6), as well as Mc Burnie et al. (119) found a Phe-
associated tendency to overweight and Fisberg et al. (56) revealed lower height/weight ratios 
in PKU-children compared with healthy children. In the present study, blood pressure was 
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highly significantly greater, as well as the heart rate was found to be higher in the group of 
PKU-patients compared with the control group. This might be a result of the higher body 
weight and lower height, as well as of less sportive activity and nutritional influences which 
will be discussed in a different chapter. 
 
4.2 Nutritional status 
 
Phe-levels of the patients 
As index for the quality of dietary control the blood Phe-level throughout life (mean of all 
yearly medians of Phe-levels since start of treatment collected in patient files) was used. The 
advantage of this method is reflected in the lower rates of extreme values compared to 
current blood Phe-levels (56). During the study, sixteen patients (48.5 %) were still or again 
adhering to low-protein diet supplemented with special amino acid mixtures. Three of them 
had restarted due to health problems (n=1) or pregnancy (n=2). These proportions are higher 
than data presented about phenylketonuric adults in the collaborative study of PKU in 
adulthood (96) in which 12.3 % never discontinued and 87.7 % never resumed low-protein 
diet although they received some additional treatment.  
Daily dietary intake of Phe calculated from food records was about 2,362 mg. In adults the 
target value usually lies between 150 and 1,000 mg per day (131). Seven PKU-patients 
(including 3 pregnant women on strict diet) had Phe-intakes less than 10 mg per kg body 
weight and about 58.1 % of the PKU-patients (n=18) had Phe-intakes greater than 20 mg per 
kg weight. The average Phe-tolerance normally determined in adult PKU-patients amounts to 
10-20 mg/kg. Only about every fifth PKU-patient had a Phe-intake within these ranges (n=6). 
Most of the patients seem to have higher Phe-intakes than considered advisable. 
Regarding the blood Phe-levels, eleven (34.4 %) patients exceeded the recommendations of 
the APS (11) with a blood Phe-level greater than 20 mg/dl. The mean blood Phe-level in the 
study amounted to 15.9 mg/dl and the mean blood Phe-level throughout life amounted to 
13.6 mg/dl. There was a highly significant positive correlation between the blood Phe-level in 
the study (excluding very low values, n=6) and the daily mean Phe-intake calculated from 
food records, or the blood Phe-level throughout life respectively. In the collaborative study of 
PKU in adulthood (96) the majority of the 73 PKU-patients had blood Phe concentrations 
above 19-20 mg/dl except the group of PKU-patients who always continued diet (n=9, mean 
Phe-level=15.4 mg/dl). Both facts demonstrate the importance of a strict low-Phe diet and 
adequate treatment which should be implemented early and continued for lifetime (96). 
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Method for dietary evaluation 
Data of nutritional supply of the PKU-patients was collected by using dietary protocols. A 
modified form of the “Freiburger Ernährungsprotokoll” was used adding special low-protein 
products often consumed by PKU-patients for reminding patients of food like sweets usually 
eaten between the dishes. The dietary protocol consists of different food groups with typical 
food items. The patients estimated the quantities of consumed food items and beverages 
using common household measurements according to provided instructions (slice, piece, 
teaspoon, mug etc.). PKU-patients were asked to make precise descriptions, e.g. the content 
of fat to minimize failures in calculation of fat and calorie intake. Their food consumption was 
recorded over three consecutive days covering 2 weekdays and one weekend day for 
obtaining results which are representative for the intake of the whole week. PRODI, version 
4.5 LE 2003 (NutriScience GmbH, Freiburg, Germany) commonly used for dietary treatment 
in Germany was used to record dietary intake based on the German Nutrient Data Base 
BLS, version II.3 (BgVV, Berlin, Germany). The results were compared to recommended 
ranges of the German Nutrition Society (47). To minimize failures in calculation of nutritional 
supply using PRODI we proved results for similar nutrients. “Vitamin E” concentrations were 
used because “α-tocopherol” values were lower or missing. In case of vitamin A, the “retinol 
equivalent” was used for calculation because “vitamin A” was not measured in amino acid 
mixtures. For folic acid there were three possibilities by using PRODI. Values were available 
for “free folic acid”, “free folic acid equivalent” and “folate”. The concentrations of folate 
exceeded those of free folic acid equivalent and free folic acid, therefore “folate” was used to 
calculate folic acid supply. Above choosing the right method for calculation, eating a variety 
of food products enriched with vitamins, or supplementation with vitamins and minerals might 
bias the results. For that reason blood vitamin levels might be higher than expected by 
calculated dietary intake derived from dietary protocols. In contrast to that, underreporting 
might result in lower calculated nutrient levels than the real intake. 
 
Dietary intake and nutrient supply in PKU 
Many studies reported untoward effects of the semi-synthetic diet on the intake or status of 
critical nutrients (6;22;24;35;44;62;70;108-110;144;146;148;172). In the present study energy 
intake was about 96 % of D-A-CH reference values (47) in women and 99 % in men, 
compared to 101 % (men) and 122 % (women) determined in the German population (46). 
The energy requirements of patients with PKU are the same as in healthy subjects 
(11;176;193) and result from basal metabolic rate, working metabolic rate and thermo 
genesis after dietary intake, as well as the requirements for growth, pregnancy and nursing 
period. An important part of the energy turnover is based on the energy requirement for 
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physical activities. The daily energy requirement results from the duration of activities. As 
PKU-patients seem to do rarely sports, they might have lower energy requirements. In 
contrast to our results meeting the recommendations, Fisberg et al. (56) found lower energy 
intakes in PKU-children compared with healthy children which might be a result of the strict 
diet excluding many high caloric food items e.g. chocolate. However, the participation in a 
nutritional study might have caused larger reductions in dietary intakes or underreporting of 
consumed foods than before the investigation at the days of the dietary record. Another 
explanation might be an appetite lowering effect of the amino acid mixtures. 
The protein intake (calculated from total nitrogen intake) of the PKU-patients in the present 
study was about 108 % (women) and 104 % (men) of D-A-CH reference values, compared to 
138 % or 169 % referring to the Nutrition Report 2004 (46). The protein intake measured in 
% of energy taken in exceeded the D-A-CH recommendations (14 % vs. 10 %). In contrast to 
results in adults, Fisberg et al. (56) found normal protein intakes in PKU-children which 
shows again the importance of diet in adulthood. The PKU-diet is very restricted in protein 
content and the amount of natural protein depends on the individual Phe-tolerance. Studies 
showed that patients with PKU have the same capacity of protein turnover as healthy 
subjects and requirements of Phe are the same as in healthy subjects regarding the 
compensation of tissue losses, specific functions of Phe, as well as need for growth 
(3;6;26;101;127). Therefore the protein intake is often calculated following the 
recommendations of the German Nutrition Society (DGE) from 1985, which are the same for 
adult women. The recommendation for adult men was about 0.9 g protein per kg body weight 
whereas current D-A-CH recommendations (47) propose 0.8 g per kg. As determined in 
other studies PKU-patients tend to have protein intakes higher than recommended (128). 
Patients with little restriction of protein intake may require supplementation of protein by 
amino acid mixtures in special situations e.g. in competitions or bodybuilding. However, 
further scientific investigations are needed to allow a final comment about a sufficient protein 
intake. 
The fat intake of the PKU-patients was about 111 % in women and 98 % in men compared 
with D-A-CH recommendations (47). The fat intake determined in % of energy was about 107 
%. These facts show that adult PKU-patients tend to have fat intakes higher than 
recommended  (128). Results from the Nutrition Report 2004 (46) revealed a different fatty 
acid profile among the German population reporting higher intakes of fat (142 % ♀,  
117 % ♂), SFA (176 % ♀, 136 % ♂) and MUFA (119 % ♀, 102 % ♂) but a lower intake of 
PUFA (88 % ♀, 84 % ♂). The PUFA intake in our PKU-patients was also lower than 
recommended but much lower compared with results of the Nutrition Report (PKU: 51 % ♀, 
43 % ♂). The MUFA intake was similar to the recommendations (108 % ♀, 95 % ♂) and SFA 
intake (123 % ♀, 116 % ♂) exceeded the recommendations by D-A-CH (47). The intake of 
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linoleic acid was about 10.4 g in women and 10.5 g in men compared with higher results of 
12.8 g and 16.3 g reported in the German population (46). The intake of α-linolenic acid 
amounted to 1.3 g in women and 1.5 g in men (168/135 % of D-A-CH) compared to 2.0 g 
and 2.2 g from the Nutrition Report (46). Referring to D-A-CH (47) the intake was higher than 
reference intakes (168/135 % ♀/♂). Regarding the fatty acid profil of plasma phospholipids 
PKU-patients had lower mean blood levels (wt%) of linoleic acid and DHA compared with 
healthy omnivores of a same age and gender (61). No difference was observed for  
α-linolenic acid levels, whereas the median arachidonic acid proportion was higher compared 
to healthy omnivores. However, some of the critical nutrients in adults with PKU are the 
same as in the German population e.g. PUFA which might be a result of the diet containing 
small amounts of fatty acids. Furthermore, the dietary intake of EPA (2 mg/d) and DHA (42 
mg/d) was very low in PKU-patients possibly due to abdiction of fish and fish products. In 
comparison to our results, higher intakes of both EPA (53 mg ♀, 98 mg ♂) and DHA (87 mg 
♀, 134 mg ♂) were reported in the Nutrition Report 2004 (46). Recently, the dietary intake of 
EPA and DHA combined in the German population has been estimated to be 141 mg/d 
among women and 186 mg/d among men (medians) (13). In conclusion, PKU-patients have 
lower intakes of DHA and EPA compared to healthy adults and lower intakes of PUFA 
compared with D-A-CH recommendations and results of the Nutrition Report as previously 
reported in several studies (4;63;130;148;177). These findings must be taken into 
consideration to ensure an optimal nutritional supply in PKU. 
The intake of carbohydrates in g per day was about 82 % (♀) and 90 % (♂) in relation to 
recommendations of D-A-CH. Carbohydrates in % of energy taken in by PKU-patients were 
about 108 % of D-A-CH whereas the intake of fiber was 43 % lower than the recommended 
30 grams per day (17 ♀ and 9 g ♂ per day). Higher intakes than determined in our study 
were reported among the German population in the Nutrition Report 2004 (108 %) in which 
also fiber intake exceeded our results (25 g ♀, 22 g ♂). In conclusion, the intake of 
carbohydrates and fiber was lower than reference values for adults. The proposed 30 g fiber 
per day often cannot be realized due to a restriction of food assortment in the PKU-diet. 
Moreover, PKU-patients tend to have high intakes of food rich of sugar and little content of 
fiber. 
Regarding the vitamin supply of PKU-patients, intakes and blood levels were determined and 
compared with reference values of D-A-CH (47), as well as results of the Nutrition Report 
2004 (46). The intakes of retinol were about 175 % among women and 150 % among men 
compared with D-A-CH reference values. The thiamin intake was about twice as much than 
the reference value (220/142 % ♀/♂), the riboflavin intake was about 183/157% (♀/♂), the 
pyridoxine intake was 192/153 % (♀/♂) and the daily intake of folic acid about 83 % in 
relation to the reference values. The intake of ascorbic acid amounted to 162 %, the intake of 
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vitamin D achieved 92 %, the intake of α-tocopherol was 155 % and the vitamin K intake 
exceeded the D-A-CH reference values several times (393 % ♀, 413 % ♂). The intake of 
panthotenic acid was about 115 %, the intake of biotin 246 % and the cobalamin intake 
amounted to 170 % of the D-A-CH values. Thus, lower levels than reference values were 
determined for folic acid and vitamin D. In contrast to that, the mean intakes of vitamin A, B-
group vitamins, ascorbic acid and α-tocopherol were higher than reference values. In 
comparison with our results the intake among the German population was for retinol  
173/112 % (♀/♂), vitamin B1 136/113 % (♀/♂), vitamin B2 128/111 % (♀/♂), vitamin B6 
143/119 % (♀/♂), vitamin D 49/66 % (♀/♂), vitamin E 106/106% (♀/♂) and vitamin K 
526/403 % (♀/♂) of the D-A-CH reference values. Determining blood samples in one PKU-
patient we found a blood retinol concentration less than the reference range. Three PKU-
patients had reduced levels of α-tocopherol, five PKU-patients had higher folic acid and one 
PKU-patient higher cobalamin levels compared to the reference range. All PKU-patients met 
the reference intake values for vitamin D. A lack of panthotenic acid, biotin and ascorbic acid 
as determined in the German population (46) was not found in PKU-patients. These results 
indicate that adult PKU-patients, mainly with loosened diet and only little restriction of protein 
intake, as well as without intake of an amino acid mixture, have to pay attention to an 
adequate intake of vitamins. A substitution might become necessary. Numerous studies 
showed inadequate intakes of vitamins (41;70;70;144;147;153;158;177) in adult PKU-
patients due to a vegetarian diet. We found mainly low intakes of folic acid and vitamin D 
which was also reported in the general German population, as well as low blood levels of α-
tocopherol and retinol (3). However, a lack of B-group vitamins (129), or vitamin B12 (70), 
vitamin B6 (144), and vitamin B2 (108) was not found. 
Regarding the intake of minerals and trace elements, calcium intake amounted to 108 %, 
phosphorus 177 %, magnesium 137/133 % (♀/♂), iron 193/121 % (♀/♂), zinc 216 %, iodine 
83 %, copper 208 %, chloride 142 %, fluoride 26 % and manganese 393/413 % (♀/♂)in 
relation to reference values of D-A-CH. Results of the Nutrition Report showed the following 
supply: calcium 181/90 % (♀/♂), magnesium 142/110 % (♀/♂), iron 101/134 % (♀/♂), zinc 
159/111 % (♀/♂), copper 154/147 % (♀/♂), manganese 129/110 % (♀/♂), phosphorus 
196/198 % (♀/♂) and iodine 48 %. In contrast to intakes almost 38 % of the PKU-patients 
had blood iron or zinc concentrations below the laboratory’s reference range. Two PKU-
patients had low contents of ferritin. A high intake of zinc and iron but low blood levels might 
be caused by higher requirements or worse utilization of zinc and iron. Schäfer et al. 
concluded that the growth retardation found in PKU-patients might be caused mainly by poor 
supply of zinc and other trace elements (149). In 56 % of the subjects, reduced blood levels 
of selenium were found which were significantly positively correlated with blood Phe-levels 
throughout life (r=0.451, p=0.024). As food items rich of selenium are often rich of protein this 
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might cause a low intake of selenium adhering to a low-protein diet. Regarding blood levels, 
we revealed a higher Ca level in two of the PKU-patients, one patient had higher blood 
ferritin and seven higher blood copper concentrations. In conclusion, mean intakes of 
sodium, potassium, magnesium, iron, zinc, copper, chloride and manganese were found 
higher than the reference values. Levels of iodine and fluoride turned out to be lower but this 
was also reported among healthy adults in the Nutrition Report. The blood levels of iron, 
ferritin, selenium and zinc were lower than reference ranges in some of the PKU-patients but 
not in other minerals and trace elements as it was shown in numerous studies 
(5;22;24;44;67;74;110;122).  
4.3 Immune status  
There are indications that PKU-patients show alterations in the immune system (88;146). 
Karagoz and colleagues (88) found that children with PKU had lower immunoglobulin levels 
compared to healthy children. Regarding the concentrations of immunoglobulins no major 
abnormal results were detected for IgG, IgA and IgM. IgG levels were normal in all patients, 
elevated IgA was found in one and two PKU-patients had greater IgM values compared with 
normal ranges. The most significant result was that in about 30 % (n=10) of all patients 
elevated serum IgE levels were determined. In these patients, an Elisa immunoassay was 
performed for measurement of special IgE. Searching for correlations significant positive 
correlations were noticed between IgE and blood Phe-level in the study (p=0.029). 
Furthermore significantly negative correlations were found between the PUFA content of 
blood and IgA (p=0.036), as well as IgE (p=0.012). In contrast to our results, Riva et al. (146) 
revealed significantly decreased serum concentrations of IgG, IgA and IgM in PKU-patients 
compared with reference values but increased IgE levels without a higher incidence of 
infections or allergic diseases but a more frequent allergic sensitation. Gropper et al. (68) 
found significantly lower mean plasma IgG and IgA concentrations in PKU-children 
compared to values in healthy controls. He reported that IgG levels were positively correlated 
with intakes of energy, protein and iron. Testing for special IgE, PKU-patients showed 
positive reactions regarding different allergens of the Elisa immunoassay. Most of the 10 
patients with elevated IgE showed allergic reactions with phleum pratense (n=6), secale 
cereale (n=5), quercus alba (n=4), as well as dermatophagoides pteronyssinus (n=4). Using 
a questionnaire, atopic disease was suspected if the subject had or ever had had at least 
one of the diseases associated with atopic disease. Based on these criteria, almost 55 % of 
all PKU-patients were suffering from atopic disease compared with only 21 % of the age-
matched controls, which means that adults with PKU had highly significantly more often 
atopic disease than the controls. Phenylketonurics had significantly more often hay fever, 
allergic coryza or allergic conjunctivitis. A trend towards a higher prevalence of asthma in 
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PKU-patients compared to healthy controls was observed (p=0.053). A running nose and 
swollen eyes as typical allergic symptoms, as well as neurodermitis, urticaria or food allergy 
were not significantly but still more often observable in patients compared with controls. 
Searching for correlations there was no significant correlation between the frequency of 
allergic diseases and blood Phe, or blood PUFA level observable in PKU-patients. 
Furthermore, the median arachidonic acid (AA) proportion was found to be higher and 
median DHA levels lower in PKU-patients compared to healthy omnivores which could 
explain alterations in the immune status. Thus, Agostoni et al. (7) found that well-compliant 
PKU-subjects had low AA concentrations in plasma but low compliance with animal food 
avoidance and higher Phe-levels resulted in elevation of plasma AA. Giovannini et al. (63) 
reported that the availability of AA from plasma in PKU was related to dietary compliance and 
seems to influence the synthesis of AA-derived eicosanoids influencing the immune system. 
Another cause for changes in the immune status in PKU might be the damage of the 
antioxidative status. We found decreased blood concentrations of selenium, zinc, retinol and 
α-tocopherol. Van Bakel (177) showed that PKU-patients had lower glutathione peroxidase 
activity compared with HPA subjects and controls and a lower glutathione concentration than 
the control group. Schulpis et al. (157) found a high plasma antioxidant status in patients with 
PKU, especially in those with a good compliance with their diet which is possibly due to the 
amounts of antioxidants present in their special low-Phe vegetarian diet. Sirtori et al. (164) 
presented data about increased oxdative stress parameters and decreased total antioxidant 
reactivity in patients with PKU indicating a stimulation of lipidoxidation and deficient capacity 
to rapidly handle an increase of reactive species. And finally, a recent multicenter study in 
the USA found that adult PKU-patients who discontinued their diet show more frequently 
eczema and bronchial asthma compared to adults who continue their diet (96).  
 
4.4 Cardiovascular risk 
BMI, consumption of cigarettes, blood pressure, hypertension, heart rate and blood 
parameters like homocysteine and the lipoprotein profile were determined as indicators of 
cardiovascular risk of the PKU-patient. We found significantly greater values for BMI, blood 
pressure and heart rate in the PKU-patients compared with controls. The adults with PKU 
were significantly more often obese.  
 
Eleven PKU-patients but only three of the controls had BMI values in the range of 25 to <30. 
Obesity grade I (BMI 30 - <35) was revealed in 4 of the PKU-patients compared to only 2 of 
the controls. BMI values of 35 and higher were found solely in two adults with PKU but in 
none of the controls. But the subjects from the control group tended to smoke more often 
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than patients with PKU (n.s.). Hypertension was not significantly different in both groups. Six 
of the PKU-patients but eight of the controls had mild, two patients but six controls moderate 
and only one control subject had heavy hypertension. Regarding the blood lipid status and 
blood homocysteine levels of the PKU-patients, elevated levels (compared to the laboratory’s 
reference range) were often observed: 3 % up to 19 % had higher concentrations of blood 
parameters that are considered as risk factors for cardiovascular disease (CVD). Five PKU-
patients (15 %) had elevated total cholesterol and six (18 %) elevated TG levels relative to 
fasted reference values, our PKU-patients were not fasting before bood sampling. Circulating 
TG levels have been associated with the severity and progression of atherosclerosis (75) 
and are considered independent risk factors for coronary heart disease (77), but how many 
fasting TG values might have been elevated is unknown. Elevated VLDL concentrations 
relative to fasting levels were detected in six adults with PKU (19 %), but again it is unclear 
how many subjects might have had elevated fasting levels. In one PKU-patient, the LDL level 
exceeded the reference range, and two subjects had LDL/HDL ratios above the reference 
range. Lp (a) was elevated in six PKU-patients (18 %), Apo A1 in six (19 %) and Apo B was 
elevated in one patient. Homocysteine was found above the reference range in 16 % of the 
PKU-patients. Schulpis et al. (153) reported that PKU-patients on a strict diet had low vitamin 
B6, vitamin B12 and folate levels resulting in moderate homocysteinemia, which might 
influence the risk of coronary artery disease. In another study (153) he showed that TG, as 
well as larger and less atherogenic LDL particles were associated with a high zinc to copper 
ratio, which might not be reached in PKU-patients due to a low dietary supply of bioavailable 
zinc. Previous studies have shown that the risk of coronary heart disease is influenced by 
dietary fatty acid intake (29;103;191). A higher degree of incorporation of n-3 LCPUFA into 
myocardial membranes reduces sudden cardiac death following myocardial ischemia (105). 
A case-control study showed that levels of DHA in plasma phospholipids were inversely 
correlated with the risk of coronary heart disease in a multivariate model that controlled for 
the effects of HDL/LDL ratio (163). Kinosian et al. (91;91;92) proposed that the LDL/HDL 
ratio is a better predictor of risk for coronary heart disease than total cholesterol or LDL 
plasma levels alone. Omega-3 LCPUFA also have a TG lowering effect in humans 
(42;45;66;135;136). N-3 LCPUFA were reported to improve blood pressure control in 
hypertensive patients (25;93;114) and to decrease the ApoA1/HDL (30;66). Testing for 
correlations between cardiovascular risk factors and blood Phe or blood PUFA level, 
significant positive correlations were detected between the blood Phe-level in the study and 
total cholesterol (p=0.017), as well as TG (p=0.050) and VLDL (p=0.033). Additionally, blood 
DHA content (wt%) was positively related to HDL (r=0.466, p=0.007), to LDL/HDL (r=0.371, 
p=0.036) and to ApoA1 (r=0.514, p=0.003). In the collaborative study of PKU in adulthood 
(96) PKU-patients who never discontinued diet rarely suffered from heart disease or 
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hypertension. It seems likely that low PUFA and DHA intakes in PKU-patients, jointly with 
elevated blood lipid levels and an elevated LDL/HDL ratio in two patients (mean 2.4, SD 0.9), 
increased obesity and hypertension, poor antioxidant status and less physical activity in 
PKU-patients might all contribute to an elevated cardiovascular risk in PKU-patients 
compared with healthy controls.   
 
4.5 Metabolic status 
For determination of differences in metabolic parameters, all patients and controls were 
asked to wear an accelerometer for three days. The total energy expenditure per day, the 
number of steps taken, as well as the sleeping duration showed no significant differences 
between the PKU and the control group. The lying duration tended to be (n.s.) different with 
8.6 hours for patients and only 8.1 hours per day for the controls (p=0.051). Significantly 
higher values for physical activity levels and the daily active energy expenditure were found 
in the control group. Significant correlations found between accelerometer results and 
inactivity parameters in all subjects were noticed. Significant positive correlations were found 
between activity energy expenditure, as well as physical activity level and duration of 
physical activity per week, but there were significant negative correlations between duration 
of watching TV per day and activity expenditure as well as physical activity level per day. A 
significant negative correlation was found between physical activity level per day and obesity, 
as well as body weight. A significant positive correlation was found between the blood PUFA 
content (see 3.2.1.) and physical activity level (r=0.371, p=0.040) and the number of steps 
taken (r=0.406, p=0.023). Healthy adults reported significantly more often sports activities 
and less frequent television viewing than PKU subjects. The duration of computer use during 
free time tended to be higher in controls compared to PKU-patients (n.s.) which might result 
from different educational levels and occupations e.g. to qualify for University entrance one 
needs to have a computer. There were no significant correlations between cardiovascular 
risk factors and blood Phe or blood PUFA levels.  
Compared with our results, Acosta et al. (6) and McBurnie et al. (119) found a Phe-
associated tendency to overweight in patients with PKU. Fisberg et al. (56) found lower 
height/weight ratios in PKU-children compared with healthy children. These findings might be 
related to the avoidance of sport club activities due to reported social isolation and anxiety of 
PKU-patients (167), but there are also further explanations. Schulpis et al. (155) revealed 
that ghrelin is negatively correlated with plasma Phe content but positively with 
catecholamine levels and energy intake. In another study (154) these investigators showed 
that leptin was significantly increased in PKU-patients on a loose diet compared with PKU-
patients on a very strict diet. Leptin was negatively correlated with the total energy intake and 
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positively with the Phe-level. In contrast to these findings, White et al. (192) reported on 
overweight which was not significantly related to the diet but to socioeconomic status and 
overweight of parents. Allen et al. (8) investigated resting expenditure in children with PKU 
and found no evidence of reduced resting energy expenditure or increased weight.   
 
4.6 Neurological status 
4.6.1 Neurophysiological findings  
The number of failures and durations of the different tasks, as well as fine motor factors like 
aiming of motion, hand unrest (tremor), arm-hand precision, arm-hand and wrist-finger speed 
were compared between patients and controls. Adults with PKU committed about three times 
more failures in the steadiness task, almost one third more in line tracking (highly significant) 
and approximately twice as much failures in aiming as controls. Regarding the measured 
duration of failures, there were significant differences for steadiness and highly significant 
differences for line tracking. The total duration of line tracking and aiming was not 
significantly different between both groups but significantly different for inserting pins. 
Controls had a higher rate of hits in tapping and almost as many hits as the PKU-patients in 
aiming. Significant positive correlation between the blood Phe-level in the study and the 
number of failures in steadiness (r=0.370, p=0.031) and aiming (r=0.398, p=0.026), the 
duration of failures in aiming (r=0.469, p=0.008), as well as the total duration of aiming 
(r=0.389, p=0.031) should be noticed. Additionally, a significantly negative correlation was 
found between the blood PUFA content and total duration of inserting pins (r=-0.361, 
p=0.042). The results of the PKU-patients are positively correlated with blood Phe-levels 
during the study. Differences were observed comparing motor factors determined by the 
MPT task. PKU-patients had worse t-values for every factor compared with controls. There 
were significant differences in aiming of motion, arm-hand precision, as well as in arm-hand 
speed, and non significant trends to worse hand unrest and wrist-finger speed. There was a 
significant negative correlation between the blood Phe-level during the study and aiming of 
motion, as well as arm-hand speed. These results indicate that fine motor skills appear to be 
correlated with the strictness of the PKU-diet, with lower blood Phe- and PUFA-levels 
associated with better results.  
From evaluable VEP results (n=23) a mean latency of 110.5 ms was calculated for PKU-
patients. In comparison, mean VEP (70’) latency in 30 healthy omnivores of comparable age 
and gender ratio was 100.8 ms. P100 latencies above 115 ms were stated as prolonged. In 
eight (34.8 %) of all 23 evaluable VEPs prolonged P100 latencies above 115 ms were 
determined, whereas in none of the 30 omnivores were found prolonged latencies. Nutt et al. 
Discussion  83 
(137) showed significantly shorter P100 latencies after administration of dopamine in healthy 
adults and Parkinson patients. Ludolph et al. and Korinthenberg et al. (99;113) found 
significantly prolonged P100 latencies independent of the actual blood Phe-level explained 
by dysmyelination (14;134). Beblo et al. (15) measured VEPs in 36 patients with early treated 
PKU (aged 1-11 yrs) and good metabolic control before and after supplementation with 
LCPUFA from fish oil. After three months, 22 of the PKU-patients with significantly longer 
P100 latencies had significantly improved P100 latencies but latencies did not change in 12 
of the PKU-patients. This might signify that LCPUFA are essential substrates for the nervous 
system function even beyond infancy. 
Patients with PKU seem to be differently vulnerable to alterations in the brain, and a few 
untreated patients with classical PKU with normal development have been described 
(48;143;160). Only Bick et al. (18;19) did not find any significant relation between VEP 
results and blood Phe-level or diet. One of the possible explanations might be dysmyelination 
of the visual nerve tract and disorders of the neurotransmitter metabolisation (14;82) but 
administration of L-dopa showed no effect on P100 latencies (175) which might be due to 
inhibition of dopa intake through blood-brain barrier (94;95). It is unclear whether Phe not 
only inhibits intake and synthesis of dopa but also interferes with its release (137). 
Additionally, the role of the density of dopamine receptors is not clear; there might be a 
compensating postsynaptic upregulation of dopamine receptors (175). 
4.6.2 Neurostructural findings 
Pathological alterations were found in all of the 16 MRIs performed. The severity of these 
findings ranged from one up to 6 points. There were no significant correlations between 
severity of deep white matter alterations and blood Phe, or blood PUFA level. Pietz et al. 
(139) reported alterations in only 10 % of the PKU-patients altered MRI findings. No relation 
to MRIs was reported by Cleary et al. (40), whereas Schafer et al. (150) reported 
improvement after strict diet and administration of transmitters (L-dopa, 5-hydroxy-
tryptophan) which explains dependency on transmitters which are decreased in PKU due to 
inhibition of synthesis of dopamine, noradrenalin, serotonin, as well as inhibition of 
expression of dopamine receptors (52;80).  
Regarding the MRI findings of patients with PKU, alterations in deep white matter were first 
described in 1989 (180) in two adult, lately treated PKU-patients (after 3rd year of life) with 
cerebral convulsions or decreased intellectual skills. Both had mainly periventricular occipital 
but also frontal, subcortical alterations with participation of corpus callosum and brainstem as 
shown in other studies (18;19). The causes are de- or dysmyelination (134;162) with inserted 
water (edemas) (19) which were found also in untreated PKU-patients post mortem (14). The 
exact pathogenesis has not not been clarified but might be caused by increase of total tissue 
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water or structural myelin alterations and consecutive increase of free, extracellular water 
(18;19). Similar to other studies (40;139) we found a high proportion of pathological MRI 
findings in adult PKU-patients. The severity of these findings ranged from one up to 6 points 
on a scale according to their extension. It was reported that such pathological morphological 
alterations are also found in PKU-patients without noticeable neurological abnormalities 
(18;19). Phe has toxic implications on brain (34;79;82) causing disorders of synthesis and 
breakdown of neuronal proteins, myelin and myelin proteins (81;83;89;171). The alterations 
are mainly periventricular, but in more severe manifestations also frontal and subcortical, and 
in some cases atrophy is found. Extension increases with age and poor diet compliance 
(183), whereas the appearance and severity are individually very different and not related to 
intelligence, neurophysiological, or neuropsychological findings (40;139). Nevertheless, it 
was shown that edemas are reversible by adhering to a very strict diet for 3 months (19;40). 
It was reported that untreated patients with classical PKU had only minimal alterations of 
deep white matter (187) which indicated that there are further causes like different brain Phe-
levels but same blood Phe-levels (190). In conclusion, these findings seem to be caused by 
dysmyelinisation with insertion of water dependent on the blood Phe-level and therefore 
reversible by strict diet in adulthood. 
4.6.3 Neuropsychological findings 
From the variety of neuropsychological tests, the d2 attention test, the color-word-
interference-task, the auditory verbal learning test and the number combination test were 
chosen to apply. In adult patients with PKU there are differences expected but the influence 
of elevated Phe-levels might have a lower impact on cognitive functions than in children 
because further brain development decreases with age and perhaps there are changes in 
the metabolisation of transmitters (84). However, it seems that most of the PKU-patients are 
not very adversely affected in normal life (145;152), but some are worse (181). The 
neuropsychological results do not generally worsen with age and higher Phe-levels (32).  
Regarding the d2 attention test, subjects from the control group had a significantly higher 
number of items completed in the whole test, a higher value for number of items completed 
subtracted by failures as well as a higher concentration performance (number of crossed out 
characters minus failures) compared to PKU-patients. The number and percentage of 
failures, as well as the spread of the number of items completed between the lines differed 
not significantly between PKU-patients and the control group. In PKU-patients (n=30), the 
number and percentage of failures were significantly positively correlated with the blood Phe-
level in the study and throughout life, whereas the number of items completed, the number of 
items completed minus failures, as well as the concentration performance were significantly 
negatively correlated with blood Phe-level in the study and throughout life. In addition to that, 
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the concentration performance was significant negatively correlated with the blood Phe-level 
throughout life.  
Regarding the color-word interference test, highly significant differences were found to be in 
the reading duration of color-words, color-strokes, as well as of the interference list between 
PKU-patients and healthy controls. Subjects from the control group had higher t-values in the 
reading duration of all three tasks, while no differences were observed for nomination and 
selectivity skills. Significant negative correlations were found between the reading duration of 
all three different tasks and blood Phe-levels during the study. Elevated Phe-levels at least 
partly contribute to consecutive impairments of the metabolism of neurotransmitters 
(52;82;111;112). The frontal brain depends on dopamine (49;50). The color-word 
interference test is a sensitive test for determination of deficits in frontal brain dependent 
cognitive functions (16). Significant differences are detectable in the number of immediately 
recalled words (of 15 presented words) and in the number of recalled words after the fifth 
recollection between PKU-patients and healthy controls, whereas for the learning and 
recalling performance, as well as for the loss after distraction and the total number of 
recognized words no significant differences were found. There were significant negative 
correlations detectable between the blood Phe-levels during life and recalled words after the 
fifth recollection, learning performance, as well as recalling performance in PKU-patients. 
The blood Phe-level during the study showed a significant negative correlation with recalling 
performance and a significant positive correlation with loss after distraction. 
Significant differences regarding the number combination test (NCT) results were found 
between PKU-patients and healthy controls. PKU-patients needed more time to complete the 
whole test. The determined IQ equivalent showed much higher values in controls (mean IQ 
104) compared with PKU-patients (mean IQ 85). Searching for significant correlations 
between total duration of the NCT, as well as IQ equivalent and blood Phe-level, blood PUFA 
content showed a significant relations regarding the Phe-level but none regarding the PUFA 
content. An explanation for the mental retardation might be the inhibition of the ATP-
sulphurylase in oligodendrocytes with decreased synthesis of sulphatides that are needed to 
protect myelin proteins against breakdown, which finally causes a decrease of synaptic 
contacts (83). Detailed studies have shown that the IQ is not any more significantly 
(33;165;166) influenced by the Phe-level after the 10th year of life.  
Neuropsychological results might be improved by a stricter diet (32). Weglage et al. (185) 
investigated 20 early-treated adolescent PKU-patients and 20 healthy controls twice (test 1 
and three years later test 2) at mean ages of 11 and 14 years, respectively, for their fine 
motor abilities (MPT), sustained (d2) and selected (CWIT) attention. He found no significant 
correlation between changes of neuropsychological test results and the blood Phe-levels 
during the three years between test times 1 and 2, as well as with the lifetime blood Phe-
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level. At the first test, examinations revealed significant blood Phe-correlated 
neuropsychological deficits in PKU-patients. However, in spite of raised blood Phe-levels 
during the following three years and significantly elevated concurrent blood Phe-levels, the 
repeated measurements revealed a significant decrease of patients’ deficits compared to 
controls. These results indicate a decreased vulnerability of the PKU-patients with respect to 
their neuropsychological functioning against elevated blood Phe-levels on ageing.  
Based on results of the PKU Adult Collaborative Study, Brumm et al. (28) suggested that 
adults with early-treated PKU demonstrate specific cognitive deficits, a number of which are 
associated with the frontal and temporal area of the brain. Deficits were noted in several 
domains including executive functioning, attention, verbal memory, expressive naming and 
verbal fluency. PKU-patients with blood Phe-levels higher than 1000 µmol/l (group 1) scored 
lower than the group with Phe-level below 1000 µmol/l (group 2) on measures of focused 
attention, verbal fluency, reaction time, verbal recognition, visual memory and naming. Tests 
of cognitive functioning were often correlated with measures of treatment during childhood 
rather than with Phe-level at the time of cognitive testing. Subjects with abnormal MRI scored 
significantly lower on two cognitive tests (Trails A and CVLT Recognition Memory). The 
investigators found no significant correlation between current brain Phe-level obtained 
through MR spectroscopy (n = 10) and neuropsychological function. Future longitudinal 
investigation with a larger sample size will assist in clarifying the etiology of 
neuropsychological deficits and association with treatment history. 
Feldmann et al. (53) assessed 35 PKU-patients between 13 and 21 years of age and 
compared them to diabetic patients with respect to IQ, information processing, sustained (d2) 
and selective (CWIT) attention. The assessments were repeated within a 3-year follow-up. 
PKU-patients had significantly poorer test results, with reduced performance speed than 
diabetic patients. He concluded that elevated Phe concentrations seem to exert a global 
effect on slowing performance speed in adolescence and early adulthood. Regarding the 
blood Phe-levels, studies showed that these are not related to Phe concentrations in the 
brain (87;102;124-126) although they are correlated with neurological results. Nevertheless, 
the Phe-level in the brain seems to be a big confounder for the development of the patients 
so that blood Phe-levels might not be optimal for dietary control (124;125).  
There are many investigations on the pathologic mechanism of the development of the 
severe mental damage due to high Phe-levels, which indicate that it may be caused by a 
multifactorial process. Perhaps the inhibition of amino acid transport into brain is not the 
major cause of structural and functional alterations in the brain. In patients with tyrosinemia 
type II and histidinemia, similar imbalances of amino acids are observed but do not lead to 
alterations of neurotransmitters (79). Another cause might be an abnormal glucose 
metabolism, as Wasserstein et al. (182) found a decreased relative glucose metabolic rate in 
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cortical regions and an increased activity in subcortical regions of the PKU-patients. The 
actual Phe-level correlated with abnormal activity in the prefrontal and visual cortices. Since 
plasma Phe-levels are negatively associated with intelligence and other cognitive functions 
(60), Channon et al. (37) suggested that continuous dietary management may be a 
successful strategy to enhance cognitive outcome in adults with PKU. 
 
4.7 Subjective assessment of health status 
All subjects were asked about their assessment of their health status. Although there was no 
significant difference between PKU-patients and controls, there is a possible indication that 
PKU-patients might be less content with their health compared to controls. The same number 
of PKU-patients and controls felt content, but about 39 % of the controls compared with only 
8 % of the PKU-patients felt very content with their health status. There were more subjects 
in the group of the PKU-patients who felt less content (12 % compared with 0 %) or even not 
at all content (6 % compared to 3 %).  
Asking for their feelings in more detail, there are again some differences detectable. More 
than 50 % of the PKU-patients, as well as of the controls feel healthy, but the proportion of 
the controls feeling very healthy exceeds that one in the group of phenylketonurics (39 % vs. 
27 %). Five PKU-patients felt less healthy in contrast to only one from the control group and 
one of the PKU-patients compared with none of the controls even felt not at all healthy. 
Expectedly, there was a strong correlation between the feelings about their health and the 
contentedness with life (fig. 16).  Both, patients and controls were more content if they felt 
healthier. Thus, considering all results there are indications of a worse (felt) physical health 
status of adults with PKU compared with controls, and concepts should be developed to 
improve the health of adult PKU-patients. 
In the present study, physical health status was investigated by evaluation of nutritional, 
immune, metabolic and neurological status, as well as the cardiovascular risk. Altogether we 
found worse results for PKU-patients regarding the nutritional, the immune, the metabolic 
and the neurological status, as well as the cardiovascular risk compared to controls. Thus, 
the current concept for treating adult patients with PKU does not ensure a desirable physical 
health outcome. Together with the results of the interviews for contentedness with health, 
these data lead us to conclude that better medical, nutritional and continuous psychosocial 
care is needed to improve the health status of adult PKU-patients and the situation for their 
families (23;64;187). 
It seams that current treatment concepts do not allow to obtain desirable blood Phe-levels in 
many adult PKU-patients. One PKU-patient had psychological problems but did not receive 
any adequate treatment. An adequate psychosocial, medical and nutritional care is 
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suggested to influence the long-term physical health of adult PKU-patients (96;159), 
independent from the early and strict diet in childhood. The mainly medically orientated 
outpatient visits in the hospital clinic, under time pressure and usually occurring only once a 
year, appear not to suffice for adequate coping with the disease and dietary treatment.  
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5 Summary 
Background 
Adult patients with PKU might benefit from an adequate medical, nutritional and 
psychological support. In addition to an early and strict diet in childhood, the nutritional and 
medical support during adolescence and adulthood appears to influence the long-term 
physical health of adult PKU-patients. Current concepts propose a “diet for life” but studies 
show that after intensive care during childhood, adult PKU-patients often lack an adequate 
medical, nutritional and psychosocial supervision. The dietary compliance of the PKU-
patients decreases with age, and there is a lack of age-adapted dietary guidelines and 
nutritional education. Since the health care for adult PKU-patients is not well developed in 
Germany, studies of this age group are urgently required. The present evaluation deals with 
the controversial question whether and how strictly adult patients with PKU should be 
treated, and furthermore which effects and side effects result from a low-Phe diet. 
Hypotheses to be tested were that adult PKU-patients exhibit diet induced nutritional 
deficiencies (e.g. LCPUFA, minerals, trace elements and vitamins), that an unbalanced diet 
in PKU-patients has implications for their immune system and cardiovascular risk profile, and 




We carried out a Case-Control study with adult PKU-patients and healthy age-matched 
controls. Thirty-three adult PKU-patients attending the Department of Metabolic Diseases of 
the Dr von Hauner Children’s Hospital, University of Munich, as well as 33 healthy subjects 
of the same gender and age took part in the investigations. 
 
In contrast to healthy age-matched controls, adult PKU-patients showed worse results 
regarding nutritional, immune, metabolic and neurological status, as well as cardiovascular 
risk profile. Blood levels of PUFA (DHA, EPA), selenium, zinc, iron, vitamin E, iodine and 
fluoride were often lower than normal. PKU-patients suffered more often from allergic 
diseases. Accelerometer data showed a lower physical activity level in patients with PKU. 
The cardiovascular risk profile of patients with PKU was worse compared with controls, with 
a higher prevalence of hypertension and obesity, as well as elevated blood lipids. PKU-
patients had worse outcomes in neurological testings, all measured MRIs were pathologically 
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Conclusions 
These data verify that there is a lack of adequate treatment of adult PKU-patients, which has 
detrimental effects upon the nutritional, immunological, metabolic and neurological status as 
well as the cardiovascular risk profile of adult patients. The development and implementation 
of improved approaches to dietary, medical and psychosocial treatment is needed to improve 
the physical health of adult PKU-patients and the situation for the whole family. 
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6 Zusammenfassung 
Hintergrund 
Derzeit fehlt ein umfassendes Behandlungskonzept für PKU-Patienten im Erwachsenenalter. 
Eine altersentsprechende medizinische, ernährungswissenschaftliche sowie psychologische 
Betreuung für diese Patientengruppe ist in Deutschland nicht sichergestellt. Es fehlen 
stichhaltige Beweise für dessen Notwendigkeit sowie Vorschläge für ein solches Konzept. 
 
Ziele: 
In der vorliegenden Arbeit sollte der Gesundheitszustand von erwachsenen PKU-Patienten 
ab 25 Jahren untersucht und dem Gesundheitszustand von gleichaltrigen gesunden 
Erwachsenen gegenüber gestellt werden. Speziell sollten mögliche Unterschiede in der 
Nährstoffversorgung, immunologischen Parametern, dem kardiovaskulären Risiko, der 




Es wurde eine Fall-Kontroll-Studie mit 33 erwachsenen PKU-Patienten im Alter zwischen 26 
und 59 Jahren (12 Männer, 21 Frauen) sowie 33 gleichaltrigen gesunden Kontrollpersonen 
im Alter zwischen 23 und 49 Jahren (11 Männer, 22 Frauen) an der Dr. von Haunerschen 
Kinderklinik in München durchgeführt.  
 
Ergebnisse 
Die PKU-Patienten wiesen einen schlechteren Versorgungszustand bezüglich einzelner 
Nährstoffe, vor allem bezüglich mehrfach ungesättigter Fettsäuren (EPA, DHA), Selen, Zink, 
Eisen, Vitamin E, Jod und Flur auf. Immunologische Parameter weisen auf eine höhere 
Anfälligkeit für allergische Erkrankungen hin. Das kardiovaskuläre Risiko von erwachsenen 
PKU-Patienten ist im Vergleich zur Kontrollgruppe aufgrund häufiger vorkommenden 
Übergewichts, Bluthochdrucks sowie eines ungünstigen Blutlipidstatuses als erhöht 
einzuschätzen. Hinsichtlich der Stoffwechselsituation wurden bei PKU-Patienten schlechtere 
Ergebnisse erreicht als bei den Kontrollen. PKU-Patienten scheinen sich weniger häufig 
körperlich zu bewegen. Darüber hinaus wies die Patientengruppe zahlreiche krankhafte 
neurologische Veränderungen auf, so waren alle MRT-Befunde auffällig und eine Großzahl 
der VEP-Befunde als pathologisch zu bewerten, außerdem erzielten PKU-Patienten 
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Schlussfolgerungen 
Anhand der vorliegenden Ergebnisse wurde nachgewiesen, dass erwachsene PKU-
Patienten einen schlechteren Gesundheitszustand aufweisen als gleichaltrige gesunde 
Erwachsene. Dies bedeutet, dass dringend Möglichkeiten und ein entsprechendes 
Behandlungskonzept geschaffen werden muss, um PKU-Patienten über das Kindesalter 
hinaus eine adäquate Behandlung und damit einen den Umständen der Erkrankung 
entsprechenden optimalen Gesundheitszustand gewährleisten zu können.  
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7 Attachment 
7.1 Tables 
Tab. A1: Daily nutrient intake of the PKU-patients in Munich 
PKU-patients (7 ♂, 24 ♀) 
 Mean 
♀ / ♂ 
SD 
♀ / ♂ 
Median 
♀ / ♂ 
Reference  
value* 
♀ / ♂ 
Mean in % of 
reference 
value 
Energy (kcal) 2283 / 2772 646 / 565 2180 / 2843 2300 / 2900 99 / 96 
Energy (kJ) 8988 / 11615 3409 / 2361 8848 / 11927 9500 / 12000 95 / 97 
Protein (g) 74 / 90  34 / 31 72 / 93 68.5 / 86.3 108 / 104 
Protein  
(% of energy) 13 4 14 8-10 163 
Total fat (g) 82 / 92 41 / 39 72 / 96 74.2 / 93.5 111 / 98 
Total fat  
(% of energy) 32 10 32 30 107 
Carbohydrates (g) 259 / 356 79 / 84 297 / 354 314.9 / 397 82 / 90 
Carbohydrates  
(% of energy) 54 12 55 > 50 108 
Phe (mg) 2362 1755 1904   
Fiber (g) 17 9 16 > 30 57 
Cholesterol (mg) 241 209 172 < 300 80 
PUFA (g) 12.5 / 13.4  6.7 / 6.0 10.8 / 13.9 < 24.7 / 31.2  51 / 43 
MUFA (g) 26.6 / 29.6  18.0 / 17.4  20.1 / 26.3 > 24.7 / 31.2 108 / 95  
SFA (g) 30.5 / 36.3  19.1 / 19.7  25.8 / 33.1 < 24.7 / 31.2 123 / 116 
Sodium 2708 1439 2512 2000 135 
Potassium 3302 957 3136 2000 165 
Calcium (mg) 1084 427 993 1000 108 
Phosphorus (mg) 1240 552 1046 700 177 
Magnesium (mg) 412 / 472 129 / 127 440 / 421 300 / 350 137 / 135 
Iron (mg) 19 / 18 9.1 / 5.6 17.6 / 18.3 15 / 10 193 / 121 
Retinol (mg) 1.4 / 1.5 0.8 / 1.1 1.3 / 1.1 0.8 / 1.0 175 / 150 
Vitamin B1 (mg) 2.2 / 1.7 1.4 / 0.6  1.9 / 1.6 1.0  / 1.2 220 / 142 
Vitamin B2 (mg) 2.2 / 2.2 1.8 / 1.5 1.7 / 1.7 1.2 / 1.4 183 / 157 
Vitamin B6 (mg) 2.3 / 2.3 1.2 / 0.9 1.9 / 2.3 1.2 / 1.5 192 / 153 
Folic acid (µg) 332 182 288 400 83 
Ascorbic acid (mg) 162 73 158 100 162 
Vitamin D (µg) 4.6 4.8 2.7 5 92 
Vitamin E (mg) 18.6 / 11.9 15.5 / 2.5  15.4 / 11.5 12 / 14 155 
Zinc (mg) 15.1 / 15.0  7.5 / 5.4 14.1 / 16.4 7 / 10 216 
Iodine (µg) 166 121 146 200 83 
Copper (µg) 2604 1083 2453 1250 208 
Chloride (mg) 4268 2983 3901 3000 142 
Fluoride (µg) 802 / 973 646 / 356 676 / 933 3100 / 3800 26 / 26 
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Manganese (µg) 4409 2187 3940 3500 126 
Vitamin K (µg) 236 / 289 133 / 104 204 / 272 60 / 70 393 / 413 
Pantothenic acid 
(mg) 6.88 4.0 5.5 6 115 
Biotin (µg) 111 141 58 45 246 
Vitamin B12 (µg) 5.2 3.4 4.7 3 170 
Niacin (mg) 31 / 35 20.4 / 18.2 28.2 / 28.0 13 / 16 240 / 216 
Linoleic acid (g) 10.4 / 10.5 5.6 / 4.4 8.7 / 10.3 6.2 / 7.8 168 / 135 
α-Linolenic acid (g) 1.3 / 1.5 1.0 / 0.8 1.0 / 1.7 1.2 / 1.6 108 / 94 
EPA (g) 0.002 0.01 0.0 > 0.23 / 0.29 1.1 / 1.1 
DHA (g) 0.042 0.01 0.0 > 0.23 / 0.29 19.7 / 19.5  
* reference values derive from D-A-CH recommendation (47); for EPA and DHA from ISSFAL (86) 
 
Tab. A2: Relative fatty acid composition (wt%) of plasma phospholipids in PKU-patients  
 
PKU-patients in Munich (n=32)  
  Mean (wt%) SD (wt%) Median (wt%) 
 14:0  0,39 0,08 0,39 
 16:0  27,43 1,51 27,44 
 17:0   0,34 0,07 0,33 
 18:0   13,54 1,30 13,38 
 20:0   0,60 0,11 0,59 
 22:0   1,48 0,27 1,46 
 24:0   1,27 0,24 1,24 
 18-1t   0,18 0,07 0,16 
 22-1   0,16 0,08 0,14 
 16-1n-7   0,71 0,28 0,63 
 17-1n-7   0,23 0,09 0,21 
 18-1n-7   1,50 0,26 1,44 
 18-1n-9   10,18 1,37 10,15 
 20-1n-9   0,15 0,02 0,15 
 22-1n-9   0,25 0,07 0,23 
 24-1n-9   2,63 0,51 2,55 
 20-3n-9   0,18 0,06 0,17 
 18-2n-6   18,77 2,56 18,55 
 18-3n-6   0,13 0,07 0,12 
 20-2n-6   0,37 0,08 0,36 
 20-3n-6   3,49 0,62 3,61 
 20-4n-6   10,21 1,14 10,29 
 22-4n-6   0,48 0,11 0,45 
 22-5n-6   0,33 0,09 0,32 
 18-3n-3   0,19 0,11 0,16 
 20-3n-3   0,12 0,02 0,13 
 20-5n-3  0,70 0,32 0,65 
 22-5n-3  1,06 0,28 1,08 
 22-6n-3  2,79 0,85 2,74 
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Tab. A3: Reproducibility of fatty acid analysis in plasma PL (mean, CV) 
 
 Intra-assay (n = 8) Inter-assay (n = 5) 
 mg/l CV (%) wt % CV (%) mg/l CV (%) wt % CV (%)
SFA         
14:0 4.82 3.07 0.45 3.05 4.10 4.70 0.40 3.94 
15:0 IS  IS  IS  IS  
16:0 301.68 1.34 28.28 0.59 281.45 3.42 27.51 1.72 
17:0 4.62 1.60 0.43 0.47 3.90 2.77 0.38 1.42 
18:0 149.57 1.55 14.00 0.41 130.25 2.95 12.73 1.28 
20:0 5.71 2.80 0.53 2.01 6.31 2.47 0.62 2.68 
22:0 14.45 1.95 1.35 0.74 14.55 6.88 1.42 4.27 
24:0 13.08 1.67 1.22 0.73 13.30 8.74 1.30 5.55 
TFA         
14:1t n.d.  n.d.  n.d.  n.d.  
16:1t 0.05 3.80 0.05 3.55 0.16 17.68 0.02 17.97 
18:1t 2.35 3.86 0.22 2.38 2.56 10.36 0.25 9.58 
18:2tt 0.58 3.69 0.05 3.56 0.52 21.07 0.05 20.72 
22:1t 0.77 3.67 0.07 3.32 1.01 3.32 0.10 2.02 
MUFA         
14:1n-5 n.d.  n.d.  n.d.  n.d.  
15:1n-5 n.d.  n.d.  n.d.  n.d.  
16:1n-7 9.48 4.06 0.89 2.53 6.19 4.78 0.61 6.14 
17:1n-7 n.d.  n.d.  n.d.  n.d.  
18:1n-7 19.33 2.23 1.81 0.50 14.89 4.54 1.46 4.21 
18:1n-9 138.03 3.26 12.91 1.67 103.78 2.10 10.15 1.73 
20:1n-9 1.91 8.43 0.18 7.96 1.62 3.74 0.16 1.98 
22:1n-9 3.31 18.26 0.31 17.20 3.11 21.2 0.31 23.51 
24:1n-9 25.23 1.83 2.36 0.79 29.85 10.31 2.91 6.95 
PUFA         
20:3n-9 3.16 1.85 0.30 0.51 2.45 4.38 2.51 2.48 
18:2n-6 189.76 1.75 17.76 0.19 188.40 3.28 18.42 0.52 
18:3n-6 1.49 3.13 0.14 2.90 1.54 3.85 0.15 14.76 
20:2n-6 3.20 2.41 0.30 1.00 3.27 3.81 0.31 2.60 
20:3n-6 33.12 1.80 3.10 0.41 25.74 5.20 2.51 2.48 
20:4n-6 96.02 1.79 8.98 0.36 127.26 4.91 12.44 2.40 
22:2n-6 0.23 8.05 0.02 7.86 0.19 17.43 0.02 17.47 
22:4n-6 4.28 2.47 0.40 1.00 5.80 4.55 0.57 1.93 
22:5n-6 3.51 2.31 0.34 1.00 4.16 5.31 0.41 3.59 
18:3n-3 1.56 3.21 0.15 1.42 1.54 5.40 0.15 2.62 
18:4n-3 0.39 17.97 0.04 18.05 0.25 17.67 0.02 18.47 
20:3n-3 1.01 8.63 0.09 8.59 1.26 5.30 0.12 4.10 
20:5n-3 5.06 2.07 0.47 0.71 7.10 5.19 0.69 3.46 
22:5n-3 8.6 2.05 0.80 0.67 9.51 6.85 0.93 4.36 
22:6n-3 19.68 2.11 1.84 1.28 25.60 7.11 2.50 5.20 
IS = internal standard, n.d. = not detected 
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Retinol  α-tocopherol 
Plasma 1 0,382 8,873 
Plasma 2 0,383 8,902 
Plasma 3 0,410 8,490 
Plasma 4 0,395 9,160 
Plasma 5 0,402 8,971 
Plasma 6 0,392 8,803 
Plasma 7 0,415 8,868 
Plasma 8 0,411 9,068 
Plasma 9 0,403 9,439 
Mean 0,399 8,953 
SD 0,012 0,261 
CV 2,972 2,916 
 
 





Plasma 1 0,652 9,431 
Plasma 2 0,652 9,413 
Plasma 3 0,652 9,457 
Plasma 4 0,642 9,500 
Plasma 5 0,660 9,308 
Plasma 6 0,645 9,433 
Mean 0,650 9,424 
SD 0,006 0,064 
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Tab. A6: Daily nutrient intake of all PKU-patients (Munich and Münster) 
 
PKU-patients  (n=73, 24 ♂, 59 ♀) 
 Mean 
♀ / ♂ 
SD 
♀ / ♂ 
Median 
♀ / ♂ 
Reference  
value* 
♀ / ♂ 
Mean in % of 
reference 
value 
Energy (kcal) 2015 / 2436 628 / 671 2009 / 2076 2300 / 2900 89 / 83 
Protein (g) 66 / 79 31 / 27 59 / 74 68.5 / 86.3 99 / 98 
Total fat (g) 74 / 91 35 / 39 69 / 78 74.2 / 93.5 100 / 97 
Carbohydrates (g) 259 / 299 86 / 96 255 / 275 314.9 / 397 84 / 71 
Fiber (g) 17 / 20 8 / 9 16 / 19 > 30 57 / 63 
Cholesterol (mg) 213 / 315 170 / 231 176 / 283 < 300 71 / 95 
PUFA (g) 11.7 / 13.3  6.0 / 6.8 10.1 / 12.4 < 24.7 / 31.2 47 / 44 
MUFA (g) 24.8 / 30.4 14.8 / 16.0 20.8 / 25.2 > 24.7 / 31.2 101 / 96 
SFA (g) 26.9 / 34.1 15.8 / 16.6 24.2 / 32.5 < 24.7 / 31.2 108 / 111 
Sodium 2382 / 2922 1331 / 1162 2121 / 2816 2000 119 / 144 
Potassium 3016 / 3519 927 / 783 2934 / 3424 2000 151 / 173 
Calcium (mg) 981 / 1006 475 / 363 879 / 986 1000 102 / 107 
Phosphorus (mg) 1075 / 1374 411 / 450 970 / 1334 700 154 / 193 
Magnesium (mg) 391 / 458 143 / 142 393 / 437 300 / 350 134 / 135 
Iron (mg) 16.1 / 17.0 7.6 / 7.4 14.5 / 14.8 15 / 10 150 / 132 
Retinol (mg) 1.8 / 1.5 1.7 / 1.1 1.3 / 1.0 0.8 / 1.0 215 / 149 
Vitamin B1 (mg) 1.8 / 1.6 1.1 / 0.5 1.4 / 1.6 1.0  / 1.2 175 / 132 
Vitamin B2 (mg) 1.9 / 1.9 1.4 / 1.0 1.5 / 1.6 1.2 / 1.4 158 / 132 
Vitamin B6 (mg) 2.1 / 2.5 1.0 / 0.9  1.9 / 2.3 1.2 / 1.5 172 / 163 
Folic acid (µg) 287 / 308 161 / 144 239 / 275 400 72 / 77 
Ascorbic acid (mg) 144 / 141 75 / 74 140 / 133 100 144 / 140 
Vitamin D (µg) 4.9 / 4.5 5.2 / 4.1 2.7 / 2.4 5 98 / 88 
Vitamin E (mg) 15.7 / 12.7 11.7 / 3.7 13.0 / 12.0 12 / 14 131 / 90 
Zinc (mg) 12.2 / 13.4 6.1 / 5.7 10.6 / 14.8 7 / 10 185 / 139 
Iodine (µg) 147 / 127 110 / 77 118 / 96 200 74 / 64 
Copper (µg) 2234 / 2558 895 / 896 2188 / 2166 1250 188 / 214 
Chloride (mg) 3591 / 4310 2530 / 1592 3022 / 4420 3000 120 / 142 
Fluoride (µg) 798 / 928 553 / 413 574 / 833 3100 / 3800 26 / 24 
Manganese (µg) 4175 / 4979 2218 / 2816 3537 / 4372 3500 119 / 136 
Vitamin K (µg) 312 / 312 287 / 97 251 / 312 60 / 70 520 / 439 
Pantothenic acid 
(mg) 6.0 / 6.5 3.4 / 3.1 4.9 / 5.9 6 100 / 107 
Biotin (µg) 96 / 68 120 / 55 44 / 46 45 214 / 150 
Vitamin B12 (µg) 4.4 / 5.8 3.3 / 3.6 3.4 / 4.9 3 162 / 185 
Niacin (mg) 29.5 / 34.5 15.3 / 13.1 26.0 / 32.8 13 / 16 227 / 215 
Linoleic acid (g) 9.9 / 10.5 5.2 / 5.1 8.6 / 10.1 6.2 / 7.8 158 / 142 
α-Linolenic acid (g) 1.2 / 1.5 0.8 / 0.7 0.9 / 1.3 1.2 / 1.6 96 / 94 
EPA (g) 0.03 / 0.005 0.15 / 0.01 0.00 / 0.00 > 0.23 / 0.29 10 / 8 
DHA (g) 0.06 / 0.08 0.16 / 0.10 0.00 / 0.03 > 0.23 / 0.29 27 / 35 
* reference values derive from D-A-CH recommendation (47); for EPA and DHA from ISSFAL (86) 












retinol y = 0,3865x + 0,0075 
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7.3 Used information and documentation materials  
 
On the following pages are shown these used information and documentation materials: 
 
 Invitation to participate in the study  
 Subject information  
 Leaflet with study information 
 Informed consent of the subjects  
 3-day dietary protocol  
 Protocol for clinical investigation  
 Standardized interview 
 Atopic disease questionnaire 
 Auditory verbal learning test 
 d2 attention test  
 Number combination test  
 Color-word interference test  
 MPT finding 
 VEP finding 
 Accelerator data 
 Activity protocol 
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Lebensqualität und Gesundheit  
bei Erwachsenen mit Phenylketonurie (PKU) 
 
Sehr geehrte/r PKU-Patient/in, 
 
Wir wenden uns heute an Sie, weil wir Sie über die Entwicklungen bei der Behandlung Ihrer 
Stoffwechselstörung Phenylketonurie (PKU) unterrichten und Sie zu einer Untersuchung in 
Ihr Stoffwechselzentrum nach München einladen möchten.  
  
Glaubte man früher, die eiweißarme Diätbehandlung mit ca. 10 Jahren gänzlich beenden zu 
können, so haben sich in den vergangenen Jahren zunehmend Hinweise ergeben, die zur 
Vorsicht mahnen und für eine dauerhafte Weiterführung einer gelockerten Diätbehandlung 
sprechen. Sind die Diätempfehlungen für die ersten 10 Lebensjahre durch wissenschaftliche 
Untersuchungen sehr gut belegt, so fehlen jedoch systematische Grundlagen für das 
Erwachsenenalter. In den letzten Jahren wurde jedoch von einzelnen erwachsenen PKU-
Patienten berichtet, die seit Jahren die Diät gelockert bzw. aufgegeben hatten und bei denen 
neurologische Störungen auftraten. Hier handelt es sich um Einzelfälle insbesondere bei 
Patienten mit Behandlungsbeginn erst nach dem frühen Säuglingsalter. Wir wissen jedoch 
nicht, ob im Verlauf langer Zeit abhängig von der Diätführung ein nennenswertes Risiko für 
das Auftreten von Störungen besteht, denn die ältesten frühbehandelten Patienten sind 
heute erst ca. 45 Jahre alt. 
  
Zurzeit besteht kein Grund zur Beunruhigung. Wir sehen jedoch Anlass, Sie über den Stand 
der Dinge ausführlich zu informieren und Sie zu einer vorbeugenden und begleitenden 
Untersuchung in die Dr. von Haunersche Kinderklinik einzuladen (Kinderklinik deshalb, weil 
es bisher kein eigenes Behandlungszentrum für erwachsene Patienten mit angeborenen 
Stoffwechselstörungen wie der PKU gibt). Wir werden Sie im Laufe der kommenden Wochen 
 
anrufen, um Ihre Fragen und das Vorgehen mit Ihnen zu besprechen. Gern sprechen wir 
auch mit Ihrem Hausarzt/Hausärztin, um diese über das Vorgehen und den Sinn der 
Untersuchungen zu informieren.  
  
Sollten Sie nach unserem Anruf zu einer solchen Untersuchung bereit sein, werden wir Ihnen 
nochmals schriftlich Dauer und Art der Untersuchungen, Termin und Anfahrtsweg, sowie 
weitere Einzelheiten mitteilen. Es wird sich zunächst um eine einmalige Untersuchung 
handeln, die wir ggf. in Abständen von ca. 3 Jahren wiederholen können. Alles Weitere 
werden wir zunächst telefonisch und dann hoffentlich im persönlichen Gespräch in unserer 
Klinik besprechen.  
  
Bitte erschrecken Sie nicht über den Inhalt dieses Briefes. Wir sehen es jedoch als unsere 
Pflicht an, Sie über mögliche mit der PKU verbundene Risiken zu informieren und 
gemeinsam mit Ihnen das weitere Vorgehen zu überlegen. Für alle weiteren Fragen stehen 
wir Ihnen jederzeit zu Verfügung. 
 
Mit freundlichen Grüßen 
Dipl. oec. troph. J. von Berlepsch               Susanne Bauske                                     Prof. Dr. B. Koletzko 
   Ernährungswissenschaftlerin                              Ärztin                                        Projektleiter und Leiter der Abt. 
                                                                                                                   Stoffwechselkrankheiten & Ernährung             
                                                                                                                                                                    Dr. v. Haunersches Kinderspital 
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Ein Vergleich von Lebensqualität und Gesundheit 
erwachsener Patienten mit Phenylketonurie (PKU) 
 
Abt. Stoffwechselerkrankungen & Ernährungsmedizin (Leiter: Prof. Dr. med. Berthold Koletzko) 
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Klinikum der Universität 




Sehr geehrte/r PKU-Patient/in, 
Als PKU-Patient/in hängen für Sie Lebensqualität und Gesundheit entscheidend von Ihrer 
Ernährungsweise und Betreuung ab. Langzeituntersuchungen zeigen, dass PKU-Patienten 
im Jugend- und Erwachsenenalter oftmals keine optimale, regelmäßige Betreuung haben 
und altersentsprechende Diätpläne und Schulungen fehlen. Um angemessene Betreuungs- 
und Behandlungskonzepte entwerfen zu können, bedarf es der Erfassung bestehender 
Risiken und Probleme an einer ausreichend großen Gruppe von erwachsenen PKU-
Patienten.  
Wir wollen daher in dieser Studie mittels einer Nachuntersuchung die Lebensqualität und 
Gesundheit bei erwachsenen PKU-Patienten prüfen und speziell untersuchen, welche 
psychosozialen Einschränkungen (z.B. im Berufsleben) sich für Sie aus Ihrer Erkrankung 
und der Diät ergeben, wie Sie ernährungswissenschaftlich (professionelle 
Ernährungsberatung, Diät), psychologisch (Selbsthilfegruppen, Beratungsstellen, 
psychosomatisch-psychiatrische Betreuung) bzw. neurologisch betreut werden, um 
Möglichkeiten einer Verbesserung der medizinischen, nutritiven und sozialen Betreuung zu 
erkennen. 
Zur Datenerfassung sollen uns dabei strukturierte Fragebögen, neuropsychologische 
Testverfahren, verschiedene Untersuchungsmethoden und die Analyse von Blutproben 
dienen. 
Um Ihre Ernährungsweise erfassen zu können, bitten wir Sie in einem Ernährungsprotokoll 
für drei Tage aufzuschreiben, welche Speisen und Getränke sie an diesen Tagen zu sich 
genommen haben sowie Angaben zu Ihren Ernährungsgewohnheiten zu machen. 
Für die Durchführung der vorgesehenen Untersuchungen, bitten wir Sie nach Ihrer 
Einverständniserklärung zu einem vereinbarten Termin in unsere Klinik zu kommen und das 
3-Tage-Ernährungsprotokoll ausgefüllt sowie den aktuellsten MRT-Befund (falls vorhanden) 
mitzubringen. 
Zu diesem Termin werden Ihnen 18 ml Blut abgenommen und anschließend werden 
verschiedene Tests durchgeführt sowie Fragen zu Ihrer Lebenssituation gestellt.  
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Anhand der Blutproben wird festgestellt, wie sich Ihre Ernährungsweise auf den Gehalt an 
Fettsäuren, Vitaminen, Mineralstoffen und Spurenelementen sowie auf Ihre Blutfette 
auswirkt. Immunologische Tests geben uns Aufschluss über Veränderungen des 
Immunsystems. Veränderungen der Feinmotorik, des Verhaltens sowie der Intelligenz und 
Aufmerksamkeit sollen anhand spezieller Tests festgestellt werden und neurophysiologische 
Untersuchungen zeigen die Reizleitungsgeschwindigkeit in Ihrem Nervensystem. Dabei 
werden auf Sie optische Reize ausgeübt und über Elektroden, die auf Ihrer Kopfhaut 
befestigt werden, das Ankommen der Signale im Gehirn erfasst.  
Alle persönlichen Daten werden streng vertraulich behandelt und nicht weiter-
gegeben, sondern nur für die Studie gespeichert. Nach Abschluss der Studie erfolgt 
die Auswertung der Daten in pseudonymisierter Form. 
Falls Sie noch weitere Fragen haben stehen wir Ihnen gerne zur Verfügung. 
 
Mit freundlichen Grüßen 
Dipl. oec. troph. J. von Berlepsch               Susanne Bauske                                     Prof. Dr. B. Koletzko 
   Ernährungswissenschaftlerin                              Ärztin                                    Projektleiter und Leiter der Abt. 
                                                                                                                Stoffwechselkrankheiten & Ernährung                           
                                                                                                                                  Dr. v. Haunersches Kinderspital 
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Merkblatt 
 
Ein Vergleich von Lebensqualität und Gesundheit 
erwachsener Patienten mit Phenylketonurie (PKU) 
Studienablauf 
 
Vor Aufnahme eines Probanden in die Studie findet telefonisch die Überprüfung der Ein- und 
Ausschlusskriterien statt. Den geeigneten Personen werden dann per Post eine 
Einverständniserklärung, ein Aufklärungsbogen, dieses Merkblatt, ein Ernährungsprotokoll 
sowie 3 Fragebögen zugesandt. Mit Hilfe der Fragebögen werden Angaben zur Häufigkeit 
von Allergien sowie zu Ihrem psychischen Befinden erfasst. Vor dem Untersuchungstermin 
in unserer Klinik füllen Sie bitte die beigelegten Fragebögen sowie an drei 
aufeinanderfolgenden Tagen (einer davon ein Samstag oder Sonntag) das beiliegende 
Ernährungsprotokoll aus. Dieses Protokoll soll eine allgemeine Übersicht über Ihre tägliche 
Aufnahme an Nährstoffen geben. Die Ergebnisse sind notwendig, um die gemessenen 
Parameter genau interpretieren zu können. 
 
Der Untersuchungstermin wird telefonisch oder schriftlich mit Ihnen abgesprochen. Zu 
diesem Termin bringen Sie bitte die unterschriebene Einverständniserklärung, das 
Ernährungsprotokoll, den Allergie-Fragebogen, den YASR sowie die SCL-90 ausgefüllt in 
die Klinik mit. Der Zeitaufwand beträgt circa 4 Stunden. Es werden dabei folgende 
Untersuchungen durchgeführt: 
 
- Klinische Untersuchung und Blutentnahme (16 ml) 
- Fragen zur Ihrer Lebenssituation 
- verschiedene Konzentrations- und Aufmerksamkeitstests 
- eine schmerzfreie, neurologische und feinmotorische Untersuchung 
 
Treffpunkt für die Untersuchung 
Pforte am Haupteingang des Dr. von Haunerschen Kinderspitals 
 
Wegbeschreibung 
Das Dr. von Haunersche Kinderspital befindet sich in der Lindwurmstraße 4 direkt in der 
Münchner Innenstadt am Goetheplatz (U-Bahn U3/U6; MetroBus 58). 
Per Bus/Tram/U-Bahn: 
Haltestelle Goetheplatz: Bus Linie 58, U-Bahn U3, U6. 
Haltestelle Sendlinger Tor (Gehstrecke ca. 500 m): Bus Linien 56, 31, Tram Linien 16, 17, 
18, 27, U-Bahn U1, U2, U3, U6.  
Vom Goetheplatz aus in Richtung Innenstadt circa 50 m die Lindwurmstraße entlanggehen, 
links am Haupteingang des Kinderspitals an der Pforte melden und nach Frau von 
BERLEPSCH fragen (Klinikdurchwahl 3486). Sie werden von dort abgeholt. 
 
Mit der Deutschen Bahn: 
München Hauptbahnhof, Ausgang Bayerstraße (Südseite), über die gegenüberliegende 
Goethestraße, ca. 800 m weiter in Richtung Süden bis zur Kreuzung am Goetheplatz, dann 
links nach ca. 50 m  am Haupteingang des Kinderspitals an der Pforte melden und nach 
Frau von  BERLEPSCH fragen (Klinikdurchwahl 3486). Sie werden von dort abgeholt. 
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Lageplan 
 
Und noch ein paar Hinweise: 
 
- Falls Sie eine Brille oder Kontaktlinsen tragen, bringen Sie diese bitte unbedingt zu den 
Untersuchungen mit! 
- Bitte benutzen am Morgen der Untersuchungen kein Haargel oder ähnliches, da es sonst 
Probleme mit der Leitung der Elektroden bei den neurologischen Untersuchungen geben 
kann! 
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Ein Vergleich von Lebensqualität und Gesundheit 
erwachsener Patienten mit Phenylketonurie (PKU) 
 
Abt. Stoffwechselerkrankungen & Ernährungsmedizin (Leiter: Prof. Dr. med. B. Koletzko) 
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Klinikum der 










Ich bin mit der Teilnahme an der oben genannten Untersuchung entsprechend dem Inhalt 
des Aufklärungsbogens einverstanden. Alle aufgetretenen Fragen konnten besprochen 
werden. 
 
    Name: ______________________        Vorname:__________________________  
   Anschrift: ______________________  
 ______________________  





                      _______________________                _______________________  
                                       Ort, Datum                                                       Unterschrift 


















Ein Vergleich der Lebensqualität und Gesundheit 







Name: ___________________  
Datum: ___________________
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• Bitte notieren Sie an drei aufeinanderfolgenden Tagen (Donnerstag bis Samstag ODER 
Sonntag bis Dienstag) vor der Untersuchung was und wie viel Sie gerade essen und 
trinken. Notieren Sie das Datum der Tage. 
 
 
Bitte essen und trinken Sie an diesen Tagen genauso wie immer !!! 
 
 
Wie soll dies notiert werden? 
 
• Tragen Sie bitte grundsätzlich alles ein, was Sie verzehren, d.h. alle Speisen und 
Getränke (auch Wasser, Milch und Zucker für den Kaffee oder Tee), Süßigkeiten und 
andere Kleinigkeiten zwischendurch und auch Präparate (z.B. Vitamin-, 
Mineralstoffpräparate, Stärkungsmittel) sowie Medikamente. 
 
• Suchen Sie ein verzehrtes Lebensmittel in der entsprechenden Lebensmittelgruppe 
(z.B. Marmelade in der Gruppe Brotbelag). 
 
• Falls verlangt, benennen Sie bitte Sorte bzw. Fettgehalt genauer. z.B. Mineralwassersorte 
 
• Schätzen Sie die Menge bitte gut ab und machen Sie in der Spalte Anzahl an dem 
entsprechenden Tag (1, 2 oder 3) entweder für jede Portion einen Strich oder notieren Sie 
eine Ziffer (z.B. für 3 Scheiben Graubrot entweder 3 Striche oder eine „3“ eintragen). 
 
• Für die einzelnen Lebensmittel sind jeweils die gewöhnlichen Maßeinheiten angegeben. 
So wird Brot in Scheiben angegeben, Kuchen in Stück, Kaffee in Kaffeetassen und 
Getränke in Gläsern oder Tassen. Ändern Sie die Mengenbezeichnungen nicht! 
Hat man eine kleinere Portion als angegeben gegessen bzw. getrunken (z.B. ½ Portion 
Nudeln oder ¼ Apfel) trägt man einfach ½ oder ¼ ein. 
 
• Gerichte/Lebensmittel, die Sie nicht in der Liste finden können, tragen Sie bitte unter 
Sonstiges in der jeweiligen Lebensmittelgruppe oder unter Lebensmittel, die nicht 





• Notieren Sie am besten während oder direkt nach der Mahlzeit. 
 
• Am einfachsten ist es, wenn man den Fragebogen immer dabei hat, auch im 
Restaurant, bei Verwandten oder Freunden. So kann nichts vergessen werden. 
 
• Am Abend sollte man noch einmal über den vergangenen Tag nachdenken - am 
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Verzehr über drei Tage 
 
Brot • Brötchen Anzahl 
  
Einheit 
Tag 1 Tag 2 Tag 3 
Graubrot  Scheibe  45 g    
Weißbrot  Scheibe  35 g    
Toastbrot  Scheibe  20 g    
Vollkornbrot  Scheibe  50 g    
Knäckebrot  Scheibe  10 g    
Zwieback  Scheibe  10 g    
Hefezopf  Scheibe  45 g    
Normales Brötchen  Stück      45 g    
Vollkornbrötchen  Stück      55 g    
Croissant  Stück      50 g    
Sonstiges:      
      
      
      
      
Brotbelag • Butter • Margarine Anzahl 
  
Einheit 
Tag 1 Tag 2 Tag 3 
Butter   TL     5 g    
Margarine  Sorte: 
...............….. TL     5 g 
   
Margarine halbfett  Sorte: 
.................... TL     5 g 
   
Marmelade, Konfitüre, 
Gelee 
 EL   20 g    
Honig  EL   20 g    
Nuss-Nougat-Creme  EL   20 g    
Vegetarischer Brotaufstrich Sorte: 
.........................
.........................
EL   30 g 
   
Frischkäse Fettgehalt (% i. Tr.) 
................…… EL   30 g 
   
Quark Fettgehalt (% i. Tr.) 
................…… EL   20 g 
   
Schmelzkäse Fettgehalt (% i. Tr.) 
................…… Portion   30 g
   
Schnittkäse Fettgehalt (% i. Tr.) 
................…… Scheibe  30 g
   
Weichkäse Fettgehalt (% i. Tr.) 
................…… Scheibe  30 g
   
Bierschinken  Scheibe  25 g    
Corned Beef  Portion   25 g    
Fleischwurst  Scheibe  20 g    
Fleischkäse (Aufschnitt)  Scheibe  30 g    
Fleischsalat  Portion   50 g    
Leberwurst  Portion   30 g    
Mettwurst  Portion   30 g    
Teewurst  Portion   30 g    
Salami/Cervelatwurst  Scheibe  20 g    
Schinken roh  Scheibe  15 g    
Schinken gekocht  Scheibe  30 g    
Speck  Portion   30 g    
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Sonstiges:      
      
      
      





Tag 1 Tag 2 Tag 3 
Gekochtes Ei  Stück     55 g    
Cornflakes trocken Sorte: 
........................... 
EL          4 g    




............................ EL          6 g 
   
Haferflocken trocken  EL        10 g    
Müsli trocken  EL        15 g    
Sonstiges:      
      
      
Milch • Milchprodukte • Sojaprodukte Anzahl 
  
Einheit 
Tag 1 Tag 2 Tag 3 
Buttermilch  Glas      200 g    
Joghurt natur Fettarm (1,5% Fett) Becher  150 g    
Joghurt natur Vollfett (3,5 % Fett) Becher  150 g    
Joghurt mit Frucht Fettarm (1,5 % 
Fett) Becher  150 g
   
Joghurt mit Frucht Vollfett (3,5 % Fett) Becher  150 g    
Milch Fettarm (1,5 % 
Fett) Glas      200 g
   
Milch Vollfett (3,5 % Fett) Glas      200 g    
Kakao/Trinkschokolade Fettgehalt (%) 
........................... Glas      200 g
   
Sojamilch Sorte: 
........................... Glas      200 g
   
Tofu Sorte: 
........................... Portion  100 g
   
Sahne Fettgehalt (%) 
........................... EL           10 g
   
Kondensmilch  Fettgehalt (%) 
........................... Portion    12 g
   
Sonstiges: Fettgehalt (%) 
...........................     
 Fettgehalt (%) 
........................... 
    
 Fettgehalt (%) 
........................... 
    
Obst Anzahl 
  
Einheit Tag 1 Tag 2 Tag 3 
Brombeere, Erdbeere, 





Portion  125 g    
Weintrauben  Portion  150 g    
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Portion  150 g    
Banane  Stück    120 g    





Portion  150 g    
Grapefruit, Mandarine,  









Portion    50 g    
Kompott, Obstkonserven Sorte: ........................... Portion 150 g    
Sonstiges: 
    
     
Gemüse • Salate Anzahl 
  
Einheit Tag 1 Tag 2 Tag 3 
Blattsalat  (Dressing bitte 





Portion   50 g    
Rohkost / 
Salatgemüse  (Dressing 









Portion 200 g    
Grüne Bohnen  Portion 200 g    
Aubergine, Gurke, 





Portion 200 g    
Gemüsemais  Portion 200 g    
Blumenkohl, Broccoli, 







Portion 200 g    
Sauerkraut  Portion 150 g    




Portion 200 g    
Möhre, Radieschen, 






Portion 200 g    
Pilze  Portion 120 g    





EL            1g    
Gewürzgurken  Port. 50 g    
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Sonstiges: 
     




Einheit Tag 1 Tag 2 Tag 3 
Weiße / Rote Bohnen 
gegart 
 Portion 200 g    
Erbsen gegart  Portion 200 g    
Linsen gegart  Portion 200 g    
Sonstiges 
    
     
Beilagen (Kartoffeln, Nudeln, Reis,...) Anzahl 
  
Einheit 
Tag 1 Tag 2 Tag 3 
Salzkartoffeln  Portion 200 g    
Pellkartoffeln  Portion 200 g    
Bratkartoffeln  Portion 200 g    
Kartoffelbrei  Portion 200 g    
Kartoffelknödel  Stück   100 g    
Kartoffelsalat  Portion 250 g    
Pommes Frites  Portion 200 g    
weißer Reis gekocht Portion 180 g    
Natur-Reis gekocht Portion 180 g    
Nudeln eifrei gekocht Portion 180 g    
Eiernudeln gekocht Portion 180 g    
Vollkornnudeln eifrei gekocht Portion 180 g    
Vollkornnudeln mit Ei gekocht Portion 180 g    
Spätzle gekocht Portion 200 g    
Beilagen (Kartoffeln, Nudeln, Reis,...) Anzahl 
  
Einheit 
Tag 1 Tag 2 Tag 3 
Schupfnudeln  Portion 200 g    
Sonstiges:     
     
     
     
     
Soßen • Fette • Öle Anzahl 
 
 






Portion  40 g    
Essig-Öl-Marinade  Portion  20 g    
Bechamelsoße  Portion  75 g    
Grundsoße  Portion  75 g    
Hackfleischsoße  Portion 100 g    
Jägersoße  Portion  75 g    
Käsesoße  Portion  75 g    
Tomatensoße  Portion  75 g    
Grillsauce  Portion  20 g    
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Tomatenketchup  Portion  20 g    
Tomatenmark  TL           6 g    
Senf  TL           6 g    
Mayonnaise  Sorte: ........................... EL        12 g    
Kokosfett, Butterschmalz Sorte: ........................... EL        10 g    
Pflanzenöl Sorte: ........................... EL        10 g    
 
Sonstiges: 
     
      
      
      
Fleisch • Fisch  
  
Einheit Tag 1 Tag 2 Tag 3 
Hackfleisch  Portion 125 g    
Kalbfleisch  Portion 125 g    
Rindfleisch  Portion 125 g    
Schweinefleisch  Portion 125 g    
Innereien  Portion 125 g    
Kotelett  Portion 125 g    
Schnitzel paniert  Portion 125 g    
Würstchen  Portion 125 g    
Brathähnchen (1/2)  Portion 370 g    
Geflügel  Portion 125 g    
Fisch Sorte: ........................... Portion 150 g    
Fischfilet paniert Sorte: .......................... Portion 170 g    
Fischkonserve abgetropft Sorte: .......................... Portion   65 g    
Sonstiges:     
     
     
     
     
Suppen • Eintöpfe Anzahl 
  
Einheit Tag 1 Tag 2 Tag 3 
als Vorsuppe      
Suppe klar   Portion 200 g    
Suppe gebunden  Portion 200 g    
Cremesuppe  Portion 200 g    
Gulaschsuppe  Portion 200 g    
Nudelsuppe mit Huhn  Portion 200 g    
als Hauptgericht     
Gemüsesuppe  Portion 400 g    
Kartoffelsuppe  Portion 400 g    
Linseneintopf  Portion 400 g    
Sonstiges:     
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Fertig- und Schnellgerichte Anzahl 
  
Einheit Tag 1 Tag 2 Tag 3 
Bratwurst (ohne Brötchen)  Stück   150 g    
Currywurst (mit Brötchen)  Portion 160 g    
Hamburger  Stück   100 g    
Cheeseburger  Stück   120 g    
Big Mac  Stück   200 g    
Maultaschen/Ravioli  Portion 200 g    
Pizza  Portion 370 g    
Lasagne  Portion 250 g    
Pfannkuchen  Portion 180 g    
Sonstiges:      
      
      
Dessert • Kuchen  • Gebäck • Süßes Anzahl 
 
 
Einheit Tag 1 Tag 2 Tag 3 
Pudding  Portion 150 g    
Eiscreme  Kugel     50 g    
Obstkuchen  Stück   120 g    
Cremetorte  Stück   150 g    
Rührkuchen  Stück     60 g    
Plätzchen, Kekse  Stück     10 g    
Schokolade  Riegel   20 g    
Praline  Stück    10 g    
Bonbon, Hartkaramelle  Stück      3 g    
Fruchtgummi  Portion 50 g    
Zucker  TL          5 g    
Gummibonbons Fantasie Zauberstäbchen (SHS)    
Gummibonbons Fanatsie Bärchen (SHS)    
Gummibonbons Fantasie Magic-Cola (SHS)    
Zitronentaler (SHS)     
Schoko-Dupletten (SHS)     
Vanille-Waffeln (SHS)     
Waliser Plätzchen (SHS)     
Lp-bar (Milupa)     
Lp-ringlets (Milupa)     
Knabbereien  • Nüsse Anzahl 
 
 
Einheit Tag 1 Tag 2 Tag 3 
Nüsse Sorte: ............................ EL        20 g    
Erdnüsse gesalzen  Tasse 100 g    
Erdnussflips  Tasse   50 g    
Chips  Tasse   30 g    
Salzstangen  Portion 30 g    
Lp-chips (Milupa)      
Sonstiges:      
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Wasser • Säfte  • alkoholfreie Getränke Anzahl 





Glas  200 g    
Leitungswasser  Glas  200 g    





























Glas   200 g    




Glas   200 g    
Sonstiges:      
      
      
Kaffee  • Tee  Anzahl 
 
 
Einheit Tag 1 Tag 2 Tag 3 
Kaffee (koffeinhaltig)  Tasse 150 g    
Kaffee (entkoffeiniert)  Tasse 150 g    
Malzkaffee / Zichorienkaffee  Tasse 150 g    
Schwarzer Tee  Tasse 150 g    
Kräutertee, Früchtetee  Tasse 150 g    
Sonstiges:      
      
      
Alkoholische Getränke Anzahl 
 
 
Einheit Tag 1 Tag 2 Tag 3 
Bier  Glas  330 g    
Bier alkoholfrei  Glas  330 g    
Weizenbier  Glas  500 g    
Weißwein  Glas  200 g    
Rotwein  Glas  200 g    
Sekt  Glas  100 g    
Likör  Glas   40 g    
Schnaps, Branntwein  Glas   20 g    
Sonstiges:      
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Aminosäuremischungen und Phe-arme Lebensmittel Anzahl 
 
 Einheit Tag 1 Tag 2 Tag 3 
PAM 3 SHS    
PAM maternal SHS    
p-am Anamix SHS    
p-am Easiphen SHS    
PKU 3 - advanta Milupa    
PKU 3 - tablets Milupa    
PKU 3 - shake Milupa    
PKU 3 (für Schwangere) Milupa    
Lp-fruity Milupa    
Lp-drink Milupa    
Lp-flakes Milupa    
Lp-pasta Milupa    
Weißbrot, ohne Salz Hammermühle    
Kastanienbrot ohne Salz Hammermühle    
Waffelbrot eiweißarm Hammermühle    
Aproten-Knusperbrot Hammermühle    
Aproten-Zwieback Hammermühle    
Aprotenkekse Hammermühle    
Aproten Spaghetti Hammermühle    
Spiralnudeln (Phe-arm) Hammermühle    
Harifen PKU-Milch Hammermühle    
Loprofin PKU-Milch Hammermühle    
Mehlmischung (Phe-arm) Hammermühle    
Spezialgrieß Hammermühle    
Backmix eiweißarm MetaX    
 
Sonstige Lebensmittel, die nicht aufgeführt sind 
 
                   Anzahl 
  
Einheit Tag 1 Tag 2 Tag 3 
     
     
     
     
     
     
     
     
 
Attachment  116 
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Ο  PKU-Patient 
    Ο  Kontrollperson 
 











1. MER                rechts   links 
  BSR 
  PSR 
  Grobe Kraft 
 
2. LR Pupillen  Ο isokor           Ο anisokor 
  Direkt 
  Indirekt 
 
 
3. Tremor            Ruhetremor 
   Haltetremor 
   Intentionstremor 
 
 
4. Ataxie            Standataxie:  Romberg 
      Unterberger 
   Gangataxie:  Linienlauf 
      Blindlauf 
 
 
5. Muskeltonus    Ο normal           Ο erhöht                  Ο sehr erhöht 
 
6. Sensibilität     Zahlen auf Handrücken 
   Fingerstellung 
 




8. Sprachauffälligkeiten:   Wortfindung 
     Artikulation 
     Syntax 
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Probandennr. Datum 
PKU-Erwachsenen-Studie    
 
„Entwicklung erwachsener Patienten mit PKU“ 
 
    Standardisiertes Interview 
 
FRAGEN TEIL 1 
 
 
A Angaben zum Patienten  Fragen 1 bis 8 
 
 
B Wohnsituation    Fragen 9 bis 11 
 
 
C Ausbildung und Beruf  Fragen 12 bis 23 
Schule    Fragen 12 bis 15 
Beruf    Fragen 16 bis 23 
 
 
D Gesundheit    Fragen 24 bis 38 
Allgemein    Fragen 24 bis 30 
Diät     Fragen 31 bis 34 
Subjektive Angaben zur Diät  Fragen 35 bis 38 
 
E Angaben zum Geschwister Fragen 24 bis 38 
Person des Geschwister  Fragen 39 bis 42 
Wohnsituation des Geschwister  Fragen 43 bis 44 
Schulbesuch des Geschwister  Fragen 45 bis 48 
Beruf des Geschwister  Fragen 49 bis 52 
Gesundheit des Geschwister   Fragen 53 bis 57 
 
F Eltern des Patienten Fragen 58 bis 59 
 
 
FRAGEN TEIL 2 
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A Angaben zum Patienten 
 
1. Geburtsdatum:  ..... ..... 19 ..... 
 
2. Geschlecht:  weiblich 






5. Bekannte krankheitsbezogene Daten: 
 
 
6. Familienstand:  ledig 
   verheiratet 
   mit festem Partner zusammenlebend 
   geschieden  
   getrennt lebend 
   verwitwet 
   anders, nämlich .......................................................... 
 
7. Kinder:  Nein 
  Ja. Wenn ja, wie viele eigene Kinder: ..... 
           und viele angenommene Kinder:  ..... 
 
8.  Maternale PKU-Problematik (nur Frauen) 
 
 Kinder:  Nein 
  Ja. Wenn ja:  
 Schwangerschaft  ohne Diät 
  mit Diät  
 Sind die Kinder  gesund 
   krank (Klartext:) 
 
9. Höchster Schulabschluß bzw. zur Zeit noch besuchte Schulform der Kinder: 
 
  Kind1 Kind2 Kind3 Kind4 
Haupt- (Volksschule)     
Realschule     
Gymnasium /FOS     
Sonderschule für Lernbehinderte     
Sonderschule für geistig Behinderte     
Sonderschule für Sehbehinderte     
Sonderschule für Schwererziehbare     
Sonderschule für Körperbehinderte     
Ohne Schulabschluß     
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B Wohnsituation des Patienten 
 
9. Wo ist der Patient aufgewachsen? 
 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
   anders, nämlich .......................................................... 
     .......................................................... 
 
10. Aktuelles Wohnumfeld des Patienten (mit Zeitangabe, auch Mehrfachangaben)  
 
   Allein 
   Mit Partner 
   Mit Partner und Kindern 
   Wohngemeinschaft 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
      ..........................................................   
   Betreutes Wohnen 
   Psychiatrie, Name ..........................................................  
     ..........................................................   
   anders, nämlich .......................................................... 
     .......................................................... 
     .......................................................... 
 
 
11. Mit wie vielen Personen wohnt der Patient zusammen? 
 Patient mit eingerechnet: ....................................... 
  
 





12. Alter bei Einschulung:    
 
 Dabei Rückstellung?   Nein 
   Ja, Anzahl Jahre: ..... ..... ..... ..... 
  
13. Wechsel des Schultyp (z.B. Von Gymnasium 6. Klasse nach Realschule 6. Klasse). 
Alle Wechsel eintragen. 
 
Von (Schultyp) Klasse nach (Schultyp) Klasse 
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14. Klassen wiederholt?  Nein 
   Ja. Wenn ja welche: ..... ..... ..... ..... 
 
15. Höchster Schulabschluss bzw. zur Zeit noch besuchte Schulform: 
 
  Abgeschlossen zur Zeit besucht 
Haupt- (Volksschule)   
Realschule   
Gymnasium /FOS   
Sonderschule für Lernbehinderte   
Sonderschule für geistig Behinderte   
Sonderschule für Sehbehinderte   
Sonderschule für Schwererziehbare   
Sonderschule für Körperbehinderte   
Ohne Schulabschluß   





16. Name und Art der letzten Berufsausbildung, die bereits abgeschlossen wurde oder der 
Patient zur Zeit noch absolviert: 
 
 Berufsausbildung zum/zur: .......................................... 
  
 Abgeschlossen zur Zeit besucht 
   
  
 
17. Art der Ausbildung: 
 schulische Berufsausbildung 
 Lehre 
 Lehre mit Meister 
 Studium 
 ohne abgeschlossene Berufsausbildung 
 Anders, und zwar: .................................................. 
 
18. Abgebrochene  Berufsausbildungen: 
   Nein 
   Ja. Wenn ja wie oft: .............................. 
  Warum abgebrochen? .............................. 
 
19. Derzeitige/r Tätigkeit/Beruf: 
 
 .................................................................................  als Angestellter 
 
   als Selbständiger 
 
20. Wann hat der Patient zuletzt gearbeitet, falls derzeit keine Tätigkeit? ..... ..... ..... 
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22. Arbeitsfähigkeit im letzten halben Jahr: 
 
 immer arbeitsfähig 
 zeitweise arbeitsunfähig 
 überwiegend arbeitsunfähig 
 immer arbeitsunfähig 
 (Früh-)Rentner 
 Anders, und zwar: .................................................. 
 
 





 Gar nicht 









 Sehr zufrieden 
 Zufrieden 
 Wenig zufrieden 
 Gar nicht zufrieden 
Partnerschaft 
 Sehr zufrieden 
 Zufrieden 
 Wenig zufrieden 
 Gar nicht zufrieden 
Gesundheit 
 Sehr zufrieden 
 Zufrieden 
 Wenig zufrieden 
 Gar nicht zufrieden 
 
25. Gesundheitliches Befinden (subjektives Gefühl) 
 
 Sehr gesund 
 Gesund 
 Weniger gesund 
 Gar nicht gesund 
 
26. War/ist der Patient in den letzten 5 Jahren erkrankt?  
 
Erkrankung Behandlung Arzt Medikation Erfolg? 
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27. Aktuelle gesundheitliche Beschwerden (Klartext) 
 
 




29. Wurde der Patient psychotherapeutisch oder psychiatrisch behandelt?  
 
  Nein  Ja. Wenn ja:  
 
Von - bis: Grund:  Art der Einrichtung: 
    
    
    
 





31. Beginn der Diät, Dauer der Diät und Angaben zur Diätänderung 
 
Beginn und Dauer 
Von - bis: 
Diät gelockert oder 
abgebrochen? 
 Angabe von Gründen: 
    
    
 
32. Einnahme der AS-Mischung 
 
Beginn und Dauer 
Von - bis: 
Einnahme der AS-Mischung 
abgebrochen? 
 Angabe von Gründen: 
    
    
 
33. Angaben zur Betreuung (Arzt, Zentrum) 
 
Beginn und Dauer 
Von - bis: 
Warum abgebrochen? Datum der letzten 
Vorstellung: 
Wo vorgestellt? 
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Subjektive Angaben zur Diät 
 
35. Wie belastend empfanden oder empfinden Sie die Diät? 
 
 
Gar nicht belastend Etwas belastend Ziemlich belastend Sehr belastend 
    
 
 
36. a Wie stark war/ist Ihr Wunsch, die Diät zu beenden? 
 
 
Gar nicht stark Etwas stark Ziemlich stark Sehr stark 
    
 
 





37. Wie schätzen Sie Ihren bisherigen Diätverlauf ein? 
 
 Sehr zufrieden 
 Zufrieden 
 Weniger zufrieden  
 Gar nicht zufrieden 
 Anders, nämlich:  
 
38. Einschränkungen durch die Diät in 
 
 Schule, Beruf 
 
Gar nicht stark Etwas stark Ziemlich stark Sehr stark 





Gar nicht stark Etwas stark Ziemlich stark Sehr stark 
    
 
 
 allgemeiner Lebensgestaltung 
 
Gar nicht stark Etwas stark Ziemlich stark Sehr stark 
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E Angaben zum altersmäßig nächstliegenden Geschwister 
 
Angaben zur Person des Geschwister 
 
39. Geburtsdatum:  ..... ..... 19 ..... 
 
40. Geschlecht:  weiblich 
   männlich 
 
41. Familienstand:  ledig 
   verheiratet 
   mit festem Partner zusammenlebend 
   geschieden  
   getrennt lebend 
   verwitwet 
   anders, nämlich .......................................................... 
 
42. Kinder:  Nein 
  Ja. Wenn ja, wie viele eigene Kinder: ..... 
           und viele angenommene Kinder:  ..... 
 
Wohnsituation des Geschwister 
 
43. Wo ist das leibliche Geschwister aufgewachsen? 
 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
   anders, nämlich .......................................................... 
     .......................................................... 
44. Aktuelles Wohnumfeld des leiblichen Geschwister: 
 
   Allein 
   Mit Partner 
   Wohngemeinschaft 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
   Betreutes Wohnen 
   Psychiatrie, Name ..........................................................   
   JVA   ..........................................................   
   anders, nämlich .......................................................... 
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Schulbesuch des Geschwister 
 
45. Alter bei Einschulung: 
 
46. Wechsel des Schultyp (z.B. Von Gymnasium 6. Klasse nach Realschule 6. Klasse). 
Alle Wechsel eintragen. 
 
Von (Schultyp) Klasse nach (Schultyp) Klasse 
    
    
    
    
  
47. Klassen wiederholt?  Nein 
   Ja. Wenn ja welche: ..... ..... ..... ..... 
 
48. Höchster Schulabschluß bzw. zur Zeit noch besuchte Schulform: 
 
  Abgeschlossen zur Zeit besucht 
Haupt- (Volksschule)   
Realschule   
Gymnasium /FOS   
Sonderschule für Lernbehinderte   
Sonderschule für geistig Behinderte   
Sonderschule für Sehbehinderte   
Sonderschule für Schwererziehbare   
Sonderschule für Körperbehinderte   
Ohne Schulabschluß   
Anders, und zwar: .....................   
 
Beruf des Geschwister 
 
49. Name und Art der letzten Berufsausbildung, die bereits abgeschlossen wurde oder der 
Patient zur Zeit noch absolviert: 
 
 Berufsausbildung zum/zur: .......................................... 
  
 Abgeschlossen zur Zeit besucht 
   
  
50. Art der Ausbildung: 
 schulische Berufsausbildung 
 Lehre 
 Lehre mit Meister 
 Studium 
 ohne abgeschlossene Berufsausbildung 
 Anders, und zwar: .................................................. 
 
51. Abgebrochene  Berufsausbildungen: 
   Nein 
   Ja. Wenn ja wie oft: .............................. 
  Warum abgebrochen? .............................. 
 
52. Derzeitige/r Tätigkeit/Beruf des Geschwister: 
 .................................................................................  als Angestellter 
   als Selbständiger 
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Gesundheit des Geschwister 
 
53. War/ist das Geschwister in den letzten 5 Jahren erkrankt?  
 
Erkrankung Behandlung Arzt Medikation Erfolg? 
     
     
     
     
     
     
 
54. Aktuelle gesundheitliche Beschwerden (Klartext) 
 
55. Aktuelle Medikation (Klartext) 
 
 
56. Wurde das Geschwister psychotherapeutisch oder psychiatrisch behandelt?  
  Nein  Ja. Wenn ja:  
 
Von - bis: Grund:  Art der Einrichtung: 
    
    
 
57. Möchte der Patient sonstige Angaben zu seinem Gesundheitszustand machen?  
 
F Eltern des Patienten 
 
58. Höchster Schulabschluß der biologischen Eltern: 
 
 Vater Mutter 
Haupt- (Volksschule)   
Realschule   
Gymnasium /FOS   
Sonderschule   
ohne Schulabschluß   
Anders, und zwar:  ....................... ....................... 
 
59. Namen und die Art der Berufsausbildung der Eltern: 
 
 Berufsausbildung des Vaters: .......................................... 
 
 Berufsausbildung der Mutter: .......................................... 
 
 Art der Ausbildung: 
 Vater Mutter 
schulische Berufsausbildung   
Lehre   
Lehre mit Meister   
Studium   
ohne abgeschlossene Berufsausbildung   
Anders, und zwar:  ..................... ..................... 
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A Angaben zur KONTROLLPERSON 
 
 
1. Geburtsdatum:  ..... ..... 19 ..... 
 
2. Geschlecht:  weiblich 






6. Familienstand:  ledig 
   verheiratet 
   mit festem Partner zusammenlebend 
   geschieden  
   getrennt lebend 
   verwitwet 
   anders, nämlich .......................................................... 
 
7. Kinder:  Nein 
  Ja. Wenn ja, wie viele eigene Kinder: ..... 
           und viele angenommene Kinder:  ..... 
 
9. Höchster Schulabschluss bzw. zur Zeit noch besuchte Schulform der Kinder: 
 
  Kind1 Kind2 Kind3 Kind4 
Haupt- (Volksschule)     
Realschule     
Gymnasium /FOS     
Sonderschule für Lernbehinderte     
Sonderschule für geistig Behinderte     
Sonderschule für Sehbehinderte     
Sonderschule für Schwererziehbare     
Sonderschule für Körperbehinderte     
Ohne Schulabschluss     
Anders, und zwar: .....................     
 
 
B Wohnsituation des Probanden 
 
9. Wo ist der Proband aufgewachsen? 
 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
   anders, nämlich .......................................................... 
     .......................................................... 
 
10. Aktuelles Wohnumfeld des Probanden (mit Zeitangabe, auch Mehrfachangaben)  
 
   Allein 
   Mit Partner 
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   Mit Partner und Kindern 
   Wohngemeinschaft 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
      ..........................................................   
   Betreutes Wohnen 
   Psychiatrie, Name ..........................................................  
     ..........................................................   
   anders, nämlich .......................................................... 
     .......................................................... 
     .......................................................... 
 
 
11. Mit wie vielen Personen wohnen Sie zusammen? 
 (sich selbst mit eingerechnet) ....................................... 
  
 





12. Alter bei Einschulung:    
 
 Dabei Rückstellung?   Nein 
   Ja, Anzahl Jahre: ..... ..... ..... ..... 
  
13. Wechsel des Schultyp (z.B. Von Gymnasium 6. Klasse nach Realschule 6. Klasse). 
Alle Wechsel eintragen. 
 
Von (Schultyp) Klasse nach (Schultyp) Klasse 
    
    
    
    
  
14. Klassen wiederholt?  Nein 
   Ja. Wenn ja welche: ..... ..... ..... ..... 
 
15. Höchster Schulabschluss bzw. zur Zeit noch besuchte Schulform: 
 
  Abgeschlossen zur Zeit besucht 
Haupt- (Volksschule)   
Realschule   
Gymnasium /FOS   
Sonderschule für Lernbehinderte   
Sonderschule für geistig Behinderte   
Sonderschule für Sehbehinderte   
Sonderschule für Schwererziehbare   
Sonderschule für Körperbehinderte   
Ohne Schulabschluß   
Anders, und zwar: .....................   
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Beruf 
 
16. Name und Art der letzten Berufsausbildung, die bereits abgeschlossen wurde oder der 
Patient zur Zeit noch absolviert: 
 
 Berufsausbildung zum/zur: .......................................... 
  
 Abgeschlossen zur Zeit besucht 





17. Art der Ausbildung: 
 schulische Berufsausbildung 
 Lehre 
 Lehre mit Meister 
 Studium 
 ohne abgeschlossene Berufsausbildung 
 Anders, und zwar: .................................................. 
 
18. Abgebrochene  Berufsausbildungen: 
   Nein 
   Ja. Wenn ja wie oft: .............................. 
  Warum abgebrochen? .............................. 
 
19. Derzeitige/r Tätigkeit/Beruf: 
 
 .................................................................................  als Angestellter 
 
   als Selbständiger 
 
20. Wann hat der Proband zuletzt gearbeitet, falls derzeit keine Tätigkeit?  
         ..... ..... ..... 
 
21. Dabei wöchentliche Arbeitszeit (in Stunden) ........... 
 
22. Arbeitsfähigkeit im letzten halben Jahr: 
 
 immer arbeitsfähig 
 zeitweise arbeitsunfähig 
 überwiegend arbeitsunfähig 
 immer arbeitsunfähig 
 (Früh-)Rentner 
 Anders, und zwar: .................................................. 
 
 




 Gar nicht 











 Sehr zufrieden 
 Zufrieden 
 Wenig zufrieden 
 Gar nicht zufrieden 
Partnerschaft 
 Sehr zufrieden 
 Zufrieden 
 Wenig zufrieden 
 Gar nicht zufrieden 
Gesundheit 
 Sehr zufrieden 
 Zufrieden 
 Wenig zufrieden 
 Gar nicht zufrieden 
 
25. Gesundheitliches Befinden (subjektives Gefühl) 
 
 Sehr gesund 
 Gesund 
 Weniger gesund 
 Gar nicht gesund 
 
26. War/ist der Proband in den letzten 5 Jahren erkrankt?  
 
Erkrankung Behandlung Arzt Medikation Erfolg? 
     
     
     
     
     
     
 
27. Aktuelle gesundheitliche Beschwerden (Klartext) 
 
 
28. Aktuelle Medikation (Klartext) 
 
 
29. Wurden Sie psychotherapeutisch oder psychiatrisch behandelt?  
  Nein  Ja. Wenn ja:  
 
Von - bis: Grund:  Art der Einrichtung: 
    
    
 
30. Möchte der Patient sonstige Angaben zu seinem Gesundheitszustand machen?  
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E Angaben zum altersmäßig nächstliegenden Geschwister 
 
Angaben zur Person des Geschwister 
 
39. Geburtsdatum:  ..... ..... 19 ..... 
 
40. Geschlecht:  weiblich 
   männlich 
 
41. Familienstand:  ledig 
   verheiratet 
   mit festem Partner zusammenlebend 
   geschieden  
   getrennt lebend 
   verwitwet 
   anders, nämlich .......................................................... 
 
42. Kinder:  Nein 
  Ja. Wenn ja, wie viele eigene Kinder: ..... 
           und viele angenommene Kinder:  ..... 
 
Wohnsituation des Geschwister 
 
43. Wo ist das leibliche Geschwister aufgewachsen? 
 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
   anders, nämlich .......................................................... 
     .......................................................... 
44. Aktuelles Wohnumfeld des leiblichen Geschwister: 
 
   Allein 
   Mit Partner 
   Wohngemeinschaft 
   Familie, beide Eltern 
   Familie, ein Elternteil 
   bei Verwandten  
   Adoptivfamilie 
   Pflegefamilie 
   Heim, Name ..........................................................   
   Betreutes Wohnen 
   Psychiatrie, Name ..........................................................   
   JVA   ..........................................................   
   anders, nämlich .......................................................... 
 
Schulbesuch des Geschwister 
 
45. Alter bei Einschulung: 
 
46. Wechsel des Schultyp (z.B. Von Gymnasium 6. Klasse nach Realschule 6. Klasse). 
Alle Wechsel eintragen. 
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Von (Schultyp) Klasse nach (Schultyp) Klasse 
    
    
    
  
47. Klassen wiederholt?  Nein 
   Ja. Wenn ja welche: ..... ..... ..... ..... 
 
48. Höchster Schulabschluss bzw. zur Zeit noch besuchte Schulform: 
 
  Abgeschlossen zur Zeit besucht 
Haupt- (Volksschule)   
Realschule   
Gymnasium /FOS   
Sonderschule für Lernbehinderte   
Sonderschule für geistig Behinderte   
Sonderschule für Sehbehinderte   
Sonderschule für Schwererziehbare   
Sonderschule für Körperbehinderte   
Ohne Schulabschluß   
Anders, und zwar: .....................   
 
Beruf des Geschwister 
 
49. Name und Art der letzten Berufsausbildung, die bereits abgeschlossen wurde oder der 
Patient zur Zeit noch absolviert: 
 
 Berufsausbildung zum/zur: .......................................... 
  
 Abgeschlossen zur Zeit besucht 
   
  
50. Art der Ausbildung: 
 schulische Berufsausbildung 
 Lehre 
 Lehre mit Meister 
 Studium 
 ohne abgeschlossene Berufsausbildung 
 Anders, und zwar: .................................................. 
 
51. Abgebrochene  Berufsausbildungen: 
   Nein 
   Ja. Wenn ja wie oft: .............................. 
  Warum abgebrochen? .............................. 
 
52. Derzeitige/r Tätigkeit/Beruf des Geschwister: 
 
 .................................................................................  als Angestellter 
   als Selbständiger 
 
Gesundheit des Geschwister 
 
53. War/ist das Geschwister in den letzten 5 Jahren erkrankt?  
 
Erkrankung Behandlung Arzt Medikation Erfolg? 
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54. Aktuelle gesundheitliche Beschwerden (Klartext) 
 
 
55. Aktuelle Medikation (Klartext) 
 
 
56. Wurde das Geschwister psychotherapeutisch oder psychiatrisch behandelt?  
  Nein  Ja. Wenn ja:  
 
Von - bis: Grund:  Art der Einrichtung: 
    
    
    
 
57. Möchte der Patient sonstige Angaben zu seinem Gesundheitszustand machen?  
 
 
F Eltern des Probanden 
 
58. Höchster Schulabschluss der biologischen Eltern: 
 
 Vater Mutter 
Haupt- (Volksschule)   
Realschule   
Gymnasium /FOS   
Sonderschule   
ohne Schulabschluß   
Anders, und zwar:  ....................... ....................... 
 
59. Namen und die Art der Berufsausbildung der Eltern: 
 
 Berufsausbildung des Vaters: .......................................... 
 
 Berufsausbildung der Mutter: .......................................... 
 
 Art der Ausbildung: 
 Vater Mutter 
schulische Berufsausbildung   
Lehre   
Lehre mit Meister   
Studium   
ohne abgeschlossene Berufsausbildung   
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1. Haben oder hatten Sie jemals Asthma? 
 
2. Wurde dies durch einen Arzt bestätigt? 
 
3. Hatten Sie in den letzten 12 Monaten einen Asthmaanfall? 
 
4. Wurde dies durch einen Arzt bestätigt? 
 
5. Nehmen Sie derzeit Medikamente gegen Asthma (Inhalationen, 





6. Haben oder hatten Sie jemals Heuschnupfen, allergischen 
Schnupfen oder allergische Bindehautentzündung? 
 
7. Wurde dies durch einen Arzt bestätigt? 
 
8. Leiden Sie derzeit - ohne dabei erkältet zu sein - an einer 
verstopften oder laufenden Nase und/oder an geschwollenen, 
juckenden Augen und zwar regelmäßig im Frühjahr oder Sommer 
oder fast immer beim Umgang mit bestimmten fell- oder 
federtragenden Tieren? 
 
9. Litten Sie jemals - ohne dabei erkältet zu sein - an einer verstopften 
oder laufenden Nase und/oder an geschwollenen, juckenden Augen 
und zwar regelmäßig im Frühjahr oder Sommer oder fast immer 
beim Umgang mit bestimmten fell- oder federtragenden Tieren? 
 
10. Wurde dies durch einen Arzt bestätigt? 
 
11. Leiden Sie derzeit an einer Neurodermitis (auch endogenes Ekzem 
oder atopische Dermatitis genannt)? 
 
12. Litten Sie jemals an einer Neurodermitis (auch endogenes Ekzem 
oder atopische Dermatitis genannt)? 
 
13. Wurde dies durch einen Arzt bestätigt? 
 
14. Hatten Sie wiederholt Nesselsucht, auch Urtikaria genannt, mit 
Quaddeln wie nach Brennnesselkontakt und/oder Schwellungen der 
Lippen und Augen? 
 
15. Wurde dies durch einen Arzt bestätigt? 
 
 
16. Reagieren Sie regelmäßig auf bestimmte Nahrungsmittel 
allergisch (Nesselsucht, Verschlimmerung eines Ekzems, Übelkeit, 
Erbrechen, Durchfall, Asthma)? 
 
17. Wurde dies durch einen Arzt bestätigt? 
ja   Ο    nein  Ο 
 
ja   Ο    nein  Ο 
 
ja   Ο    nein  Ο 
 
 
ja   Ο    nein  Ο 
 








ja   Ο    nein  Ο 
 
 
ja   Ο    nein  Ο 
 
 












ja   Ο    nein  Ο 
 




ja   Ο    nein  Ο 
 
 
ja   Ο    nein  Ο 
 
 
ja   Ο    nein  Ο 
 
 
ja   Ο    nein  Ο 
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19.  Rauchen Sie? Wenn ja, was und wie viel pro Tag? 
__________________________________________________ 
        __________________________________________________ 
 
 
ja   Ο    nein  Ο 
 
 
ja   Ο    nein  Ο 
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1 Wie viele Stunden haben Sie von gestern auf heute geschlafen? 






2a Haben Sie gestern Sport getrieben? 
 
  ja                                  nein 
 
 







3 Wie viel Zeit verbrachten Sie in den vergangenen 12 Monaten durchschnittlich pro Woche 
mit Sport? (Gymnastik, Aerobic, Joggen, Walken, Wandern, Schwimmen usw.) 






4 Wie viel Zeit haben Sie in den vergangenen 12 Monaten durchschnittlich in Ihrer Freizeit 
pro Tag vor dem Fernseher oder am PC verbracht? 
 
Fernseher:      Std.:_____Min.:____        sehe nicht Fernsehen 
 
PC:                Std.:_____Min.:____        benutze keinen PC 
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